<SUBMISSION>
<ACCESSION-NUMBER>0001144204-06-033075
<TYPE>6-K/A
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20060511
<FILING-DATE>20060814
<DATE-OF-FILING-DATE-CHANGE>20060814
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K/A
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>061029213
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K/A
<SEQUENCE>1
<FILENAME>v049585_6ka.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="return"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION<br></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></a></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 16pt; FONT-FAMILY: Times New Roman"><strong>FORM
      6-K/A</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT
      OF
      FOREIGN ISSUER<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to Rule 13a-16 or 15d-16 of<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
      Securities Exchange Act of 1934</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
      the month of August 2006</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commission
      File Number 000-5112</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 20pt; FONT-FAMILY: Times New Roman"><strong>pSivida
      Limited</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant&#8217;s name into English) </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
      12
      BGC Centre</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28
      The
      Esplanade</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth
      WA
      6000</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form&#160;20-F or Form&#160;40-F). </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
      40-F </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant by furnishing the information contained
      in
      this Form is also thereby furnishing the information to the Commission pursuant
      to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      "Yes"
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule&#160;12g3-2(b): 82- ___. <BR><BR>
Explanatory Note: Amended to make certain changes as requested by the staff of the SEC.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant,
      pSivida Limited, has duly caused this report to be signed on its behalf by
      the
      undersigned, thereunto duly authorized. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">pSivida
              Limited</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Date:&#160;August 10, 2006</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/&#160;Michael J. Soja</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="80%">
            </td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Michael J. Soja</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Vice President, Finance and Chief Financial Officer</em></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="1">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>EXHIBIT
      INDEX</u></em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                99.1:</strong></font></div>
            </td>
            <td align="left" valign="top" width="62%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SUPPLEMENTAL
                DISCLOSURE OF PSIVIDA LIMITED RELATED TO ITS RIGHTS OFFERING PROSPECTUS,
                DATED MAY 10, 2006</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-2-</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="1">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v049585_ex99-1.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SUPPLEMENTAL
      DISCLOSURE OF PSIVIDA LIMITED RELATED TO ITS RIGHTS ISSUE PROSPECTUS, DATED
      MAY
      10, 2006.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>As
      previously announced, pSivida Limited (the &#8220;Company&#8221;) has proposed to conduct a
      Non-Renounceable Rights Issue (the &#8220;Rights Issue&#8221;). In connection with the
      Rights Issue, the Company is distributing a prospectus to its shareholders
      eligible to receive it. The Company is furnishing as an exhibit to a Report
      of
      Foreign Issuer on Form 6-K this Supplemental Disclosure regarding its business
      which was contained in the prospectus relating to the Rights Issue.
</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>THE
      ENTITLEMENTS AND NEW SHARES BEING OFFERED IN THE RIGHTS ISSUE HAVE NOT BEEN
      REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE
      "U.S.
      SECURITIES ACT"), OR ANY U.S. STATE SECURITIES LAWS, AND MAY NOT BE OFFERED,
      SOLD OR TRANSFERRED IN THE UNITED STATES OR TO ANY UNITED STATES PERSONS (OTHER
      THAN DISTRIBUTORS) UNLESS SUCH SECURITIES ARE REGISTERED UNDER THE U.S.
      SECURITIES ACT OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE U.S.
      SECURITIES ACT IS AVAILABLE.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>THIS
      SUPPLEMENTAL DISCLOSURE SHALL NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION
      OF AN OFFER TO BUY ANY SECURITIES. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>YOU
      SHOULD ASSUME THAT THE INFORMATION CONTAINED IN THIS SUPPLEMENTAL DISCLOSURE
      IS
      ACCURATE AS OF THE DATE HEREOF ONLY. PSIVIDA&#8217;S BUSINESS, FINANCIAL CONDITION,
      RESULTS OF OPERATIONS AND PROSPECTS MAY HAVE CHANGED SINCE THAT DATE. THE
      COMPANY RESERVES THE RIGHT TO, BUT IS NOT OBLIGATED TO, REVISE THE INFORMATION
      AND/OR THE MATERIALS CONTAINED THEREIN. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>In
      accordance with General Instruction B of Form 6-K, the information set forth
      in
      this Supplemental Disclosure shall not be deemed to be &#8220;filed&#8221; for purposes of
      Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange
      Act&#8221;), or otherwise subject to the liabilities of that section, nor shall such
      information be deemed incorporated by reference in any filing under the
      Securities Act or the Exchange Act, except as shall be expressly set forth
      by
      specific reference in such a filing. The information set forth in this
      Supplemental Disclosure shall not be deemed an admission as to the materiality
      of any information in this Supplemental Disclosure.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>THE
                COMPANY</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is a global bio-nanotech company committed to the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">development
      of drug delivery products</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      in the
      healthcare sector, initially</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      in
      ophthalmology and oncology.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida&#8217;s
      Boston based business has developed the only two FDA approved sustained release
      back of the eye treatments for chronic eye disease - Vitrasert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>&#174;</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      and
      Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      Both
      products are manufactured and sold by global ophthalmology company, Bausch
&amp;
Lomb Incorporated (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>B&amp;L</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
      Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      is
      co-promoted in the U.S. by Novartis Ophthalmic, a business unit of Novartis
      Pharmaceuticals (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Novartis</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">),
      and
      B&amp;L. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">1</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
      next
      generation product, Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      which
      is in Phase III clinical trials, is licensed to Alimera Sciences Inc.
      (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Alimera</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
      for the
      treatment of Diabetic Macular Edema (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>DME</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">),
      the
      leading cause of vision loss for U.S. patients under the age of 65.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      also owns the rights to develop and commercialize a modified form (porosified
      or
      nano-structured) of silicon known as BioSilicon&#8482;, which has potential
      applications in drug delivery, wound healing, orthopedics, and tissue
      engineering. pSivida has granted exclusive licenses to its subsidiaries, AION
      Diagnostics Inc. and pSiNutria Limited (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSiNutria</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">),
      to
      develop and commercialize diagnostic and food technology applications
      respectively, using BioSilicon&#8482;.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida&#8217;s
      lead BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8482;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      product
      is BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      a
      brachytherapy product in pivotal Phase IIb clinical trials, which is being
      developed for the treatment of inoperable primary liver cancer. Phase IIa
      clinical trials demonstrated significant tumour regression as well as
      BrachySil&#8217;s being both safe and well tolerated in humans. pSivida has a license
      agreement with Beijing Med-Pharm Corporation for the clinical development,
      marketing and distribution of BrachySil&#8482; in China. pSivida is also investigating
      BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      in the
      treatment of pancreatic cancer and, subject to raising sufficient funds under
      the Rights Issue, plan to initiate Phase IIa clinical trials in the near
      future.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      has multiple evaluation agreements for the Company&#8217;s&#160;drug delivery
      technologies with some of the largest pharmaceutical and medical device
      companies in the world, including a recently announced evaluation agreement
      with
      an undisclosed global medical device company to evaluate </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">cardiovascular
      delivery of drugs using pSivida&#8217;s drug delivery technologies.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is listed on the NASDAQ (PSDV), Australian (PSD), and Frankfurt (PSI) stock
      exchanges and is a member of the NASDAQ Health Care Index (NASDAQ: IXHC) and
      the
      Merrill Lynch Nanotechnology Index.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CORE
      FOCUS: TARGETED AND CONTROLLED RELEASE DRUG DELIVERY </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><img src="graph.jpg" alt=""></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">2</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>OPHTHALMOLOGY</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      December 2005, pSivida acquired Control Delivery Systems Inc. (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>CDS</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">),
      a
      private U.S. drug delivery company based near Boston, Massachusetts in a
      transaction that was declared &#8216;Biotech M&amp;A Deal of the Year&#8217; by a respected
      Australian biotech publication. As a result of the acquisition, pSivida now
      has
      an extended product range that includes drug delivery treatments for various
      eye
      diseases.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      stated
      above, pSivida Inc (formerly CDS) has developed two FDA approved treatments
      for
      chronic eye disease - Vitrasert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>&#174;</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      and
      Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      is an
      intravitreal drug implant that has been approved for the treatment of chronic
      non-infectious Uveitis, the third highest cause of blindness in the U.S.
      affecting 175,000 people, and is designed to deliver sustained levels of drug
      to
      the back of the eye for a period of up to 30 months. Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      was
      approved as an orphan drug by the FDA in April 2005 and subsequently approved
      for full US Medicare reimbursement set at 106% of the wholesale price
      (US$18,250). </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Recent
      studies in Europe showed the recurrence rate for uveitis was significantly
      lower
      in eyes receiving Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>&#8482;</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      than in
      eyes receiving standard of care treatment. Further studies in the U.S. have
      also
      demonstrated that patients with DME who received Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      were
      more likely to have an improvement in vision of at least three lines on an
      eye
      chart and experience a stabilization or improvement of their Diabetic
      Retinopathy. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Diabetic
      Retinopathy is a complication of diabetes and a leading cause of blindness.
      It
      occurs when diabetes damages the tiny blood vessels inside the retina, the
      light-sensitive tissue at the back of the eye</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      DME is
      the leading cause of vision loss in people under 65 years of age and occurs
      when
      retinal blood vessels in diabetic&#8217;s eyes deteriorate and leak, causing the
      retina to swell. These clinical data help to demonstrate that sustained delivery
      of Fluocinolone acetonide (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>FA</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">),
      the
      drug used in Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      can
      provide lasting improvement in patients&#8217; vision. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is now developing an injectable implant, Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      that is
      designed to release the same drug as Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      FA, at
      a similar rate over 18 to 36 months. This product is now in Phase III clinical
      trials and is being co-developed by pSivida and Alimera. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      implant
      is injected into the back of the eye in an office visit rather than a surgical
      procedure and can potentially be used to deliver a wide variety of drugs.
      pSivida now has multiple new evaluation agreements with various companies,
      including some of the largest global pharmaceutical companies,&#160;to evaluate
      our&#160;ophthalmic drug delivery technologies with their compounds to treat
      other eye diseases.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida&#8217;s
      first product, Vitrasert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>&#174;</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      , was
      the first FDA approved sustained delivery system for the back of the eye. Whilst
      Vitrasert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>&#174;</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      is still
      sold by B&amp;L as an effective approved treatment for CMV Retinitis, a blinding
      viral infection that occurs in AIDS patients, the level of sales of this older
      product, and therefore amount of royalty paid by B&amp;L to pSivida, are no
      longer material to the Company.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is also developing next generation drug delivery treatments to the back of
      the
      eye incorporating BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      drug
      delivery technology.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">3</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>ONCOLOGY</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      part
      of its core &#8216;early to market&#8217; strategy, pSivida is developing BioSilicon&#8482;
products for the treatment of cancer.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Brachytherapy</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Brachytherapy
      is a form of treatment for cancer and involves the delivery of radioisotopes
      directly into the tumours. With improved tumour location and mapping, this
      approach to cancer therapy has grown substantially in recent years allowing
      clinicians to specifically expose tumour tissue to radioisotopes in a targeted
      manner, while minimizing damage to healthy surrounding tissues.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      brachytherapy market is currently large and growing and is dominated by the
      use
      of radioactive &#8216;seeds&#8217; for the treatment of hormone non-responsive prostate
      cancer. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida&#8217;s
      lead BioSilicon&#8482; product, BrachySil&#8482;, is based on a non-degradable form of
      BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      that
      contains radioactive 32-phosphorus (32-P). BrachySil&#8482; offers interventional
      radiologists a short-range, longer life isotope that can be delivered through
      a
      fine gauge needle making it a more user friendly product for both patient and
      physician. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      brachytherapy treatment, BioSilicon&#8482; has many significant potential
      advantages:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Short
                range - 32-P isotope has a short active range resulting in less damage
                to
                healthy tissue</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Range
                of tumours - fine gauge needle delivery allows potential application
                to
                many solid tumours, unlike current brachytherapy products
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Direct
                delivery - via fine gauge needle reduces side effects and tissue
                trauma</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cost
                effective raw materials - low cost, abundant availability of silicon,
                with
                the proven ability to make large quantities of material, or scale
                up</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Distribution
                - 32-P half-life of 14 days allows more convenient distribution to
                hospitals and application in the
                patient</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Immobilization
                - 32-P device is immobilized in the tumour, significantly reducing
                risk of
                leakage or systemic side effects</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Clinical
      evaluation of BrachySil&#8482; has shown preliminary evidence of safety and tumour
      regression.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Successful
      BrachySil&#8482; Trials</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Phase
      IIa
      clinical trials for BrachySil&#8482;, as a potential new brachytherapy treatment for
      inoperable liver cancer conducted by pSivida at Singapore General Hospital,
      have
      demonstrated that BrachySil&#8482; is safe and well tolerated. Furthermore,
      significant tumour regression was achieved with a maximum regression of 100
      percent in some smaller tumours treated as determined by CT scanning.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Phase
      IIa trial established four key findings in relation to BrachySil&#8482;:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Safety
                - no product-related adverse events</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">4</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Efficacy
                - treated tumours demonstrate significant tumour
                regression</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Specificity
                - retention of radioactivity in the tumour with insignificant detectable
                radioactive leakage</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ease
                of application - practical and rapid treatment of tumours with ultrasound
                and CT guidance, patients discharged from hospital in 24 hours
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      commenced a Phase IIb dose profiling study in October 2005 using a new
      fine-gauge needle, multi-injection device which enables for the first time,
      large and also multiple tumours to be treated. A total of 50 patients will
      be
      entered into this multi-centre trial conducted in Singapore, Malaysia,
      Philippines and Vietnam. The multi-centre pivotal registration trials are
      expected to provide sufficient data to support the registration of BrachySil&#8482; as
      an approved treatment for primary liver cancer, initially in Asian and European
      countries followed by the US. The Company plans to pursue a &#8216;device-based&#8217;
regulatory strategy, with BrachySil&#8482; to be filed initially as a treatment for
      liver cancer and thereafter for the treatment of other cancers involving solid
      tumours. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Following
      significant independent market research and medical opinion feedback, pSivida
      has selected pancreatic cancer as the second indication for BrachySil&#8482; and,
      subject to raising sufficient funds under the Rights Issue, plans to commence
      Phase IIa clinical trials in the third quarter of calendar 2006 to evaluate
      the
      safety and tolerability of the treatment. The trial will also monitor the
      efficacy of the treatment based on CT measurements of tumour regression as
      a
      foundation for subsequent Phase IIb dose-profiling and registration studies.
      As
      one of the world&#8217;s most aggressive cancers and with an average five-year
      survival of 4% and no approved treatment, pSivida considers that pancreatic
      cancer represents a significant area of unmet clinical need.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      has a license agreement with Beijing Med-Pharm Corporation for the clinical
      development, marketing and distribution of BrachySil&#8482; in China. The licence
      includes upfront and milestone payments and royalties on sales ranging up to
      30%. China has the highest incidence of primary liver cancer in the world,
      with
      over 345,000 estimated new cases per annum, currently representing 55% of total
      worldwide cases. The Company is also currently seeking development and marketing
      partners for BrachySil&#8482; in the other major territories.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      is
      manufactured to good manufacturing practice (GMP) regulatory requirements with
      scale-up planned for commercialisation.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>BIOSILICON&#8482;
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BioSilicon&#8482;
      is a new, unique and proprietary biomaterial produced from elemental silicon.
      Its structure can be engineered to contain a &#8216;honeycomb&#8217; of pores that allows
      BioSilicon&#8482; to retain various drugs while also making it biodegradable. The
      extent of the nanostructuring determines the size of the molecules and the
      dose
      it can hold within its honeycomb matrix and the rate of biodegradation, enabling
      predictable and controlled release of its therapeutic payload. In pre-clinical
      studies pSivida has shown that BioSilicon&#8482; can be both biodegradable and
      biocompatible. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Furthermore,
      BioSilicon&#8482; maintains the key semiconductor properties of silicon, is
      machineable at a micro level, and also demonstrates optical properties that
      provide the basis for a variety of potential devices for biodegradable and
      biocompatible diagnostic products.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">5</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida&#8217;s
      research and development work was recognized in 2004 when it received the
      prestigious Frost &amp; Sullivan Excellence in Research Award for its work in
      the area of nanomedicine.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Competitive
      Advantages of BioSilicon&#8482;</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 9pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8226;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
                pure and controllable environment for highly efficient drug loading
                and
                release</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 9pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8226;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Abundant
                and low cost raw material - production of extremely pure silicon
                is a
                well-established process</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 9pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8226;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Scale
                up and manufacture of BioSilicon&#8482; established with the track record of
                silicon manufacture of more than 40 years from the electronics
                industry</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 9pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8226;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Potential
                applications in delivery of drugs, including small molecules, peptides,
                proteins and vaccines</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 9pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8226;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Control
                of drug loading and release kinetics through physical (not chemical)
                optimization</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 9pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8226;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Biodegradable
                scaffold providing potential applications in tissue engineering and
                orthopedics</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 9pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8226;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Sensor,
                optical and semiconductor properties for potential applications in
                diagnostics</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>QinetiQ</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BioSilicon&#8482;
      was developed by QinetiQ, pSivida&#8217;s largest shareholder and one of Europe&#8217;s
      largest research and development organizations with an annual turnover of more
      than US$1.4 billion. Previous QinetiQ inventions include liquid crystal
      displays, carbon fiber, infra-red sensors, night vision, radar and
      sonar.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commercialization
      Strategy - BioSilicon</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup><strong>TM</strong></sup></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      diverse potential applications of BioSilicon&#8482; enable pSivida&#8217;s commercialization
      strategy to combine internal product development and the out-licensing of the
      BioSilicon&#8482; technology platform in non-core areas: </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Internally
                developed applications include and are expected to
                include:</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 108pt;">
            </td>
            <td align="left" style="width: 135pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-FAMILY: Wingdings">&#216;</font><font style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt" size="3">&#160;</font>Cancer
              Treatment</font></font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
                BrachySil&#8482; (radiotherapy)</font></div>
            </td>
          </tr>

      </table>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 108pt;">&#160;</td>
            <td align="left" style="width: 135pt;">&#160;</td>
            <td align="left"><font size="2">- Localized
              chemotherapy</font></td>
          </tr>

      </table>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 108pt;">&#160;</td>
            <td align="left" style="width: 135pt;"><font style="FONT-FAMILY: Wingdings" size="2">&#216;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Improved
              Drug Delivery</font></td>
            <td align="left"><font size="2">- Proprietary and generic
              drugs</font></td>
          </tr>

      </table>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 108pt;">&#160;</td>
            <td align="left" style="width: 135pt;"><font style="FONT-FAMILY: Wingdings" size="2">&#216;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Diagnostics</font></td>
            <td align="left"><font size="2">- Biosensors for disease
              detection</font></td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 125.1pt">&#160;</font></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Core
                Licensing - out-licensing BioSilicon&#8482; for delivery of third party
                proprietary drugs, generic drugs, vaccines and for device
                applications</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Out-licensing
                of non-core intellectual property - tissue engineering and orthopedics
                (biodegradable and coated devices and scaffolds) and food
                (nutraceuticals)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">6</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Drug
      Delivery - BioSilicon</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup><strong>TM</strong></sup></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida&#8217;s
      core focus is in the rapidly growing market for new drug delivery formulations.
      The value of the global drug delivery market is large and growing. Drug delivery
      has proved to be a critical element in the drug development process resulting
      in
      enhanced safety and efficacy of many medicines.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Improvement
      of drug delivery is important for better patient safety and drug
      bioavailability. Furthermore, the use of novel drug delivery systems is an
      increasingly important strategy for major pharmaceutical and biotechnology
      companies as they recognize the opportunities in forging relationships with
      drug
      delivery companies, to enable the delivery of new drugs while also extending
      the
      commercial life of their current drugs.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BioSilicon&#8217;s&#8482;
      properties make it an ideal drug delivery platform for drug companies, with
      potential advantages including:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">high
                efficiency/capacity of drug loading up to
                95%</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ability
                to control release kinetics (over
                hours/days/weeks/months)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">silicon
                biodegradation to naturally occurring silicic
                acid</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">controlled
                nanostructuring and micro machining can vary nano-pores to accommodate
                different drug sizes</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">conduction
                of charge and semiconductor properties uniquely allow the potential
                construction of &#8216;smart&#8217; processor controlled
                delivery</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">intelligence
                - potential microchip incorporation for &#8216;smart&#8217;
                diagnostics</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Unlike
      polymer-based drug delivery systems, the manufacture of BioSilicon&#8482; does not
      require complex chemistry, the delivery platform is silicon irrespective of
      the
      delivery characteristics imparted by the nanostructuring process. BioSilicon&#8482;
also distinguishes itself from other delivery systems by its heat and radiation
      stability, simplifying manufacture and sterilization.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>NON-CORE
      APPLICATIONS</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Diagnostics</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      recently incorporated AION Diagnostics Inc. (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>AION</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
      in the
      United States, the world&#8217;s largest healthcare and financial market, and AION has
      assumed ownership of our existing Australian subsidiary AION Diagnostics Ltd.
      AION owns the rights to commercialize diagnostics applications of pSivida&#8217;s
      intellectual property for human and animal healthcare. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AION
      is
      focused on the development of products that facilitate accurate and immediate
      diagnosis, at the early pre-symptomatic stage. Pre-symptomatic detection is
      a
      significant advance in the diagnostic sector and will also significantly impact
      the therapeutics sector as early correct diagnosis of disease will alter the
      course of disease and the resultant demand for therapeutics. AION has targeted
      markets where there is a strong patient, provider and government need for early
      diagnosis that results in the opportunity to save lives and reduce the financial
      burden on the healthcare system.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">7</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AION
      has
      developed plans for a number of different potential products as well as
      commencing preclinical work on near to market products in the areas of Imaging
      and Biosensors. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It
      is
      expected that AION will be seeking to raise additional funds by issuing
      additional shares to third party institutional investors in the near future
      which will have a dilutive effect on pSivida&#8217;s ownership of the subsidiary. Any
      funds raised by the issue of shares by AION will be restricted for use by AION
      in the development of AION products.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Food
      Applications</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      has seed funded and granted its subsidiary pSiNutria Limited a royalty bearing
      exclusive license for the use of BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      as an
      ingestible ingredient in food applications. pSiNutria is also developing
      patentable intellectual property using silicon in the food packaging area.
      BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      applications in food primarily pertain to its biodegradability and optical
      properties. Potential pSiNutria products being developed include: products
      to
      deliver active ingredients and food additives, to detect pathogens in food,
      for
      food tracing, for food preservation, and products to detect variations of
      temperature in food storage. These products may include ingestible
      BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      which
      will dissolve into silicic acid in the body or silicon used in modified
      atmosphere packaging.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Orthopedics</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BioSilicon&#8482;
      also has potential as a biodegradable scaffold for orthopedic tissue
      engineering. A porous silicon structure could be deliberately sculpted to
      provide bone-building cells with a scaffold that they can penetrate and anchor
      to. As the bone tissue deposits itself onto the scaffold, the silicon would
      slowly dissolve away, eventually leaving just the new bone. Silicon&#8217;s ability to
      carry an electrical current charge bias may also give BioSilicon&#8482; an advantage
      in the treatment of bone conditions, promote bone growth and may have other
      orthopedic applications. Data gathered to date indicates that cells will grow
      and divide in BioSilicon&#8482; substrates and that BioSilicon&#8482; can be osteoinductive,
      promoting bone growth and deposition.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Wound
      Management</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Biocompatible
      materials are used extensively for tissue engineering and wound management
      both
      on the body and in the body. Such materials are intended to provide fixing
      surfaces and scaffolds for the growth of cells and establishment of new tissues.
      Some biomaterials, although compatible within the body, are not biodegradable
      and as such need to be removed subsequently. BioSilicon&#8482; therefore potentially
      provides a biocompatible and biodegradable surface for cell adhesion and tissue
      growth. pSivida has demonstrated that BioSilicon&#8482; is also particularly suited to
      bone cell attachment and growth. BioSilicon&#8482; can, in certain conditions, induce
      hydroxyapatite deposition on its surface. The ability to load drugs, antibiotics
      and growth factors into BioSilicon&#8482; potentially allows for further potential
      specialist applications in tissue engineering and wound management.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      has signed an agreement with US-based specialist PureTech Development LLC to
      investigate and evaluate out-licensing opportunities for BioSilicon&#8482; in these
      non-core areas of orthopaedics and wound management with partners with specific
      expertise in these healthcare sectors.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">8</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      has entered into several evaluation agreements with large biotechnology and
      medical device companies and institutions to evaluate the use of BioSilicon&#8482; in
      the above non-core application areas to enhance those organisations&#8217;
products.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>INTELLECTUAL
      PROPERTY</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida&#8217;s
      intellectual property position is strong, with core biomaterial patents granted
      in the US, Asia and Europe. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      owns or has the exclusive rights to use the intellectual property pertaining
      to
      BrachySil&#8482;, Medidur&#8482;, Retisert&#8482; and Vitrasert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>&#174;</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      The
      Company&#8217;s IP portfolio consists of 70 patent families, 74 granted patents and
      over 290 patent applications. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>PARTNERING
      STRATEGY</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida&#8217;s
      broader commercialization strategy involves a high degree of partnering at
      various levels to leverage the expensive development process. The R&amp;D
      process is progressed and coordinated through pSivida&#8217;s US-based subsidiary,
      pSivida Inc, its UK-based subsidiary, pSiMedica Ltd, and its strategic partner
      QinetiQ as well as through collaborative partnerships. Non-core applications
      are
      expected to be out-licensed, providing interim cash flow and allowing the
      Company to focus on its core commercialization strategy.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company has adopted research collaborations, from time to time, with other
      biotech companies and universities in various parts of the world, researching
      potential products and applications in non-core areas.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>RECENT
      FINANCIAL INFORMATION </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company released its Appendix 4C quarterly cash flow report with ASX on 28
      April
      2006. Cash on hand and available at 31 March 2006 amounted to approximately
      $17.4&#160;million. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It
      is
      important to note that the net operating cash outflow for the quarter was
      limited to $4.8&#160;million, an increase of $203,000 or 4.4% when compared to
      the previous quarter. The increase in cash outflows was mitigated by cost
      synergies being realised subsequent to the acquisition</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>&#160;</em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
      CDS, a
      review of costs being undertaken and implemented during the period and the
      receipt of payments from collaborative partners and Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      royalties. Cost synergies from the merger are continuing to be pursued with
      greater use to be made of our Watertown, Boston facilities.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Retisert</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup><strong>TM</strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
      licence - the B&amp;L Agreement</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under
      the
      B&amp;L Agreement, pSivida Inc (formerly CDS) has granted B&amp;L a worldwide,
      exclusive license to certain of pSivida Inc technologies to make and sell
      Vitrasert&#174; and pSivida Inc.&#8217;s first generation products, including the
      Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      device,
      for the treatment, prevention and diagnosis of any disease, disorder or
      condition of the human eye. A first generation product is defined as an implant
      that is required to be surgically inserted through an incision of at least
      2 mm,
      is secured in the posterior of the eye, cannot be injected and uses a reservoir
      design generally conforming to specifications set out in the license. B&amp;L
      agreed to pay pSivida Inc royalties based on net sales for any products that
      meet the definition of first generation products. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">9</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      Inc also granted B&amp;L a non-exclusive license to these technologies to make
      and sell certain other products for the delivery of specified active
      ingredients, using specified delivery systems, methods of delivery and anchoring
      methods, to be used in specified locations for specified indications.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B&amp;L
      is responsible for funding and managing the development and commercialization
      of
      all products under the agreement. B&amp;L also agreed to pay pSivida Inc
      specified amounts if it achieved certain milestones related to certain licensed
      products.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      Inc agreed not to develop, commercialize or license to a third party rights
      to
      develop or commercialize any product to treat posterior uveitis so long as
      (1)
      B&amp;L is actively pursuing the commercialization of a product to treat uveitis
      for which B&amp;L would be required to pay pSivida Inc a specified level of
      royalty, and (2) B&amp;L is not selling any other uveitis product for which it
      would not be required to pay pSivida Inc a specified level of royalty. pSivida
      Inc also may not develop, commercialize or license any product that meets the
      definition of first generation product as long as B&amp;L has an exclusive
      license to such products using pSivida Inc technologies.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B&amp;L
      may terminate the B&amp;L Agreement, in its entirety or with respect to
      Vitrasert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>&#174;</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      or any
      non-exclusively licensed product, at any time on 90 days&#8217; written notice. In the
      event B&amp;L terminates the agreement in its entirety, B&amp;L&#8217;s license to the
      pSivida Inc technologies will terminate. In the event B&amp;L terminates the
      agreement with respect to Vitrasert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>&#174;</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      or a
      non-exclusively licensed product, B&amp;L will lose the right to rely upon
      pSivida Inc.&#8217;s intellectual property to make and sell the relevant
      product.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>B&amp;L
      Agreement - royalty advance</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      was
      approved by the FDA in April 2005. Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      royalties that would have otherwise been earned by pSivida Inc in the second
      half of calendar 2005 and by pSivida in the quarter ended 31 March 2006 totaled
      $1.25&#160;million (US$894,144). However this amount is reduced by 50% in
      accordance with an advance royalty arrangement pSivida Inc entered into with
      B&amp;L in June 2005 as further detailed below.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under
      the
      B&amp;L Agreement, pSivida Inc received US$3&#160;million from B&amp;L in June
      2005 as an advance payment in lieu of US$6.25 million of future royalties that
      would otherwise be payable to pSivida Inc. Under the terms of the royalty
      arrangements, the royalty payable will be reduced as follows: </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 72pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B&amp;L
                will retain 50% of the first US$3 million of royalties (ie retaining
                US$1.5 million, of which US$447,072 has already been retained to
                31 March
                2006); and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 72pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B&amp;L
                will retain 100% of the next US$4.75 million of royalties.
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">10</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Since
      this advance is non refundable, other than as an offset to future royalties
      receivable by pSivida Inc, and there are no future performance obligations
      by
      pSivida Inc, the full US$3 million was reflected by pSivida Inc as royalty
      revenue in the month of June 2005. On the basis that the acquisition of pSivida
      Inc completed on 30 December 2005 the pSivida Inc results will be consolidated
      in pSivida's accounts from that date. As a result of the B&amp;L Agreement, and
      as a result of royalties earned by pSivida Inc in the second half of calendar
      2005 (US$277,712), pSivida will record as revenues 50% of the royalty revenue
      that is otherwise payable by B&amp;L for the first US$2,444,576 of royalties
      otherwise payable subsequent to 1 January 2006 and will record no royalty
      revenue on the next US$4.75&#160;million of royalty revenue that is otherwise
      payable.&#160; </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">After
      cumulative royalties otherwise payable reach a total of US$7.75 million (or
      US$7,194,000 of royalties otherwise payable subsequent to 1 January 2006),
      pSivida will record the full amount of subsequent royalties as royalty income
      in
      its consolidated financial statements. The cumulative total of royalties
      otherwise payable subsequent to 1 January 2006 is US$338,720 as at 31 March
      2006. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>USE
                OF PROCEEDS OF THE RIGHTS
                ISSUE</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subject
      to the discussion below, it is intended that the funds raised by the Rights
      Issue will be used by pSivida as described below and in a descending order
      of
      priority (ie (a), (b) then (c)):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <table cellpadding="0" cellspacing="0" width="90%">

          <tr>
            <td align="justify" valign="top" width="6%">&#160;</td>
            <td align="justify" valign="top" width="74%">&#160;</td>
            <td valign="top" width="20%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>A$</strong></font></div>
            </td>
          </tr>
          <tr>
            <td align="justify" valign="top" width="6%">&#160;</td>
            <td align="justify" valign="top" width="74%">&#160;</td>
            <td valign="top" width="20%">&#160;</td>
          </tr>
          <tr>
            <td align="justify" valign="top" width="6%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font></div>
            </td>
            <td align="justify" valign="top" width="74%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">General
                working capital requirements including drug delivery research and
                ongoing
                Phase IIb Primary Liver Cancer BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM
                </sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">trials.</font></div>
            </td>
            <td valign="top" width="20%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Up
                to 5 million</font></div>
            </td>
          </tr>
          <tr>
            <td align="justify" valign="top" width="6%">&#160;</td>
            <td align="justify" valign="top" width="74%">&#160;</td>
            <td valign="top" width="20%">&#160;</td>
          </tr>
          <tr>
            <td align="justify" valign="top" width="6%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font></div>
            </td>
            <td align="justify" valign="top" width="74%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Phase
                IIa Pancreatic BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                trials to evaluate the safety and tolerability of the treatment.
                The trial
                will also monitor the efficacy of the treatment based on CT measurements
                of tumour regression as a foundation for subsequent Phase IIb
                dose-profiling and registration studies.</font></div>
            </td>
            <td valign="top" width="20%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7
                million</font></div>
            </td>
          </tr>
          <tr>
            <td align="justify" valign="top" width="6%">&#160;</td>
            <td align="justify" valign="top" width="74%">&#160;</td>
            <td valign="top" width="20%">&#160;</td>
          </tr>
          <tr>
            <td align="justify" valign="top" width="6%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font></div>
            </td>
            <td align="justify" valign="top" width="74%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Phase
                III Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                trials for DME (for the Phase III registration trials undertaken
                in
                conjunction with Alimera).</font></div>
            </td>
            <td valign="top" width="20%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">17
                million</font></div>
            </td>
          </tr>
          <tr>
            <td align="justify" valign="top" width="6%">&#160;</td>
            <td align="justify" valign="top" width="74%">&#160;</td>
            <td valign="top" width="20%">&#160;</td>
          </tr>
          <tr>
            <td align="justify" valign="top" width="6%">&#160;</td>
            <td align="justify" valign="top" width="74%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">TOTAL
                FUNDS RAISED BY THE RIGHTS ISSUE AT FULL SUBSCRIPTION</font></div>
            </td>
            <td valign="top" width="20%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">29
                million</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Alimera
      Agreement and Medidur</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup><strong>TM</strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
      Trials</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Alimera
      and pSivida Inc have entered into an agreement for the joint funding and
      development of products licensed under that agreement, including
      Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      February 2005, pSivida Inc (as CDS) granted Alimera a world-wide exclusive
      right
      to use certain pSivida Inc technologies to make and sell, for the treatment
      and
      prevention of eye diseases (except uveitis) in humans, products that have a
      drug
      core within a polymer layer and are approved or designed to be approved to
      deliver only specified compounds by a direct delivery method to the posterior
      portion of the eye. In addition, pSivida Inc granted to Alimera a world-wide
      exclusive right to use certain pSivida Inc technologies to treat DME by
      delivering a compound or formulation by a direct delivery method other than
      through specified incisions, and which are not exclusively licensed to B&amp;L.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">11</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
      joint
      development team of both parties is responsible for monitoring the execution
      of
      activities under the development plan for licensed products. pSivida Inc and
      Alimera each pays co-development costs that are incurred included in the
      development budget. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      agreement provided for Alimera to pay a licensing fee and milestone payment
      to
      pSivida Inc which has been paid. Alimera has sole responsibility for making
      commercially reasonable efforts to commercialize products licensed under the
      Alimera Agreement and for paying all costs and expenses incurred in connection
      with such commercialization. After a product becomes profitable in a country,
      Alimera and pSivida Inc share the net profits for that product in that country,
      subject to Alimera recovering pre-profitability net losses for that product
      and
      provided pSivida has met its portion of development costs for the product.
      If
      the level of funds raised under the Rights Issue, and pSivida's funding
      priorities result in pSivida choosing not to meet its development costs
      obligations, Alimera may exercise certain rights it has to restructure the
      arrangements with pSivida into a royalty agreement over the exclusive right
      to
      use certain pSivida Inc technologies, rather than the existing co-development
      and profit share agreement. If there are unpaid development payments, the amount
      of unpaid development costs plus a fee for non-payment and interest will be
      deducted from pSivida&#8217;s&#160;profit share payments.&#160;If the agreement is
      converted to a royalty based agreement by Alimera&#160;then the amount of the
      unpaid development payments without penalty or interest are deducted from
      pSivida&#8217;s royalty payment.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      expects to receive a significantly greater return by funding the
      Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      trials
      under the Alimera Agreement to receive a profit share with Alimera rather than
      having the agreement converted to a royalty based licence if pSivida did not
      co-fund the trials.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Further
      details on risk factors associated with the Alimera Agreement are set out in
      section 9, under the heading "risks related to pSivida and its
      business".</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Placement
      Agent Fees</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      has appointed a Placement Agent to act as US-based Lead Manager for the
      shortfall under the Rights Issue. Under pSivida's arrangement with the placement
      agent as set out in the Mandate Letter, the placement agent will place any
      shortfall with institutional and sophisticated investors on behalf of
      pSivida.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6%
      of
      funds raised in this manner will be used to pay the placement agent its fees
      under the Mandate Letter. The maximum fee payable to the placement agent, if
      no
      Rights Issue entitlements are taken up, and the shortfall comprises all of
      the
      new shares the subject of the Rights Issue, is approximately
      $1,740,000.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">12</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Costs
      of the Rights Issue and existing expenditure obligations</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Costs
      of
      the Rights Issue (including the placement agent fees) will be met through
      existing cash reserves. The Rights Issue is seeking to raise funds for the
      objectives set out above, and the Company's current operations are able to
      be
      funded from existing cash reserves.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      the
      event that insufficient funds are raised under the Rights Issue to fully fund
      each of the Company's objectives set out in (a), (b) and (c) in the table above,
      the Company will consider each objective and the funds available to it, and
      will
      proceed with those objectives in the order of priority in which they are listed
      above. To the extent that insufficient funds are raised in respect of a
      particular objective, the Company will seek a co-development partner (or
      alternative funding) for those projects. There is no assurance that acceptable
      co-development arrangements or alternative funding on acceptable terms will
      be
      able to be obtained. Accordingly there is no guarantee that the objectives
      will
      be able to be funded. This may have an adverse impact on the Company's future
      prospects which is not currently capable of being determined.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Risk
      factors relating to the Company's future funding requirements are set out in
      section 9, under the heading "Risks related to pSivida and its
      business".</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td align="left" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>POTENTIAL
                EFFECT OF THE </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>RIGHTS
                ISSUE</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.1</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Amount
                to be Raised</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Rights Issue will raise up to approximately AU$29,028,650 (before costs of
      the
      Rights Issue), excluding the</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">effect
      of
      vested options which may be exercised prior to the Record Date and any new
      shares which the Convertible Noteholder may subscribe for under the terms of
      the
      Convertible Note (as set out in section&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.3</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      below).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.2</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Capital
                Structure</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      potential effect of the Rights Issue on pSivida's capital structure is set
      out
      below:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Issued
      Capital as at 10 May 2006:</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A.</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Shares</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">387,048,696
      Shares</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B.</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Options</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div align="center">
      <table border="1" bordercolor="#000000" cellpadding="0" cellspacing="0" width="50%">

          <tr bgcolor="white">
            <td align="right" valign="top" width="34%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Number</strong></font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Exercise
                Price</strong></font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Expiry
                Date</strong></font></div>
            </td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="right" valign="top" width="34%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4,375,000</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AU$0.61</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">31-Dec-07</font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td align="right" valign="top" width="34%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2,050,000</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AU$1.09</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5-Aug-08</font></div>
            </td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="right" valign="top" width="34%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8,934,672</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AU$1.18</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5-Aug-09</font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td align="right" valign="top" width="34%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">115,000</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AU$0.80</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">31-Dec-08</font></div>
            </td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="right" valign="top" width="34%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">200,000</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AU$1.02</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">22-Apr-10</font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td align="right" valign="top" width="34%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3,852,000</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AU$0.80</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">31-Mar-10</font></div>
            </td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="right" valign="top" width="34%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1,330,000</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AU$1.25</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5-Aug-08</font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td align="right" valign="top" width="34%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2,250,000</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AU$0.92</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">30-Sept-10</font></div>
            </td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="right" valign="top" width="34%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6,338,030</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">US$0.72</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">15-Nov-11</font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td align="right" valign="top" width="34%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">70,400</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">US$3.22159</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12-Jun-06</font></div>
            </td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="right" valign="top" width="34%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">38,720</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">US$3.22159</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9-Jul-06</font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td align="right" valign="top" width="34%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">38,720</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">US$2.99148</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">19-Apr-07</font></div>
            </td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="right" valign="top" width="34%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">704,000</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">US$0.17756</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">18-Sept-07</font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td align="right" valign="top" width="34%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">70,400</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">US$2.99148</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">31-Oct-07</font></div>
            </td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="right" valign="top" width="34%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">58,080</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">US$2.99148</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">15-Apr-08</font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td align="right" valign="top" width="34%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">352,000</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">US$0.22727</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">25-Aug-09</font></div>
            </td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="right" valign="top" width="34%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">352,000</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">US$0.34091</font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12-Nov-09</font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td align="right" valign="top" width="34%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>31,129,022</strong></font></div>
            </td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="top" width="33%" style="border-bottom: black thin solid;">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">13</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Issued
      Capital immediately after the Rights Issue:</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A.</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Shares</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">435,429,783
      Shares, on the assumption that all Shares available to be issued in the Rights
      Issue</font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">are
      issued</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(excluding
      the</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">effect
      of
      any new shares which the Convertible Noteholder may subscribe for under the
      terms of the Convertible Note (as set out in section&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.3</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B.</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Options</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Unchanged
      (assuming no existing options are exercised).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.3</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Convertible
                Note</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
      8
      October 2005, pSivida entered into a Securities Purchase Agreement (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SPA</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
      with
      the Convertible Noteholder, under which, subject to shareholder approval,
      pSivida agreed to issue:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">an
                unquoted subordinated convertible note, with a face value of US$15,000,000
                (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Convertible
                Note</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">);
                and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">an
                unlisted option issued as a warrant to purchase 633,803 ADSs with
                an
                exercise price of US$7.20 per ADS and expiry date of
                15&#160;November&#160;2011 (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Warrants</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      issue
      of the Convertible Note and Warrant on the terms set out in the SPA was approved
      by shareholders at pSivida's 2005 Annual General Meeting on
      15&#160;November&#160;2005. Full terms of the Convertible Note and Warrant are
      available from the U.S. Securities and Exchange Commission website
      www.sec.gov.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      subsequently issued the Convertible Note and Warrants to the Convertible
      Noteholder on 16&#160;November&#160;2005.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      at the
      date hereof, pSivida has paid US$472,603 (A$628,847) in interest payments,
      but
      the full principal amount of US$15,000,000 (A$20,545,131) remains payable,
      with
      the first of three equal installments due on 15 November 2006 unless such
      installment is converted earlier into ADSs.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">14</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under
      the
      terms of the Convertible Note, the Convertible Noteholder has a right to
      subscribe for new shares on the same terms as offered to eligible shareholders
      in the Rights Issue, as if the Convertible Note were converted to Shares prior
      to the Record Date. The Convertible Note is convertible into 21,126,760 Shares,
      represented by 2,112,676 ADSs, at the current conversion rate. As such, on
      the 1
      for 8 basis of the Rights Issue, the Convertible Noteholder may subscribe for
      2,640,845 new shares, raising AU$1,584,507. The price at which the Convertible
      Note is converted into Shares is subject to a reset on 6&#160;August 2006, based
      on an 8% premium to the weighted average price for the 10 trading days prior
      to
      6 August 2006.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      the
      Rights Issue is fully subscribed, and the Convertible Noteholder decides to
      take
      up all of its rights under the Convertible Note to subscribe for Shares, the
      issued capital of pSivida immediately after the Rights Issue and issue of the
      Shares to the Convertible Noteholder would be 438,070,628 Shares.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      the
      Rights Issue is fully subscribed, the additional $1,584,507 raised by the issue
      of new shares to the Convertible Noteholder (assuming the maximum number of
      rights is exercised) will be used by pSivida to augment working capital
      requirements. If the Rights Issue is not fully subscribed, then the total funds
      raised (including the funds raised through the issue of Shares to the
      Convertible Noteholder) will be used as set out in section </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Risks
      in
      relation to the Convertible Note are dealt with in section&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      under
      the heading "Risks related to pSivida's recent acquisition of CDS and other
      recent transactions".</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">15</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.4</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Financial
                impact.</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="85%">

          <tr>
            <td colspan="10" valign="bottom" width="99%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Unaudited
                Pro Forma Consolidated Balance Sheet</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>as
                at 31 December 2005</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="48%" style="border-bottom: medium none;">&#160;</td>
            <td width="2%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" colspan="2" valign="bottom" width="15%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>31
                December 2005</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(see
                Note (a))</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: medium none;">&#160;</td>
            <td colspan="2" valign="bottom" width="15%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Consolidated</strong></font></div>
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pro
                Forma Adjustments (not audited or reviewed)</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: medium none;">&#160;</td>
            <td colspan="2" valign="bottom" width="15%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pro
                Forma 31 December 2005 (not audited or reviewed)</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="48%">&#160;</td>
            <td width="2%">&#160;</td>
            <td colspan="2" valign="bottom" width="15%">&#160;</td>
            <td align="left" valign="bottom" width="2%">&#160;</td>
            <td colspan="2" valign="bottom" width="15%">&#160;</td>
            <td align="left" valign="bottom" width="2%">&#160;</td>
            <td colspan="2" valign="bottom" width="15%">&#160;</td>
            <td align="left" valign="bottom" width="1%">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="48%" style="border-bottom: white;">&#160;</td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td colspan="2" valign="bottom" width="15%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>$</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td colspan="2" valign="bottom" width="15%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>$</strong></font></div>
              </div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td colspan="2" valign="bottom" width="15%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>$</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="left" valign="bottom" width="48%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Current
                assets</strong></font></div>
            </td>
            <td width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="48%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cash
                and cash equivalents</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">27,683,278</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">28,924,640</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">56,607,918</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="left" valign="bottom" width="48%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Trade
                and other receivables</font></div>
            </td>
            <td width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,238,335</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,238,335</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="48%" style="border-bottom: white solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other</font></div>
            </td>
            <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">514,988</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">514,988</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="left" valign="bottom" width="48%" style="border-bottom: #ccffcc solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Total
                current assets</strong></font></div>
            </td>
            <td width="2%" style="border-bottom: #ccffcc thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">29,436,601</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">28,924,640</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">58,361,241</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="48%" style="border-bottom: white;">&#160;</td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="left" valign="bottom" width="48%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Non-current
                assets</strong></font></div>
            </td>
            <td width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="48%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Property,
                plant and equipment</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,864,981</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,864,981</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="left" valign="bottom" width="48%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Goodwill</font></div>
            </td>
            <td width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">53,280,689</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">53,280,689</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="48%" style="border-bottom: white solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
                intangible assets</font></div>
            </td>
            <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">167,714,239</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">167,714,239</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="left" valign="bottom" width="48%" style="border-bottom: #ccffcc solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Total
                non-current assets</strong></font></div>
            </td>
            <td width="2%" style="border-bottom: #ccffcc thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">224,849,909</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">224,849,909</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="48%" style="border-bottom: white;">&#160;</td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="left" valign="bottom" width="48%" style="border-bottom: #ccffcc solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Total
                assets</strong></font></div>
            </td>
            <td width="2%" style="border-bottom: #ccffcc thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">254,286,510</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">28,924,640</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">283,211,150</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="48%" style="border-bottom: white;">&#160;</td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="left" valign="bottom" width="48%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Current
                liabilities</strong></font></div>
            </td>
            <td width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="48%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Trade
                and other payables</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">10,978,448</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">10,978,448</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="left" valign="bottom" width="48%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Borrowings</font></div>
            </td>
            <td width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6,848,377</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6,848,377</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="48%" style="border-bottom: white solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Provisions</font></div>
            </td>
            <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">735,929</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">735,929</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="left" valign="bottom" width="48%" style="border-bottom: #ccffcc solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Total
                current liabilities</strong></font></div>
            </td>
            <td width="2%" style="border-bottom: #ccffcc thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">18,562,754</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">18,562,754</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="48%" style="border-bottom: white;">&#160;</td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="left" valign="bottom" width="48%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Non-current
                liabilities</strong></font></div>
            </td>
            <td width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="48%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Borrowings</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">11,443,535</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">11,443,535</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="left" valign="bottom" width="48%" style="border-bottom: #ccffcc solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Deferred
                tax liabilities</font></div>
            </td>
            <td width="2%" style="border-bottom: #ccffcc thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">35,049,999</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">35,049,999</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="48%" style="border-bottom: white solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Total
                non-current liabilities</strong></font></div>
            </td>
            <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">46,493,534</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">46,493,534</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="left" valign="bottom" width="48%" style="border-bottom: #ccffcc;">&#160;</td>
            <td width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="48%" style="border-bottom: white solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Total
                liabilities</strong></font></div>
            </td>
            <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">65,056,288</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">65,056,288</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="left" valign="bottom" width="48%" style="border-bottom: #ccffcc;">&#160;</td>
            <td width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="48%" style="border-bottom: white solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Net
                assets</strong></font></div>
            </td>
            <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">189,230,222</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: black double;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">28,924,640</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: black double;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">218,154,862</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="left" valign="bottom" width="48%" style="border-bottom: #ccffcc;">&#160;</td>
            <td width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="48%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Equity</strong></font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="left" valign="bottom" width="48%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Issued
                capital</font></div>
            </td>
            <td width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">224,897,860</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">28,924,640</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">253,822,500</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="48%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Reserves</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,797,322</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,797,322</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="left" valign="bottom" width="48%" style="border-bottom: #ccffcc solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accumulated
                losses</font></div>
            </td>
            <td width="2%" style="border-bottom: #ccffcc thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(39,464,960</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(39,464,960</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="48%" style="border-bottom: white;">&#160;</td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="left" valign="bottom" width="48%" style="border-bottom: #ccffcc solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Total
                equity</strong></font></div>
            </td>
            <td width="2%" style="border-bottom: #ccffcc thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">189,230,222</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: black double;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">28,924,640</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: black double;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
            <td align="right" valign="bottom" width="14%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">218,154,802</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Notes:</em></font></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 45pt;">&#160;</td>
            <td style="width: 18pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Extracted
                from the half year financial statements of pSivida Limited for the
                6
                months ended 31 December 2005 that were prepared in accordance with
                Australian equivalent to International Financial Reporting Standards
                (A-IFRS) and&#160;filed with ASX on 16 March
                2006.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 45pt;">&#160;</td>
            <td style="width: 18pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">387,048,696
                Shares currently on issue. On a fully subscribed Rights Issue of
                1 for 8,
                an additional 48,381,087 Shares may be issued pursuant to the Rights
                Issue. On the assumption all such Shares are issued at a price of
                A$0.60,
                net proceeds on issue will amount to A$28,924,640 (note this excludes
                the
                effect of vested options which may be exercised prior to the Record
                Date
                and any new shares which the Convertible Noteholder may subscribe
                for
                under the terms of the Convertible Note (as set out in
                section&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.3</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">16</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 45pt;">&#160;</td>
            <td style="width: 18pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Issue
                expenses recognised in the unaudited Pro Forma Balance Sheet at 31
                December 2005 are:</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="MARGIN-LEFT: 81pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="50%">

          <tr bgcolor="white">
            <td align="left" valign="bottom" width="75%" style="border-bottom: white;">&#160;</td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="right" colspan="2" valign="bottom" width="22%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A$</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="left" valign="bottom" width="75%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ASIC
                lodgement fees</font></div>
            </td>
            <td width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="21%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,010</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="75%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ASX
                fees</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="21%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">12,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="left" valign="bottom" width="75%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Printing
                &amp; Postage</font></div>
            </td>
            <td width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="21%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">10,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="75%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Legal
                fees</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="21%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">60,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="left" valign="bottom" width="75%" style="border-bottom: #ccffcc solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Miscellaneous</font></div>
            </td>
            <td width="2%" style="border-bottom: #ccffcc thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="21%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">20,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="75%" style="border-bottom: white solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">TOTAL</font></div>
            </td>
            <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="21%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">104,010</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Placement
      fees that may be payable under the Rights Issue</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">are
      not
      included in the above table</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td align="left" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>RISK
                FACTORS</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There
      are
      a number of factors, both specific to pSivida and of a general nature, which
      may
      affect the future operating and financial performance of the pSivida and the
      value of an investment in pSivida.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Some
      of
      these factors can be mitigated by the use of safeguards and appropriate
      commercial action. However, many are outside the control of pSivida and cannot
      be mitigated.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      section describes certain risks associated with an investment in
      pSivida.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>The
      following risk factors, in addition to the other information and financial
      data
      contained herein, should be considered carefully in evaluating pSivida and
      its
      business.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Risks
      related to pSivida and its business</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>pSivida's
      products and planned products are based upon new and unproven
      technologies</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>.</em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      is a new
      and unproven technology. The successful development and market acceptance of
      BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      is
      subject to many risks. These risks include the potential for ineffectiveness,
      lack of safety, unreliability, failure to receive necessary regulatory
      clearances or approvals and the emergence of superior or equivalent products,
      as
      well as the effect of changes in future general economic conditions. If pSivida
      fails to develop products based on BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      that
      overcome these risks, this would have a material adverse effect on pSivida's
      business, financial condition and results of operations.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      recently acquired CDS, (now renamed pSivida Inc) which develops drug delivery
      products based upon its proprietary AEON and CODRUG drug delivery systems.
      The
      full application of pSivida's products has not yet been determined and they
      remain subject to many of the same risks as described above for
      BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>pSivida
      has a history of losses and expects to continue to incur
      losses</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      was formed in 2000. As pSivida is primarily a research and development company,
      it has incurred operating losses in every year since it was formed. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      has not yet achieved profitability and expects to continue to incur net losses
      through to at least 2008, and may incur losses beyond that time, particularly
      if
      it is not successful in having BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      approved
      and widely marketed by that time. Even if BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      is
      approved and is being marketed at some point in 2008 or beyond, pSivida may
      not
      achieve sufficient sales of BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      or any
      other product to become profitable at that time or at any other time. The extent
      of future losses and whether or how long it may take for pSivida to achieve
      profitability are uncertain. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">17</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
      account of pSivida's recent acquisition of CDS (now pSivida Inc), pSivida
      expects to receive royalties from sales of Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      but is
      not able to predict the amount or timing of such royalties. pSivida also expects
      to receive royalties from sales of Vitrasert</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>&#174;</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      its
      first commercial product. However, such sales have declined in each of the
      past
      four years and pSivida does not expect that they will comprise a significant
      portion of its future revenue. CDS has incurred net losses in each of its last
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">five</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      fiscal
      years ended 31 December. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>pSivida
      relies heavily upon patents, trade secrets and other proprietary technologies
      and any future claims that its rights to such intellectual property are invalid
      could seriously harm pSivida's business.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Protection
      of intellectual property rights is crucial to pSivida's business, since that
      is
      how pSivida keeps others from copying the innovations which are central to
      its
      existing and future products. pSivida's success is dependent on whether it
      can
      obtain patents, defend existing patents and operate without infringing on the
      proprietary rights of third parties. pSivida intends to aggressively patent
      and
      protect its proprietary technologies. However, pSivida cannot be sure that
      any
      additional patents will be issued to it as a result of pending or future patent
      applications or that any of its patents will withstand challenges by others.
      If
      pSivida were found to be infringing any third party patent, it could be required
      to pay damages, alter its products or processes, obtain licenses or cease
      certain operations. pSivida may not be able to obtain any required licenses
      on
      commercially favorable terms, if at all. If pSivida fails to obtain a license
      for any technology that it may require to commercialize BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      or its
      other drug delivery products, this could have a material adverse effect on
      pSivida's business, financial condition and results of operations. In addition,
      many of the laws of foreign countries in which pSivida intends to operate may
      treat the protection of proprietary rights differently from, and may not protect
      proprietary rights to the same extent as laws in Australia, the United States
      and Patent Co-operation Treaty countries.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      relies, in part, on confidentiality agreements with employees, advisors, vendors
      and consultants to protect its proprietary expertise. These agreements may
      be
      breached and there is a risk that pSivida may not have adequate remedies in
      the
      event of a breach. In addition, pSivida's un-patented proprietary technological
      expertise may otherwise become known or independently discovered by
      competitors.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>pSivida
      has a limited ability to market its products, and if it is unable to find
      marketing partners, or marketing partners do not successfully market its
      products then pSivida's business will suffer.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      presently has no marketing or sales staff. Achieving acceptance for the use
      of
      BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      and
      other products (including drug delivery products originated by CDS) will require
      extensive and substantial efforts by experienced personnel as well as
      expenditure of significant funds. pSivida may not be able to establish
      sufficient capabilities necessary to achieve market penetration.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">18</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      intends to license and/or sell BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      and
      other products to companies who will be responsible in large part for sales,
      marketing and distribution of products utilizing BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      and
      pSivida's other products. The amount and timing of resources which may be
      devoted to the performance of their contractual responsibilities by these
      licensees are not expected to be within pSivida's control. These partners may
      not perform their obligations. pSivida also may not derive any revenue from
      such
      arrangements from royalties, license or option fees, milestone payments or
      otherwise.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B&amp;L
      is responsible for funding and managing the development and commercialization
      of
      all products under its agreement with pSivida Inc and can terminate the
      agreement at any time upon 90 days&#8217; written notice. B&amp;L may decide not to
      continue with or commercialize any or all of the licensed products, change
      strategic focus, pursue alternative technologies, develop competing products
      or
      terminate their agreements with pSivida Inc. While B&amp;L has significant
      experience in the ophthalmic field and substantial resources, there is no
      assurance as to whether and the extent to which that experience and those
      resources will be devoted to pSivida Inc.&#8217;s technologies.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Alimera
      and pSivida Inc are jointly funding the development of products licensed under
      the Alimera Agreement, and Alimera may terminate its agreement with pSivida
      Inc
      if pSivida Inc fails to make a development payment or may terminate the
      agreement with respect to a particular product if Alimera abandons the product
      or upon 30 days&#8217; notice following pSivida&#8217;s failure to make development payments
      exceeding US$2 million for that product. To date pSivida has chosen not to
      make
      development payments to Alimera in an aggregate amount of US $1.1 million.
      Alimera was only incorporated in June 2003 and has limited resources.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      we do
      not currently have sufficient funding or internal capabilities to develop and
      commercialize these products and proposed products, decisions, actions, breach
      or termination of these agreements by B&amp;L or Alimera could delay or stop the
      development or commercialization of Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      for DME
      or other of our products licensed to such entities. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
      the
      extent that pSivida chooses not to or are unable to enter into future license
      agreements with marketing and sales partners, pSivida may experience increased
      capital requirements to develop the ability to market and sell future products.
      There is a risk that pSivida may not be able to market or sell its technology
      or
      future products independently in the absence of such agreements.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>pSivida's
      markets are competitive and competitors could develop more effective products,
      making pSivida's products less competitive, uneconomical or obsolete, thereby
      impacting future operations.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida's
      competitors include many major pharmaceutical companies and other biotechnology,
      drug delivery, diagnostics and medical products companies. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Many
      of
      pSivida's potential competitors have substantially greater financial,
      technological, research and development, marketing and personnel resources.
      These competitors may succeed in developing alternate technologies and products
      that are more effective, easier to use, more economical than those which pSivida
      has developed or that would render pSivida's technologies and products obsolete
      and non-competitive in these fields. These competitors may also have greater
      experience in developing products, conducting clinical trials, obtaining
      regulatory approvals or clearances and manufacturing and marketing such products
      or technologies.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">19</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Risks
      associated with international business operations could affect pSivida's ability
      to manufacture and sell its products.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      currently maintains offices in Australia, Singapore, the UK and (following
      the
      acquisition of CDS) the U.S. BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      is
      produced for pSivida in Germany and the UK. pSivida has research and development
      facilities in the UK and the U.S. and is conducting product trials in Singapore.
      Further, pSivida intends to license and/or sell products based on its
      technologies in most major world healthcare markets. A number of risks are
      inherent in this international strategy. In order for pSivida to license and
      manufacture products based on its technologies, it must obtain country-specific
      regulatory approvals or clearances or comply with regulations regarding safety
      and quality in a variety of jurisdictions. There is a risk that pSivida may
      not
      be able to obtain or maintain regulatory approvals or clearances in such
      countries and pSivida may be required to incur significant costs in obtaining
      or
      maintaining foreign regulatory approvals or clearances. In addition, pSivida's
      operations and revenues are subject to a number of risks associated with foreign
      commerce, including the following:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">managing
                foreign distributors;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">staffing
                and managing foreign operations;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">political
                and economic instability;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">foreign
                currency exchange fluctuations;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">foreign
                tax laws, tariffs and freight rates and
                charges;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">timing
                and availability of export
                licenses;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">inadequate
                protection of intellectual property rights in some countries;
                and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">obtaining
                required governmental approvals.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>There
      are risks relating to product manufacturing which could cause delays in product
      development and commercialization and impact future
      profitability.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida's
      ability to conduct timely preclinical and clinical research and development
      programs, obtain regulatory approval, commercialize its product candidates
      and
      fulfill contract manufacturing obligations to others will depend, in part,
      upon
      pSivida's ability to manufacture its products, either directly or through third
      parties, in accordance with U.S. Food and Drug Administration, or FDA, and
      other
      regulatory requirements. pSivida currently has BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      production capability at its facilities in the UK, which may be augmented where
      required by QinetiQ&#8217;s UK production facilities</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">for
      use
      in internal and collaborative research. pSivida's lead BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      product,
      BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      is
      currently manufactured under contract in accordance with applicable FDA
      regulations by Hosokawa Micron Group, Atomising Systems Ltd, HighForce Ltd
      and
      AEA Technology QSA GmbH.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">20</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      pSivida is unable to manufacture BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      or
      BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      or other
      product candidates by itself or acquire BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      from
      QinetiQ or acquire BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      or
      BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      or other
      product candidates from third parties, pSivida would be unable to proceed with
      or could experience delays in development and commercialization of its proposed
      products. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      has limited manufacturing experience and has exclusively licensed</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>&#160;</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B&amp;L
      the rights to manufacture Vitrasert</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>&#174;</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      and
      other products covered by the license agreement between pSivida Inc and Alimera,
      the rights to manufacture Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      for DME,
      if approved for marketing, and other products covered by its license agreement
      with pSivida Inc. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida's</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      current
      reliance on third party manufacturers for some of its products entails risks,
      including:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                possibility that third parties may not comply with the FDA&#8217;s</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                and comparable state and foreign regulatory agencies</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                current good manufacturing practices, regulations, other regulatory
                requirements, and those of similar foreign regulatory bodies, and
                employ
                adequate quality assurance
                practices;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">supply
                disruption, deterioration in product quality or breach of a manufacturing
                or license agreement by the third party because of factors beyond
                pSivida
                Inc.&#8217;s control; </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                possible termination or non-renewal of a manufacturing or licensing
                agreement with a third party at a time that is costly or inconvenient
                to
                pSivida Inc; and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">inability
                to identify or qualify an alternative manufacturer in a timely manner,
                even if contractually permitted to do
                so.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>pSivida's
      ability to commercialize its products depends on its ability to achieve
      regulatory approvals.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida's
      current and future activities are and will be subject to regulation by
      governmental authorities in the U.S., Europe, Singapore and other countries.
      To
      clinically test, produce and market medical products for human use, pSivida
      and
      those that license the use of BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      must
      satisfy mandatory procedural, safety and efficacy requirements established
      by
      the FDA and comparable state and foreign regulatory agencies. Typically, such
      rules require that products be approved by the government agency as safe and
      effective for their intended use prior to being marketed. The approval process
      is expensive, time consuming and subject to unanticipated delays. At present
      Vitrasert</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>&#174;</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      and
      Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      are
      pSivida's only products that have been approved for sale in the U.S. There
      is a
      risk that BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      and
      other product candidates utilizing BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      may not
      be approved.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Before
      pSivida can obtain approval from the FDA and other foreign regulatory
      authorities to manufacture and sell its proposed products, pre-clinical studies
      and clinical trials must demonstrate that each of these products is safe for
      human use and effective for its targeted disease. As outlined herein, pSivida's
      proposed products are in various stages of pre-clinical and clinical testing.
      If
      clinical trials for any of these products are not successful, that product
      cannot be manufactured and sold and will not generate revenue from sales.
      Clinical trials for pSivida's product candidates may fail or be delayed by
      many
      factors, including the following: </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">inability
                to attract clinical investigators for trials;
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">21</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">inability
                to recruit patients in sufficient numbers or at the expected
                rate;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">adverse
                side effects; </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">failure
                of the trials to demonstrate a product&#8217;s safety or
                efficacy;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">failure
                to meet FDA </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">and
                comparable state and foreign regulatory agencies</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                requirements for clinical trial design or for demonstrating efficacy
                for a
                particular product; </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">inability
                to follow patients adequately after treatment;
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">changes
                in the design or manufacture of a product;
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">inability
                to manufacture sufficient quantities of materials for use in clinical
                trials; and </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">governmental
                or regulatory delays. </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Results
      from pre-clinical testing and early clinical trials often do not accurately
      predict results of later clinical trials. Data obtained from pre-clinical and
      clinical activities are susceptible to varying interpretations which may delay,
      limit or prevent regulatory approval. Data from pre-clinical studies, early
      clinical trials and interim periods in multi-year trials are preliminary and
      may
      change, and final data from pivotal trials for such products may differ
      significantly. Adverse side effects may develop that delay, limit or prevent
      the
      regulatory approval of products, or cause their regulatory approvals to be
      limited or even rescinded. Additional trials necessary for approval may not
      be
      undertaken or may ultimately fail to establish the safety and efficacy of
      proposed products. The FDA and comparable state and foreign regulatory agencies
      may not approve proposed products for manufacture and sale.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      addition to testing, the FDA and comparable state and foreign regulatory
      agencies imposes various requirements on manufacturers and sellers of products
      under its jurisdiction, such as labeling, manufacturing practices, record
      keeping and reporting requirements. The FDA and comparable state and foreign
      regulatory agencies may also require post-marketing testing and surveillance
      programs to monitor a product's effects. Furthermore, changes in existing
      regulations or the adoption of new regulations could prevent pSivida from
      obtaining, or affect the timing of, future regulatory approvals.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>pSivida's
      proposed products will be subject to the uncertainty of third-party
      reimbursement and health care reform measures which may limit market
      acceptance.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      both
      US and other markets, pSivida's ability to commercialize its products will
      depend, in part, upon the availability of reimbursement from third-party payers,
      such as government health administration authorities, private health insurers
      and other organizations. Third-party payers are increasingly challenging the
      price and cost-effectiveness of medical products. If pSivida's products are
      not
      considered cost-effective, third-party payers may limit reimbursement.
      Government and other third-party payers are increasingly attempting to contain
      healthcare costs by limiting both coverage and the level of reimbursement for
      new therapeutic products approved for marketing by the FDA and comparable state
      and foreign regulatory agencies and by refusing, in some cases, to provide
      any
      coverage for uses of approved products for disease indications for which the
      FDA
      and comparable state and foreign regulatory agencies has not granted marketing
      approval. If government and third-party payers do not provide adequate coverage
      and reimbursement levels for uses of pSivida products, there is a risk that
      market acceptance of pSivida's products would be limited.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">22</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>The
      loss of some or all of pSivida's key personnel could harm its
      business.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is dependent upon the principal members of its management and scientific staff.
      In addition, pSivida believes that its future success in developing products
      based on its technologies and achieving a competitive position will depend
      to a
      large extent on whether it can attract and retain additional qualified
      management and scientific personnel. There is strong competition for such
      personnel within the industry in which pSivida operates and there is a risk
      that
      pSivida may not be able to continue to attract such personnel either to Malvern
      in the United Kingdom or Watertown, Boston in the U.S., the locations where
      its
      research and development is conducted. As pSivida does not have large numbers
      of
      employees and our products are unique and highly specialized, the loss of the
      services of one or more of the senior management or scientific staff, or the
      inability to attract and retain additional personnel and develop expertise
      as
      needed, could have a material adverse effect on pSivida's operations and
      financial condition.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>pSivida
      may be subject to product liability suits, and may not have sufficient insurance
      to cover damages.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      testing, manufacturing, and future marketing and sale of the products utilizing
      BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      and
      pSivida's other products involves risks that product liability claims may be
      asserted against pSivida or its licensees. There is a risk that pSivida's
      current clinical trial insurance may not be adequate or continue to be
      available, and pSivida may be unable to obtain adequate product liability
      insurance on reasonable commercial terms, if at all. In the event clinical
      trial
      insurance is not adequate, pSivida's ability to continue with planned research
      and development in the relevant area could be negatively impacted.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
      litigation risks to pSivida may include, without limitation, customer claims,
      personal injury claims and employee claims.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>pSivida
      will need additional capital to conduct its operations and develop its products,
      and pSivida's ability to obtain the necessary funding is uncertain.
</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      expects to require substantial additional capital resources in order to conduct
      its operations and develop its products. The timing and degree of any future
      capital requirements will depend on many factors, including:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                accuracy of the assumption underlying pSivida's estimates for its
                capital
                needs in the near and long term;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">continued
                scientific progress in pSivida's research and development
                programs;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                magnitude and scope of pSivida's research and development
                programs;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida's
                ability to maintain and establish strategic arrangements for research,
                development, clinical testing, manufacturing and
                marketing;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida's
                progress with preclinical and clinical
                trials;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">23</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                time and costs involved in obtaining regulatory approvals;
                and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
            </td>
            <td align="left" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                costs involved in preparing, filing, prosecuting, maintaining, defending
                and enforcing patent claims.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      and
      when it is required, pSivida will attempt to acquire additional funding through
      strategic collaborations, public or private equity financings, capital lease
      transactions or other financing sources that may be available. Additional
      financing may not be available on acceptable terms, or at all. Additional equity
      financings could result in significant dilution to stockholders. Further, in
      the
      event that additional funds are obtained through arrangements with collaborative
      partners, these arrangements may require pSivida to relinquish rights to some
      of
      its technologies, product candidates or products that it would otherwise seek
      to
      develop and commercialize. If sufficient capital is not available, pSivida
      may
      be required to delay, reduce the scope of or eliminate one or more of its
      research or development programs, each of which could have a material adverse
      effect on pSivida's business.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>pSivida
      has experienced rapid growth and changes in its business, and any failure to
      manage this and any future growth and changes could harm pSivida's
      business.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      evidenced by pSivida's recent acquisition of CDS on 30&#160;December 2005 and
      potential spin-off of AION </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Diagnostics</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      and the
      incorporation of pSiNutria Limited</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      pSivida's business is rapidly changing. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      expects to continue increasing the number of its employees, and pSivida may
      suffer if it does not manage and train its new employees effectively. Further,
      pSivida's efforts span various geographies. Continued rapid growth and operation
      in multiple locations may place significant strains on pSivida's managerial,
      financial and other resources. There is a risk that the rate of any future
      expansion, in combination with pSivida's complex technologies and products,
      may
      demand a level of managerial effectiveness in anticipating, planning,
      coordinating and meeting pSivida's operational needs which pSivida's management
      may not be able to provide.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>If
      pSivida fails </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>to
      comply with environmental laws and regulations, its ability to manufacture
      and
      commercialize products may be adversely affected.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Medical
      and biopharmaceutical research and development involves the controlled use
      of
      hazardous materials, such as radioactive compounds and chemical solvents.
      pSivida are subject to federal, state and local laws and regulations in the
      U.S.
      and abroad governing the use, manufacture, storage, handling and disposal of
      such materials and waste products. pSivida could be subject to both criminal
      liability and civil damages in the event of an improper or unauthorized release
      of, or exposure of individuals to, hazardous materials. In addition, claimants
      may sue pSivida for injury or contamination that results from its use or the
      use
      by third parties of these materials, and pSivida's liability may exceed its
      total assets. Compliance with environmental laws and regulations is expensive,
      and current or future environmental regulations may impair pSivida's research,
      development or production efforts or harm its operating results.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">24</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Changes
      in accounting standards may have an adverse effect on pSivida's future financial
      results</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accounting
      standards and policies have recently changed with the introduction of A-IFRS,
      which apply to periods beginning on or after 1&#160;January&#160;2005. Such
      changes may have an adverse impact on future reported financial results (refer
      to section&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.4</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      above).
      The adoption of A-IFRS was first reflected in pSivida's financial statements
      for
      the half-year ended 31&#160;December&#160;2005. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>pSivida's
      business may be subject to contingent liabilities</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      any
      contingent liabilities arise in the future, they may have an adverse effect
      on
      pSivida's business and prospects.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Risks
      related to Shares</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>The
      fact that pSivida does not expect to pay cash dividends may lead to decreased
      prices for Shares.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      has never paid a cash dividend on its Shares and does not anticipate paying
      any
      cash dividend as its future profitability is uncertain. pSivida intends to
      retain future cash earnings, if any, for reinvestment in the development and
      expansion of its business. pSivida's Convertible Note agreement limits pSivida&#8217;s
      ability to pay dividends.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>pSivida's
      Share price may be volatile</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      stock
      market price of Shares has seen significant volatility in the past 12 months.
      There is a risk that the market price of Shares will fluctuate in the future.
      Announcements by pSivida and others of scientific discoveries, technological
      innovation, commercial products and negotiations with third parties, patents
      or
      regulatory actions may have a significant effect on the market price of Shares.
      Further, the sale of a substantial number of Shares could depress the market
      price or, alternatively, the purchase of a substantial number of Shares could
      increase the market price. This volatility may result in shareholders receiving
      a market price for their Shares that is less or more than the Rights
      Issue</font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">price.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>The
      market for pSivida's Shares may be illiquid</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      cannot guarantee that an active market in Shares (or ADSs) will continue. There
      may be relatively few, or many potential buyers or sellers of Shares on ASX
      at
      any given time. This may increase the volatility of the market price of Shares.
      It may also affect the prevailing market price at which shareholders are able
      to
      sell their Shares.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Risks
      related to pSivida's recent acquisition of</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>CDS</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
      and</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
      other recent transactions</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>pSivida
      may fail to integrate its operations successfully with the operations of CDS.
      As
      a result, pSivida and CDS may not achieve the anticipated benefits of the
      merger, which could adversely affect the price of Shares.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">25</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      entered into the merger agreement and consummated the merger with the
      expectation that the merger will result in benefits to the combined companies,
      including the opportunities to combine the two companies&#8217; technologies, products
      and product candidates and the opportunity for pSivida to establish a
      substantial presence in the U.S. facilitating access to U.S. markets. However,
      these expected benefits may not be fully realized. Failure of the combined
      company to meet the challenges involved with successfully integrating the
      personnel, products, technology and research and development operations of
      the
      two companies following the merger or to realize any of the other anticipated
      benefits of the merger, could have a material adverse effect on pSivida's
      business, financial condition and results of operations as well as on that
      of
      pSivida's subsidiaries, including CDS (now pSivida Inc). These integration
      efforts may be difficult and time consuming, especially considering the highly
      technical and complex nature of each company&#8217;s products. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>pSivida's
      operating results could be adversely affected as a result of purchase accounting
      treatment, and the corresponding impact of amortization or impairment of other
      intangibles relating to the merger, if the results of the combined company
      do
      not offset these additional expenses</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under
      A-IFRS, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      will
      account for the merger using the purchase method of accounting. Under purchase
      accounting, pSivida will record the market value of its ADSs, cash, and other
      consideration issued in connection with the merger and the amount of direct
      transaction costs as the cost of acquiring the business of CDS. pSivida will
      allocate that cost to the individual assets acquired and liabilities assumed,
      including identifiable intangible assets, based on their respective fair values.
      Intangible assets generally will be amortized over a </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12
      year
      period on a straight line basis. Based on pSivida's preliminary allocation
      of
      the</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      purchase
      price</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      which
      is subject to change based on the actual outcome of an independent valuation,
      the amount</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      allocated to goodwill </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">is
      expected to</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      be
      approximately A$</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">33.7</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      million,
      the amount allocated to identifiable intangible assets </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">is
      expected to</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      be
      approximately A$120.0&#160;million, giving rise to a gross deferred tax
      liability of approximately A$</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">48.0</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      million
      (approximately A$29.1 million net of deferred tax assets), and approximately
      A$2.7 million </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">is
      expected to</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      be
      allocated to in-process research and development. Goodwill is not subject to
      amortization but is subject to at least an annual impairment analysis, which
      may
      result in an impairment charge if the carrying value exceeds its implied fair
      value. If identifiable intangible assets were amortized in equal quarterly
      amounts over a </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">year
      period following completion of the merger, the amortization attributable to
      these items would be approximately A$2.5 million per quarter and A$10.0 million
      per fiscal year</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strike>.</strike></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      subject
      to the identifiable intangible assets having lead to the commencement of the
      commercial production of products.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      As a
      result, purchase accounting treatment of the merger could increase pSivida's
      net
      loss or decrease its net income in the foreseeable future, which could have
      a
      material and adverse effect on the future market value of its
      Shares.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Under
      certain circumstances, pSivida may have to repay all or part of the funds
      received in the Convertible Note financing in cash.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
      16&#160;November 2005, pSivida issued the Convertible Note in the principal
      amount of US$15 million (A$19.7 million) to an institutional investor (as set
      out in section&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.3</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
      The
      Convertible Note must be repaid in full in cash on the third anniversary of
      their issuance, unless the principal is earlier converted. In addition, the
      Convertible Noteholder may require payment in cash of up to one-third of the
      principal on each of 16 November 2006, 16 May 2007 and 16 November 2007 in
      the
      event that the average trading price of ADSs does not exceed the then effective
      conversion price over the ten trading days leading up to any of those dates.
      The
      Convertible Note is currently convertible at a conversion price of US$7.10
      per
      ADS, subject to adjustment based on certain events or circumstances, including
      the market price of ADSs for the ten trading days ending on 5 August 2006.
      pSivida may make quarterly interest payments on the note by issuing ADSs if
      certain conditions are met including the effectiveness of a registration
      statement covering the ADSs, continued listing of pSivida's shares or ADSs,
      and
      timely delivery of conversion ADSs during the period preceding the payment
      date,
      among others. If any of the conditions are not met, pSivida will be required
      to
      pay the interest due in cash. Given the cash needs of pSivida's business and
      its
      current level of revenue, pSivida cannot predict whether or not it will be
      able
      to meet any of these cash payment obligations or what impact these obligations
      might have on its business and operations.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">26</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>General
      equity market risks</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There
      are
      risks associated with any investment in a company listed on ASX. The value
      of
      Shares may rise above or below the Rights Issue</font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Price
      for
      the Shares, depending on the financial and operating performance of pSivida
      and
      external factors over which pSivida and its Directors have no control. These
      external factors include:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">economic
                conditions in Australia and overseas which may have a negative impact
                on
                equity capital markets;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">changing
                investor sentiment in the local and international stock markets
                specifically relating to the biotechnology
                sector;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">changes
                in domestic or international fiscal, monetary, regulatory and other
                government policies;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">changes
                in business confidence and consumer sentiment in Australia and
                overseas;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">interest
                rate changes and inflation changes in Australia and overseas;
                and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">developments
                and general conditions in the biotechnology markets in which pSivida
                proposes to operate and which may impact on the future value and
                pricing
                of shares in biotechnology
                companies.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Forward-Looking
      Statements</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      statements contained herein discuss our future expectations and may include
      other forward-looking information within the meaning of Section 27A of the
      U.S.
      Securities Act. Our actual results may differ materially from those expressed
      in
      forward-looking statements made herein. Forward-looking statements that express
      our beliefs, plans, objectives, assumptions or future events or performance
      may
      involve estimates, assumptions, risks and uncertainties. Therefore, our actual
      results and performance may differ materially from those expressed in the
      forward-looking statements. Forward-looking statements often, although not
      always, include words or phrases such as the following: &#8220;will likely result,&#8221;
&#8220;are expected to,&#8221; &#8220;will continue,&#8221; &#8220;is anticipated,&#8221; &#8220;estimate,&#8221; &#8220;intends,&#8221;
&#8220;plans,&#8221; &#8220;projection&#8221; and &#8220;outlook.&#8221;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">27</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">You
      should not unduly rely on forward-looking statements contained herein. Various
      factors discussed herein, including, but not limited to, all the risks discussed
      in &#8220;Risk Factors&#8221; may cause actual results or outcomes to differ materially from
      those expressed in forward-looking statements. You should read and interpret
      any
      forward-looking statements together with these risks.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td align="left" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ADDITIONAL
                INFORMATION</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>New
                Shares</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      new
      shares issued in the Rights Issue will rank equally in all respects with
      pSivida's existing fully paid ordinary shares (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Shares</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
      from
      their date of issue.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      rights attaching to Shares are set out in pSivida's constitution, and, in
      certain circumstances, are regulated by the Corporations Act, the ASX Listing
      Rules, the ASTC Settlement Rules and general law. pSivida's constitution may
      be
      inspected during normal business hours at the registered office of pSivida
      at
      Level 12 BGC Centre, 28 The Esplanade, Perth WA 6000, Australia.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      following is a summary of the principal rights of the holders of Shares. This
      summary is not exhaustive nor does it constitute a definitive statement of
      the
      rights and liabilities of pSivida's members.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>General
                meeting and notices</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each
      member is entitled to receive notice of, and to attend and vote at, general
      meetings of pSivida and to receive all notices, accounts and other documents
      required to be sent to members under pSivida's constitution, the Corporations
      Act or the ASX Listing Rules.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Voting
                rights</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subject
      to any rights or restrictions for the time being attached to any class or
      classes of shares, at a general meeting of pSivida every holder of Shares
      present in person or by an attorney, representative or proxy has one vote on
      a
      show of hands (unless a member has appointed 2 proxies) and one vote per Share
      on a poll.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
      person
      who holds a share, which is not fully paid, is entitled, on a poll, to a
      fraction of a vote equal to the proportion which the amount paid bears to the
      total issue price of the share.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Where
      there are 2 or more joint holders of a Share and more than one of them is
      present at a meeting and tenders a vote in respect of the Share, pSivida will
      count only the vote cast by the member whose name appears first in pSivida's
      register of members.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">28</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Issue
                of further Shares</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Directors may, on behalf of pSivida, issue, grant options over, or otherwise
      dispose of unissued shares to any person on the terms, with the rights, and
      at
      the times that the Directors decide. However, the Directors must act in
      accordance with the restrictions imposed by pSivida's constitution, the Listing
      Rules, the Corporations Act and any rights for the time being attached to the
      shares in any special class of those shares.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Variation
                of rights</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At
      present, pSivida has on issue one class of shares only, namely fully paid
      ordinary shares.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Unless
      otherwise provided by pSivida's constitution or by the terms of issue of a
      class
      of shares, the rights attached to the shares in any class may be varied or
      cancelled only with the written consent of the holders of at least 75% of the
      issued shares of the affected class, or by special resolution passed at a
      separate meeting of the holders of the issued shares of the affected
      class.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(e)</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Transfer
                of shares</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subject
      to pSivida's constitution, the Corporations Act and the ASX Listing Rules,
      Shares are freely transferable.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Shares may be transferred by a proper transfer effected in accordance with
      the
      SCH Business Rules, by any other method of transferring or dealing with shares
      introduced by ASX and as otherwise permitted by the Corporations Act or by
      a
      written instrument of transfer in any usual form or in any other form approved
      by either the Directors or ASX that is permitted by the Corporations
      Act.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Directors may decline to register a transfer of Shares (other than a proper
      transfer in accordance with the SCH Business Rules) where permitted to do so
      under the ASX Listing Rules. If the Directors decline to register a transfer,
      pSivida must, within 5 business days after the transfer is delivered to pSivida,
      give the party lodging the transfer written notice of the refusal and the reason
      for refusal. The Directors must decline to register a transfer of Shares when
      required by law, by the ASX Listing Rules or by the ASTC Settlement Rules and
      ASX Market Rules.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(f)</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Partly
                paid shares</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Directors may, subject to compliance with pSivida's constitution, the
      Corporations Act and the ASX Listing Rules, issue partly paid shares upon which
      there are outstanding amounts payable. These shares will have limited rights
      to
      vote and to receive dividends.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(g)</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Dividends</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Directors may from time to time determine dividends to be distributed to members
      according to their rights and interests. The Directors may fix the time for
      distribution and the methods of distribution. Subject to the terms of issue
      of
      shares, pSivida may pay a dividend on one class of shares to the exclusion
      of
      another class.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">29</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each
      share carries the right to participate in the dividend in the same proportion
      that the amount for the time being paid on the share (excluding any amount
      paid
      in advance of calls) bears to the total issue price of the share.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(h)</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Winding
                up</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subject
      to the rights of holders of shares with special rights in a winding-up, if
      pSivida is wound up, members will be entitled to participate in any surplus
      assets of pSivida in proportion to the percentage of the capital paid up on
      their shares when the winding up begins.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Dividend
                reinvestment and share
                plans</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      members of pSivida, in general meeting, may authorise the Directors to implement
      and maintain dividend reinvestment plans (under which any member may elect
      that
      dividends payable by pSivida be reinvested by way of subscription for fully
      paid
      shares in pSivida) and any other share plans (under which any member may elect
      to forego any dividends that may be payable on all or some of the shares held
      by
      that member and to receive instead some other entitlement, including the issue
      of fully paid shares).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.2</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Matters
                relevant to Foreign Shareholders
</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      following matters should be noted by Foreign Shareholders:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">investing
                in securities of an Australian issuer may carry with it a currency
                exchange risk;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                financial reporting requirements applying in any jurisdiction other
                than
                Australia and those applying to pSivida may be different and so pSivida
                financial reports may not be compatible in all respects with financial
                statements prepared in accordance with laws in the other
                jurisdiction;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                may not be subject in all respects to the law in a jurisdiction other
                than
                Australia;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                contract under which the new shares will be issued may not be enforceable
                in the courts in a jurisdiction other than
                Australia;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(e)</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                Rights Issue</font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">has
                not been registered in jurisdiction other than Australia under the
                respective law of that jurisdiction and may not contain all the
                information that a prospectus registered in a jurisdiction other
                than
                Australia is required to contain.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.3</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Share
                price on ASX</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      last
      sale price of Shares on ASX on 1 May 2006 (the date before the announcement
      of
      the Rights Issue) was $0.64. The highest and lowest market sale prices of Shares
      on ASX during the 12 months immediately preceding the date hereof:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 63pt;">
            </td>
            <td align="left" style="width: 81pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Highest
              </strong>- $1.05</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
                on 15 August 2005</font></div>
            </td>
          </tr>

      </table>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 63pt;">&#160;</td>
            <td align="left" style="width: 81pt;">&#160;</td>
            <td align="left">&#160;</td>
          </tr>

      </table>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 63pt;">&#160;</td>
            <td align="left" style="width: 81pt;"><font size="2"><strong>Lowest</strong><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
              -
              $0.55</font></font></td>
            <td align="left"><font size="2">- on 28 November
              2005</font></td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">30</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>The
      30 trading day weighted average closing price after the market close on Monday
      1
      May 2006 was $0.73.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      highest and lowest market sale prices of ADSs on NASDAQ during the 12 months
      immediately preceding the date hereof were:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 63pt;">
            </td>
            <td align="left" style="width: 81pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Highest
              - </strong>US$8.75</font></td>
            <td align="left">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
                on 15 August 2005</font></div>
            </td>
          </tr>

      </table>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 63pt;">&#160;</td>
            <td align="left" style="width: 81pt;">&#160;</td>
            <td align="left">&#160;</td>
          </tr>

      </table>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 63pt;">&#160;</td>
            <td align="left" style="width: 81pt;"><font size="2"><strong>Lowest</strong><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
              -
              US$4.21</font></font></td>
            <td align="left"><font size="2">- on 28 November
              2005</font></td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB2" style="COLOR: black; LETTER-SPACING: 6.3pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.4</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Litigation</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      and its subsidiaries are not involved in any material legal or arbitration
      proceedings, nor, so far as the Directors are aware, are any such proceedings
      pending or threatened against pSivida or its subsidiaries.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.5</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Dividend
                policy</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Directors cannot give any assurance concerning the extent and timing of future
      dividends (if any), as this will depend on the future profitability and
      financial position of pSivida as well as other economic factors. There is no
      current proposal to pay dividends.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.6</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Interests
                of Directors</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
      than as set out below or elsewhere herein, no Director has, or had within 2
      years before the date hereof with ASIC, any interest in:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                promotion or formation of pSivida; </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">property
                acquired or proposed to be acquired by pSivida in connection with
                its
                promotion or formation or the Rights Issue;
                or</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                Rights Issue,</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">and
      no
      amounts have been paid or agreed to be paid and no benefits have been given
      or
      agreed to be given to any Director:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">to
                induce him to become, or to qualify him as, a Director;
                or</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(e)</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">for
                services rendered by him in connection with the formation or promotion
                of
                pSivida or the Rights Issue.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Security
      holdings</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Directors
      are not required under pSivida's constitution to hold any securities in
      pSivida.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      following table sets out certain information regarding the beneficial ownership
      of the Company's securities by each directors as at the date
      hereof:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">31</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div>
      <table cellpadding="0" cellspacing="0" id="ftable" width="100%">

          <tr>
            <td align="left" valign="bottom" width="32%" style="border-bottom: #ffffff solid;">&#160;</td>
            <td width="2%" style="border-bottom: #ffffff solid;">&#160;</td>
            <td align="justify" colspan="5" valign="bottom" width="21%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><strong>Ordinary
                Shares</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
            <td align="justify" colspan="5" valign="bottom" width="21%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><strong>Options</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
            <td align="left" colspan="5" valign="bottom" width="21%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 3.6pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><strong>Options
                in</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 3.6pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><strong>AION
                Diagnostics Inc***</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="32%">&#160;</td>
            <td width="2%">&#160;</td>
            <td align="justify" colspan="2" valign="bottom" width="10%">&#160;</td>
            <td align="left" valign="bottom" width="1%">&#160;</td>
            <td align="justify" colspan="2" valign="bottom" width="10%">&#160;</td>
            <td align="left" valign="bottom" width="1%">&#160;</td>
            <td align="justify" colspan="2" valign="bottom" width="10%">&#160;</td>
            <td align="left" valign="bottom" width="1%">&#160;</td>
            <td align="justify" colspan="2" valign="bottom" width="10%">&#160;</td>
            <td align="left" valign="bottom" width="1%">&#160;</td>
            <td align="justify" colspan="2" valign="bottom" width="10%">&#160;</td>
            <td align="left" valign="bottom" width="1%">&#160;</td>
            <td align="justify" colspan="2" valign="bottom" width="10%">&#160;</td>
            <td align="left" valign="bottom" width="1%">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="32%" style="border-bottom: white solid;">&#160;</td>
            <td width="2%" style="border-bottom: white solid;">&#160;</td>
            <td align="justify" colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><strong>Held
                Directly</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
            <td align="justify" colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><strong>Held
                Indirectly</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
            <td align="justify" colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><strong>Held</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><strong>Directly</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
            <td align="justify" colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><strong>Held
                Indirectly</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
            <td align="justify" colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><strong>Held</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><strong>Directly</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
            <td align="justify" colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><strong>Held
                Indirectly</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="left" valign="bottom" width="32%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">R
                Brimblecombe </font></div>
            </td>
            <td width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">545,067</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,424,111</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="32%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">G
                J
                Rezos </font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,018,630</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">9,300,652</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,371,030</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,800,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">249,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="left" valign="bottom" width="32%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">S
                Lake</font></div>
            </td>
            <td width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">242,061</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="32%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">D
                Mazzo</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">20,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">200,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="left" valign="bottom" width="32%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">M
                Rogers</font></div>
            </td>
            <td width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">200,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="32%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">H
                Zampatti</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">151,271</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">**</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="left" valign="bottom" width="32%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">P
                Ashton </font></div>
            </td>
            <td width="2%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">17,664,080</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,380,700</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #ccffcc;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ccffcc;">&#160;</td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">**
      Ms H.
      Zampatti has a contractual right to receive 200,000 options over our ordinary
      shares, subject to shareholder approval. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">***
      Mr G
      Rezos holds 1,000 shares in AION Diagnostics Inc (being 0.02% percent of the
      total issued capital of that company).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any
      Directors who are Eligible Shareholders will be entitled to participate in
      the
      Rights Issue on the same basis as all other Eligible Shareholders.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Directors'
      fees</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Directors'
      fees not exceeding an aggregate of $280,000 per annum have been approved by
      pSivida in general meeting. The level of these fees can be varied by general
      resolution at a meeting of shareholders in accordance with the Company's
      constitution.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Additional
      services</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each
      Director is entitled to be paid additional remuneration for any extra services
      or special exertions undertaken by that Director for pSivida.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Directors'
      expenses</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      may also pay each Director for travel and other expenses incurred by that
      Director in attending meetings of pSivida, the Board or a committee of the
      Board, in attending to pSivida business and in carrying out duties as a
      Director.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Directors'
      indemnities</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Except
      as
      may be prohibited by the Corporations Act, each Director will be indemnified
      out
      of the property of pSivida against any liability incurred by the Director in
      their capacity as a Director or a director of any related corporation in respect
      of any act or omission whatsoever and howsoever occurring or in defending
      proceedings, whether civil or criminal.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">32</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>GLOSSARY</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      this
      Supplemental Disclosure, the following words have these meanings:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>$,
      A$ </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">or</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
      AU$</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      means
      Australian dollars unless otherwise specified. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ADS
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">means
      an
      American Depositary Share issued in relation to a Share.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ASIC</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      means
      Australian Securities and Investments Commission.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ASTC
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">means</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ASX
      Settlement and Transfer Corporation Pty Limited ABN 49 008 504 532.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ASTC
      Settlement Rules</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      means
      the Settlement Rules of ASTC, which are applicable while pSivida is admitted
      to
      the Official List of ASX.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ASX</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      means
      Australian Stock Exchange Limited ABN 98 008 624 691.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ASX
      Listing Rules </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">means
      the
      Listing Rules of ASX.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Bausch
      &amp; Lomb </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">or
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>B&amp;L
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">means
      Bausch &amp; Lomb Incorporated.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Board</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      means
      the board of Directors.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>CDS
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">means
      Control Delivery Systems, Inc (the predecessor to pSivida, Inc), and where
      the
      context requires, pSivida Inc.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>CMV
      Retinitis </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">means
      Cytomegalovirus Retinitis.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Company</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      or
      pSivida means pSivida Limited ABN 78 009 232 026.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Convertible
      Noteholder</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      means
      Castlerigg Master Investments Ltd.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Convertible
      Note </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">means
      the
      convertible note issued by pSivida on 16&#160;November&#160;2005 under a
      Securities Purchase Agreement dated 5&#160;October&#160;2005.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Corporations
      Act</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      means
      the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Corporations
      Act 2001</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      (Cth).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>CT
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">means
      Computed Topography.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Director
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">means
      a
      director of pSivida.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>DME
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">means
      Diabetic Macular Edema.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>DR
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">means
      Diabetic Retinopathy.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Eligible
      Shareholder</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      means a
      shareholder whose address (as registered on the pSivida share register) is
      in
      Australia or New Zealand, or who is otherwise an eligible to participate in
      the
      Rights Issue.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
      Inc</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      means
      pSivida Inc (successor to CDS).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>QinetiQ</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      means
      QinetiQ Group plc.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">33</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Share</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      means a
      fully paid ordinary share in the capital of pSivida.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Shareholder</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      means a
      registered holder of Shares.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>US$</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      means
      United States dollars.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>U.S.
      Securities Act</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      means
      the U.S. Securities Act of 1933 as amended.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">34</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>graph.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graph.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````6@``_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0(!`0$"`@(!`0("`@("`@("`@,"
M`P,#`P(#`P0$!`0$`P4%!04%!0<'!P<'"`@("`@("`@("`$!`0$"`@(%`P,%
M!P4$!0<("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(
M"`@("`@("`@(_\``$0@!1@'T`P$1``(1`0,1`?_$`:(````&`@,!````````
M``````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+
M$``"`0(%`@,$!@8%!0$#!F\!`@,$$04&(1(`!S%!$PA1(F$4<8$RD0FA(_#!
M0K$5T1;A\5(S%R1B&$,T)8(*&7)3)F.21#6B5+(:<S;"TB=%-T;B\H.3H[-D
M52C#TRDXX_-'2%9E*CDZ24I76%E:9G1UA(5G=G=HAH>4E:2EM+7$Q=35Y.7T
M]9:7IJ>VM\;'UM?FY_;W:6IX>7J(B8J8F9JHJ:JXN;K(R<K8V=KHZ>KX^?H1
M``$#`@,$!P8#!`,&!P<!:0$"`Q$`!"$%$C$&0?!180<3(G&!D:&QP0@RT13A
M(_%"%5()%C-BTG(D@L*2DT,7<X.BLF,E-%/BLS4F1%1D154G"H2T&!D:*"DJ
M-C<X.3I&1TA)2E976%E:969G:&EJ='5V=WAY>H6&AXB)BI25EI>8F9JCI*6F
MIZBIJK6VM[BYNL/$Q<;'R,G*T]35UM?8V=KCY.7FY^CIZO+S]/7V]_CY^O_:
M``P#`0`"$0,1`#\`WD^NWJ"Z.^F;(4O4_KGG:'(&1(:NEH)<PSTU=51BKK&9
M88_+P^&HDNQ4Z[;#Q/%=E8NW"]#8E5![>?>O+\FM?S-XONV@0)@G$[,`"?=1
M-<-_&*_#3Q6OI,-I?5?@B5-=(L<#U&'9AI(`S&P+S5>'QQ1K[6=@!XGAHK=:
M_`G0?:/QJ/K?M_W/=6$B[2">E*TCU)2`/4U8GEG,V7,YY?P?->4,=H\SY8S!
M3QU6!9AH*B*KHJRFF7<DL,T#,CHP[%3;A&XVI*H(@BI:M+MJX:2XTH*0H2"#
M((.P@C:*?.4I17N>KU>YZO4%^9NM'3')W4KIQT@S+FN+"^I'5R/%)>G65V@J
MWEQ./!:=:JM*211-$GE1L&/F.M_"YXH;M7%MJ6!X4Q)Z)V437F\%G;WC5JXN
M'GM6A,'Q:!*N$"!CB1U4*'$]'->YZO5[GJ]2;S'G'*>3UP=\UYDH<N+F+$*/
M"L`^=JH:8UV)XA,*>FI*<2LIDFE=@$C6['V<<;:4K8)C'TI)=W[%N`75!.HA
M(D@2HF`!.TD[!MI2<;I71(^N7XCOHI]-?4"MZ6=;^N]#D#/V'4U+5UF7:C#<
M=J72GK8_-@?S*"AGB.]1>P>X\;<-[/(;NX1K;3*?,?,U&V\W:]N[D]V;:\?#
M;H`,:5G`[/M21[Z?.@_K\]&WJ9QYLJ]$/4'@&>,U`2-#E82U&'XG.L2AW:"D
MQ:*EFF50;DQHP&OL/*7N2W5N)<00.G:/:*6;K]J&[^<N=W9W"%K_`*.*58;2
M$J`)'6!%'`X5T/:]SU>KW/5ZO<]7J]SU>H+<S]:NF&3.I73?H_F;-D6%=2.K
MR8I)TYRNT%6\F)I@M.M56E)(HFB3RHV#'S'6_A<\4-VKBVU+`\*8D]$[*)KW
M>&SM[QJU<7#S^K0F#XM`E7"!`QQ(ZJ%+B>CFO<]7J]SU>KW/5ZO<]7J]SU>K
MW/5ZO<]7J]SU>I-YMSCE/(.`5^:L[YEH<HY:PL*<1Q[$JJ&BI(=[!%#2U#*H
M+,0JB]R2`-3QQMI2U0D2:27U^Q:M%UY00A.TD@`>II2<;I77N>KU>YZO5[GJ
M]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>
MKU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>Y
MZO5[GJ]7N>KU>YZO53K^.+64.'>C++6(XI,E-A>']3.GT^)U,HO''30XQYLK
MN+'W5123IVX*=T$DW9`VZ34`?4DZAO=Y*EX)#S<^TTK<W_B2?A+565LPTV-=
M:<@YQPFHHZA,1RI385_,ZC$86B(:GCI(Z-C,T@]T);6_&6LCS+4(2H'S_6C*
M_P"UG<<,JUNM*3!D:"9ZHTXSLCC1%O3MUMZS?A]_A.4W6H=/FIZ#%NICUG3;
MIIF"FKI*RBZ?YHS)&D,,=.E1321SO"9):96<K=U8A@UN&]]:-7N9]W/\.)']
M(#D&HWW5WBO]U=P_SG=D#OI0A0,AIQP``"003)4G'B#QH^68O6%ZI_39T6ZI
M^H'UC]*LH87@%6^"4_IXZ0Y(KL8Q#--;C&/5$E/38-B]17I\M\RI:(22TR%/
M\H5#6`).C++9]U+;"C..HJ@##B.,>=29<[^9WE&7/7V:LMA)*0RVT5*<*E&`
MA9(TZMDE(C;`.`(99S]7/XFOIVR9_M$^I3TR].Z[T^8<*6JZA9-R;CN-5&?,
MHX34.B2U54<0!H:PTV\&5*>WB;JH+!0WEN7OJ[II:N\X$@:3Y<1/71)?;\[Y
M94R;[,+5DV@@J2VM1=;2=I5/@5IXZ?;$FA[]1WK;SU09LZ$]$/1KD/"NM/7'
MU$8#-FW*^(XW6U&'Y6P')\<2,N,XG)3`3M'*T@6.*.S,01?=M5D5CE*"E3CY
M*4(,&-I/0*%.]O:)<I?8L\I;2_<W*"XDJ)#:&XP6J,2"2``,3CB#`)**[._J
M=QS\3;\/;*'JMZ78#DOJ#E3#NI4]!G;)^(5>(9/S)15V6U&ZB&)JE733TSPE
M)X9P38JZL58<-TLVZ<O>4RHE)TX':,>/#UJ.5YEG3N^.6-9FRAMY`?.ILDMK
M!:_AU0H$$04JZB"0:LBZ.^I//'4+UH>KKTYXSA.%4N2N@6'9'J\H8K30U:8I
M4R9EPV:LJ1622U$D3*C1@1^7$EAWW<(;FP0BT;=$RLJGHPBI=R'>VYNMXKVP
M6$ANW2R4D3J)<"B9QC"!$`=<U#R=ZI,T8KZV/4[Z>LS4>$85TPZ%Y,RKF?#<
MRI%5IB9DQF*:6L^;E>H>$Q1K%=`D2D:W)YIVP2+5#@G4I1'LBMV.^#R]X+FR
M<"0RPTVL'&?%JF3,0(PP%$[REZTOQ%_4EE#&?43Z3O39D*7TUT-1B9R+@^<<
M8QN+.V><.PN9X&J<,3"U^5I3,\+K$D^[WM+MW)LYE5BPKNGEJ[S"8`A,]/$^
ME1U9=H6]N<,F^RNV9_)`JTAQ2@ZZ$X2G2-*9((`5./5C18_7]U=]3_7*H_"X
MZK=-^G.!]-,/S;U&RY4Y,Z?Y_I,QX;F3">J$3XC3"CQB!(H2,'6.,_I(D$SW
M#*-K#AGD-K;,]^A9)(29*8C3'#KH#]KF?9WF1RJYM&T-)6\@I2\%A:7M1$+`
MC]F(&($G:,(K8=R*V=FR5E%NI289%U#;#:$YZCP4U+8.N+_+)\X*$UOZ8TXF
MW>5YGO;;7UX!7M&LZ)TSA.V.$UEEEAN?RR/S&GOM(UZ9TZH\6F<=,S$XQMJI
MWI=@^$8S^-!ZPX,8PJFQ:&'I+D)X8JF"*=4;YRUU$JM8V]G!+<+*<J;@QXC\
MZ@[)[9MWM!O`M(5_D[>T3_1I_P#Q9O3ET_Q;TH9ZZ]Y1P"BR+UT],T<&<^E'
M4[#*6&BQ.AJL%JHJJ2$S4RH[PRQJP,;$KNVM;3C>[E\X+D-J,H7X2#UTM[;]
MTK1>1N7K20W<V@[UM:0`H%!"B)'`@1!PF#PI6]1O7KG*@Z:^D;!>B73BCZG^
MI7U=Y8P_,F4<JXIB`P7`,&PK^24V*XABN+55F9*>`U"HD:>](QVJ;@`M,Y,G
MO'.\.E#9@QB29@`4OS3M/>%G9BS;#MU>H"TI4=*4ITA2EK,&`)``VDX#':T=
M._5[ZJNE76+I-TC]<>1.GM/A77O$9<$Z9=8>FF,XK5X13YB%.]33X7B=#CH-
M3&]4L9$,R,4+V4C4D7N<LMG&U+MRKPB2%`3'2",,.-),DW[SRRO6;7.D,#\P
MHI0XRI12%Q(0I*_$"K^$@Q.%&!]+7J.SSU0ZG^JOH?U>PC"\"ZE^G;-J4N&1
MX5#5TM/BF3,;HTQ'`L2,5;45+^;+'O29E;9O70+VXAS"Q0VVVX@DI6./`C`B
MA9N9O9<WMY=V=T$I>MG(&F0%-J&IM6).)$@P8D<-@`'`OQ%:B@Z7>L_U,9YP
M"BJ_3_T1SC4Y-Z`4>#0U/\^SAB&%R183.3+/4RPR"KQ.=8*8QQ(%569MUN+%
M9)+C;23XU"3.P3C[AB:#+':J465]F#R0;6W<+;02#J<*82<9(.I9TI@#`3C0
M:YA]7/XE72+*N)>H#K+Z?.E==T.P&E&*9TZ398S9BE1U'P+!XU$M3,TU6O\`
M+:R:FC#.\4-BW93H3Q2C++!TAMM:]9PDCPGYB:([G?K?"P;5>W=O;FU2-1;0
MXHO)'$DGP**1)($3P-.W7;.&7NH7XB'X3F?<I8@N+95SME_J5BV6\42X6HH,
M1RG2U<$@!U&Z.0&W*6;2D6-PE6!!2#_IJ5[S7[-UO9D[S1U-K1<*2>D%H$'U
M%/F8/6%ZR.OW6#K'TU]`_2/)%;DST_8O)ESJ!UNZDXAC$&$8CF6E%ZO#L*I,
MO_IW-.2`\S,5OX`%2VFLKM&&TKN5*E8D)3$QP))PQIR^W]WBS2]?M\C9:*+=
M>A;KQ5I*Q]R$)1XB4\2</=*LZ3^O+J!FSIKZO,M]5.E5)TB]6GI!P3$L3SAT
MZ:KEQ3`<1@_DU1BN%XG0SQF&26BJO)LR[@RBWO>\+,763H0MLH5J;<(@[#M@
M@]8HUW?[2;FYM;QNY9#-]9I45(G4DC25(6DX2E4>8Z:+QTY]:7XH76SH'DSU
M.])?2UT_K>FT>`0XCCV3L8Q;&Z#-F<*FFIPU?/EZG@DJ(*2E,J2+2+5R22RJ
MH8#WE!,'\IRYE]3*W%:IP(`@>?2>F-E`W*.T/?7,LJ:S*UM&2SW>I25*4''"
M!XBV!(2F9T:B2I,'B*$SKC^)W48#Z5_2+ZJ^A>1TSG@'J(SG@.`8WD6LADJ,
M8CAK?G*>MH*,T]52QKB$=52&".20M'?WBI!XFL]WYN7&7#!0DF>&$03U<:.]
MY.V,MY'9YG9([Q%RZA!2<50K4%)3B!K!3I$F)X4D<_\`KI]>GIGZF=-<+]2_
MIDR=F+)OJ)K*C`NB>6^GV.XE6X]09KDA5\.PO&*O&4AI7%0[A))X(E1`&D&X
M+M+K.46=PV2TLA2!*M0PCB1&.'12#,^TG>?)[YM.86K:FKE6AH,J45!R)2AQ
M2@$^(X:@`$@$X@4(F3O5KZU>F'JDZ*]$/63TBR%@V2_4ZV,4W2;-N0\5QFNE
MP;%<(H6Q)J#%CC*QB=WCVJ)(8XUOJ-PN%8=RVT<ME.,*5J1$A0&,F,(HVR[?
M?>.SSQFSS5ED-76H-J:4HZ2A)44KU1,C84@">GA-ZC^L'U3]4NLW5;HYZ&^G
M^0:K#N@U=#@_5#K/U,Q?$Z/`Y<PR0)5385AE%@=JJ:2F1P)IB0BM[MNQ;5ME
MELVVE=P5>+$!($QTDG#'A5\\W\SN\OGK3)FV3^7(2MQY2@C7$E"4H\1*?XB3
M`.%+'HYZV>H.:<L^J#(75_IYA'3KU2>E_`)L=QO+.&XD^-Y8QS#:G"9\0PW%
M,.J5\J5J65X#'+$Q$D9%BP)T8N\J0@H4@DMK,8B",<0>NC;=SM!N;ANY8NFT
MMWEJG40E6I"DE)*5I.!*3$$;4G`F:*-TS];WXHW7?TUY8]4O2;TV],J;I_AV
M"SXCF7!,=Q7,%/CV;9,,W+7RX!2TLCQ4=/O@E2`5<\CR`!AH0":W&49<P^67
M%JU3@0!`G9/3UQ4=Y-VC;[9KE#>96EJP&M)*DK4L+<T_<6P,$B0H)UDDB#QQ
M!_\`$VZ_=3O5'^&IZ=NOG2W+^`X!TIZH8SE7$>H."8Y+7R8]08VF8Z2GPR"@
M:D`@DIUK8I5J7D`8QA2@#$@*]W+)JWS!;;A)4D&(V;,9]T4'NVS>F_SG<ZWO
M;-*$LNJ25A9.H*U`)"8P(D*U$[1$<:ONZ+/UHDZ8Y5?U"PY:I^L31S_UTAR@
MV)/EU9?FY?)^3.+_`.D[?(\O?YG[^ZVEN`R[[GO#W4Z.$[?6*RAW<.8FR1^?
MT?F,=7=SHVF-.K'9$SQFA2XFH[KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO
M<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J
M]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZJ?/QNDAE]
M'V3H:A$E@FZI=.DFAD"LCHV-A65E:X((-B#WX*-TC%T?\4U`GU&I"L@0#B.^
M;^)JS3#NB/1C!ZZEQ3".D65\+Q.A<246(TV`85!/"XT#))%`K*=>X/"!=X\H
M05$CS-3!;[LY:RL+;9;2H;"$)!'J!5=WXS00^C?#UDL4?J)TY#`]B#FFF!'#
MC=C_`(J_S5?[Z:C+M[$[O_[LS_RJFES^*ATOZD]0?39EW,W27*<N?\Y]!,\Y
M1ZA4V0::YJL9I<L5S3U-+`H!+RF*1G5`+MMLH+$`M[O/MH?(68"TE,]$BE_;
M/E%Y=90ERU07'+=YM[0-J@VJ2!UQPVF($F!1/?5'^)_T+]3GIGZC^GSTQX%F
MCJIZFNN&"3Y9P_H@,IX[28C@%5C47R<\F,2UM-#2P)3)([,RS,+@:[;L#7+]
MW7K=]+KQ"6TF=4C&.CCCY5'F^?;3EF<Y0]E^6I<>O7T%'==VL*3J$$K)`2-(
M.W41/5)KO.N$XY^'9Z@O2%ZA^IF7,2S3T)P3HKAW1_K/GS!*&JQ?^J.*X1-3
MU\&(U-/2(TOR4SH4,BJ2`";7VJVF5"^8<:00%ES6`<)F1'G3F9M.[IYK9W]P
ME2[5%H+=Q:`5=V4E*@L@8Z3$8`\>,`]8EZNNGWJS_$?_``]\<Z+8?B>-]',M
MIU,BP?J_6X5B&#X=CV+SY4!J*;#8\6AIYYHZ6)$,LOEA-[A020>;3E;EM8O!
MR`LZ<)F!/&,,:HYOY:9]O=ECEF%*MT_F(<*5)"E=WB$A0"CI`$F(DP#A3CF/
MU%=/?0E^)QZILZ^IC^9Y!Z4>IC+&19>FG51<&Q;%,)GQ#+M#+05%"S813U4@
MF+.;+LOH+@!@31JP<O;!"6H*D%4B0#C&.,4]F.]]GNOOC=OYCJ;8NVV="]"E
M)*FPH%/A"C)D\.'6*:?3=FF;U2^O+\1+%<,RYB>0<!ZM](\HX?T_;':.2@Q*
MHPFLHZ["Z?$YJ*:TL"3OOEBCE"OY>TLH)MSU\V+>S:$@E*U3'3AA-7W3O%YS
MO+F*@A3:';=H(*A!*2%@**3B),D`P8@D"8I/>CO\0_HUZ(_2]E+TH^J/!,Q]
M.?4IT!AQ#`*?I/'EC&ZVHS<]/73S4D^"3T%++331U*2H%=I5!-VN5()>S/(G
M;M\O,PIM6,R,.F<9PHJW#[6LNW<RAO+,S2MJ\8E`0&UGO()TE!"2DA0(Q)$G
M'80:Y>L7JQU@K.A/X:7JG]5W3F/H_)D?K9@&:^K^!872XG7QY2RVL>(?*R5\
M8$\XF\CRS,H6ZNVS:&TYO*;=H//,LJU2@@3Q/5Z[*UVBYSF"LKRS,LR:[GN[
MI"W`D*5W:))!4!)G3&K#`X1.%7P9"SUE3J?DG*?4;(F+KC^2\\X?28KE7&UB
MG@6KH*Z%:B"41U*1R)N1@=KJ&'8@'@.>94VLH5@08-9-97F;%[;(N&3J;<2%
M).(D*$@P8.(Z1-429M]6OIZ](WXP?JES5ZA^HD?3K`,V=,,C8=E^O?#L8Q+Y
MBLBF^9:/9@U)5NMD%[LH'QOP9,Y5<765H#0DA1X@=/216,69]H.4;O[^W3E^
M[W25L-@'2I4GPG^%*N'33MZNO6[D[\0?I/B'H\]`L>-=9,T==JFBP?/G52'+
MV.89EC*&7/G89\2JJZLQFEI!O\I=@C522K&QW;59O+LG78N]]<PD(Q`D$D\(
M@FE>^W:5;;VY><KR/6\NX(0M80M*&T2-945I3_#A`X'#&`4Q^(YZ5^E>0.HO
MHKZG=9>B.)==_1QT:RE+TXZI8+A"XR^(Y;IX(8?Y3C+0X#/!4-!&8BDNUB`-
M""Q3E\@S-U2'$-JTNJ.H3$'I&-)NU_<3+V;JQN+NW5<9>PV6EA.O4@0-"X00
M8$0>$<"2*170#)7X4?4+U)]#J#T"^D.LZTXQ@>+Q8SG?K>F+=1\`R_D"FPLK
M51U<KYB9HZVK,NU8J0(`Y.K`7XIOW\S;MU?F7`D$0!"253Y;!UT2;GY1N'=Y
MQ;G([-3ZDKU*=U/I0T$P9/>8*5,0F,>)`HQ?XG.8L^^D3JWECUD=),$J<6Q3
MK'DW'.CF:\.HT+$YCQ*-\1R;7.JD7,-<)(BW<*0HU;A9D#;=RT6%F`DA?IL4
M/9C0Y[8KV[R&^1FMJDJ4\TNW($GQJ\3"H$;%RDG:`8&VGCU/^A#-5!^$KEWT
MP],LNC/>>NDM#EO'L3RCOE63-.*85B,>-8W`&@=9&EK'DJ2@5MS,553<@\UE
MV<I_F??+,!1(GH!$#V84[OMV8O#<099;H#CC24**<?&I*@M8PQE9U1&))PJM
M^9?P.,:R=34'3#T69DZA>J'$XH(,+])2-U4H,QQXW4;(Q1UE7-4/2T\4<C@2
M5&Y@%][:>W!#KSE*I6X`W_2\$1TCC4+FT[,76N[M[)QR^($6_P#E`7J,>%2B
M=(`)$JDB,1.RK&^H64J'('KE_!XR109.@Z<TV6,I]0Z*#I]3XE/C$&"_+Y/I
M$-#%75($E2M.08Q,P!<#=87X'F'2NSN5$S)29V3XCC'"IHS6P3:;R9(PE`;"
M&WTZ`2H)AE(TA1Q4!LD[=M!_T$]3W3K\,WJ'ZIN@OK$AQ7I9EC.?4;,F?.BO
M60X)C&*X!F7!\TRI4K3K48-3512K@,95XV&FH)%O>?N\M<S!#;C$*(0$D2`0
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M#94QW-N7QM`PVLS'C6*XW\D0I8;X$J5C<7-F!''F[M#]V^I'V]TH#T`$^ZBV
M[W;N<IW=RABY$._GFE*'05N+7I]-4>8H_?XCC!>NOX7MVM?K?06U[_[Y:OA'
MDG]R>_Q/F*E3M5_Y:&5_]Y8_WQ=8_7D0/6E^%$"0"<_9OL/;_P`90\ME/_$C
M_P#BI_WZJ]HO_3Q93_MKO_*1JK?/G0_T%=!/5KZJZ/\`$YZ)UIR_U3S95YOZ
M!^HPKGF;`J_",:43RX3.V5)P(ZJEGW"S0W-S<[=A82VU[?/6S8M%"4B%)\,R
M../3SQJ",\W5W4RS/;Q6\;"M+SI<:>'?%)2K$H/=G!23TIZ<8TR;;THY(]*_
M^;;UP=2_2)Z1<0Z)]&GR'C&"Y5Z[XOB^:%J,]@8-4UM4*/!<QM*\%'3N%VU)
M>\A-@HLP!3FUQ<E;:7W`I<SI`'AQXD<3T5(O9WD^1(M[VXRJS4Q;ELI2ZI3D
MN^$DZ4.20E.'BXG",#!O?0,1_P`-1]"B#I_FNEU_[]]3PJSO_EH+_P`:I#[+
M/^G-MO\`:!_OM579KPS%,1_X3Y>G?$,+PNIQ>GRM7Y3QC'A2025,E/AF'=09
M)ZFH*0AF*1(-S$#0:]N"9I8&>+!,3(]U01F%NXOLIME)25!&A1@20`X9,#'#
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M_P`M.J*'?_B1`N?KYN:J$`&>-96575D=0Z."'0BX(.A!!YJMD5A2DI(_(\NF
MC3Y6XIK(H\L-H=MAI?QMS<FJAM(X;*Y34]/4JJ5$"5"*P94=5<!AV(#`ZCG@
M:VI(.VNQ!"LKSK"JSR`+),%`=@.P)[D#FIK>D3/&N,E+2RRQ3RTT<L\'^1F9
M%9T_XB2+CZN;FM%`)D\*YRQ13QO%-&LT4@L\3`,K#X@Z'FJV0"(-=QQQQ(L<
M2".-``D:@!0!X`#GJ\``(%19\,PVJD,U3A\%1*0`97BC=K#MJP)Y8*(IM;"%
M&2`:S4]-34B&*EITIHR;F.-%1;GQLH'-$S5T(2D0!%9B`001<'N.:JU8:>EI
MJ1#%2TZ4T9-S'&BHMSXV4#FR9JJ$!(@"*YR113!5FB6558,H90P#*;@B_B#V
M/-36RD';63GJW4=:2E2=ZI*:-:J06DJ0BB1AH+%@+GMS<U4($SQKFT$+R1S/
M"KS0W\F4J"R;M#8G47YJ:\4@F:XU%+35:"*JITJ8P;B.1%=;CQLP/-@Q7EH"
MA!$T&O6_)&*=2^B_5OIQ@=33T6-9^RSCN"X15U;2)2Q5.*87/0Q/,T*2.(U:
M4%BJDV[`G3CUJZ$.I4=@(/L-%>?V"[NQ=820%.(4D3LE22!/5C2$])O1S&NA
M'IJZ"]'<X5-!B^;>E.6,*P3%\7P\RRT<E314BT\K4TE5#!*8V*Z%D4D=P./Y
ME=!ZX6M.Q1)HIW&R!S+,FMK1T@N,MI02-DI2`8)`,>@HP\L$,^SSH5F\I@\6
MY0VUAV(OV(]O$0-"I20=M>D@AF:)I85E:%MT+,H8HW:ZW['FIK92#MKSP0RO
M%))"LDD!)A=E!*$BQ*D]OJYN:T4@UU/34]5'Y55`E3%<'RY%5UN.QLP(YX&O
M*0%"#C7/RX_+\K8/*MM\NPV[;6M;M:W-5N*Z2&&*)8(HECA4;5A50%"^P`:6
MYZ:\$@"!7%*>"*$4\<"1TX!40*JA-I[C:!:W-S6@D`0-E=PP04T:PT\*00I]
MF)%"J+ZZ!;#GB:\E(`@5EYJK5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>
MKU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>Y
MZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[
MGJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7
MN>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU
M>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO
M5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ
M]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>
MKU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>Y
MZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[
MGJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7
MN>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU
M>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO
M5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ
M]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>
MKU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>Y
MZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[
MGJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU)_-M1/2Y5S-54TS4]338?6R4
M\Z$JZ.E,[*RD=B"+CGJ]6D-Z#NK'XK'3'TV]//Q)HL3ZPYEZ&9!].W47/OJ#
MQ+KEU@P3J#DKJ9F.ERJ,2RV<J8!A.(5.+8,@KH'EG>H\AO(/E_:ON]7JL0J_
MQ9OQ-7P/H)D?#>EG0"CZ[=2^@F/^J#.6+XUC&=<&R32],J"FP^2BR_0S5,IF
MDQ\M4R-65#R?*P1@/9E#-SU>H@?KE_'%]8?JQ]*GJ*S=Z2L*PCTH]).C&!>F
M+&.HF<*S,F/X5U@.*]:,2P;,D466CA@AI9*&*"0T=0TR@U$+2/&;>X/5ZK7L
M:_&@ZG9?S32X+6]/LJ5<='ZQ>H_IZS#A%*^)28O_`%&R+D^LS4F*T\#5@)Q2
M84\:-=3![ZC:"P//5ZB`^I'\5;\3_JS^%9U*]4^7*KHQZ?<,ZQY4RCGKT_XO
MD[.>/574C+V7,3ZG464ZJ@Q##JN+]+4&.IB27$:;RX8F,L.P2E"GJ]5K_P"*
MKUG]260ND_X>71&MZQ+Z=<=]8G5S)?3;U1^H;(<DN'-EZDQ#!*[$J^'+=?C:
M3OA[XC64:TM)4S`RQJVGOFX]7J*IUP]6?4/\*KI!GKI=T#];E/\`B+=9<S]8
M$RSD7IQU0J\>S[G?I]3-E-LRU^`SIT_AJL8QRJCC@$R?./2""*6[N1'MD]7J
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M1FK,DF>\<SU+)GW/TF6:=ZK%**%<,PO?!)&:6:NJ)Y*ASM$*@*7]7J$'`OQD
M/Q*?3M_GZR+4Y/P+U6=8>M/JLZS9`]/E'!A><<?3+.$=,L&I\6Q?#TPO"YJ6
MHJ*18IZ-,-BAD1HP:N>=GVA6]7JM)]:GK_\`4%C_`.!=0>K#*F6ZSTP>HGU"
M4>2,IS4L%<LU7DG%L\YVH<BU]=05D&I,"U,L]%,"&`,;:,.>KU%.S#^(!ZU_
M3]ZM_4KT$Z&8GA76S,74SU4=/^B72+#^JV-YDJ\!RC@U7Z?Z',\M5$^&2^>M
MZJF:IJ5129F9S82/O'J]2;S+^-1Z[>NGI^Z/Y$Z3]+^F'2KU#=3>EOJ.SEUW
MSIC68\R8;E[!J/HGFG%,AU"93JH+3+7U$M&:J&:I=DIU&YPRJ6'J]1=/3;^+
MGZF.CN3LHK\Y6=;NMO5;I/Z'\K=/L?ZA9SS/69.BSOULPFO2JQ[&Z197%-&A
MI))*N>E`GJI-@=KD$>KU&_\`7E^-YZV/13TPZ=8+5=.^B'47U.X3AW4O'>N^
M5<H8KGW/>"_R+I_614ZU5#%@5+`^$1R!W%9)BU6/E)%"%)2WN^KU%>SC^(=Z
MY\R9H_$6ZB9HSY%1=&<'Z@^C^EZ5=.L#S-FS+^,Y/CZI_P!6<4CHJ:NPIJ8&
MEDH\3E_FJD?Z1/[H'D';SU>HW^'_`(Z7J@FSO0]1*WH5T]3TH]6^H_63I%T.
MP6FQK&ZGJGA>:>EF!XGB46+9CH0%H_Y=52X2_P`Q!!LEIHI8W:1P5W^KU`A'
M^*;^(#ZH_2WZB,I]4<-RAZ;\V]0O1=7>J_TO]7>E&-YDI,:P%\!QB..##,6D
MQQW3=430QM*L/Z,0.\+-)N8CU>K9_P#2=U=K_4#Z6?37UXQ7#_Y3BG6O(.3\
MVXEA8!`IJC,>7J3&)(A=5T1J@CL.W;GJ]1@.>KU::'I3B_%"ZP^JFMZX=),V
M];JGIUTR]3_6.AZX]3<Y=8<OXKT0K>D^4LYYBPN7+F%Y$EKIL6CKDCAIJ:FF
M%,D<3(75MNTKZO4HX/QZ?Q(SZ3O1OUCI_3'TYSOU9_$)QC.;>G3(V4\)S_CX
MP7+?3>FQ`XV^-4,5;'/55M5+3Q-3)23JD,'FRS%MFWGJ]1MNG?XPWK7]06>L
MLX1TH]/72SHMAG23IITQZA>KW+'6'.F)Y7Q&9NH>/5>#O1Y4Q.GA:B%-2I0N
MZU]4DD<CRPQ;5=AN]7JKNRG^)=ZD^DO7?J1F'$L^YAZL)D/JC^)!B63\#QS.
M68SE],)Z-98&/Y<P:KPNAJ5IZR@IVB"4Z.?]'5B8"I-^>KU"1UQ_&'];V->E
M3U+X%U[Z=Y3Z<Y[I^DWIIZV=(,R])\WYVR]6TF7^K75;!,NRX7B.(LZ54=7$
MLY\UJ1Q$Z;XFWHY//5ZK`NFWXMGJ8SUGOU,=8J_)/1G(OH0]/6<>LG3^N;,V
M>L6P+JDN+]'\O/BL^*20&EJZ.HI*N6%V>E@B^8@ICY_Z2VU_5ZJB%_'%]:GJ
MUI^FF0LT8/3^GG,.3_4#Z2JJ'.N0ESME:#-.1.K.+XBM7A%72YM,59444R4J
M[9]D<57%[XB"%2?5ZMY3GJ]7N>KU%J]9^9,?R=Z//5?F_*F-U&6<T95Z:9[Q
M++>8Z25X*O#Z^ARO755/4PR169)(I$5T9=00".>KU:7>!8S^+)TW_#ZZW^L^
M/JAU\Z9="\2])=-CN,]0.IW6?`L]8AF'JCC$N#8EAN/Y'@P#$:VOP&F\B2>1
MQ4M"_E2+&T>\77U>JSG%_P`9SUH=`NDGJ9R)UWZ<]*T]371?&>@.!='*G"ZW
MJ!F#!LR+UMP&LQFEI)*"@HIL6Q3&J2'"ZC=#2K"M2]V4QJMV]7J+OC'_``HN
M]<[^FST^]=,$])N1\(I*Z/J+)ZG,TXBF=\3PK!9,A9T.6BIPS+"U^,8'234\
M;RR8E6P5-/%(#$;LC7]7J-S@WXZ/J(S]^(Y1^G_I-Z38NH?HZH.H62>FF:NL
MN'QXK/71U^=,M4^.ICD.,&:+"_E8#61NM`86J9Z57G1A8HOJ]1X\0ZM]4X_Q
M^,#Z%IU$QE.BTWI,DS3-TI%?.,`;,HZM384,4-%N\HU?RP$/FVW;/=O;GJ]5
MQG/5ZO<]7JUN/QLLU^HFM]9WX870CHAB_6C$\#ZOX9UPJL]](NB/4O"^EN9L
MQR9:P?+E;0328KCU?AU#Y="TTLA264$JS!`2;'U>JNJH]2?XS7H=S1T$P7J3
MGO"^IO7'H?Z.>LO57U"=+.H^;,5Q7!)\*R=U+7$Z&6JER?L@Q/-$."K3X:*N
MXC+O([2,H)?U>HT75;_A0IUIR]ZM_3+TTZ;=$<GYNZ']3\3Z!X#UA19<WUF9
M,LXQURP9,9AAJL9CI*7`L/GI(YD:&CD:HEJ8U>2\0#!/5Z@_R]_PHT]3G3_!
M_6+F+U1>F'*&3JOI+T_S)G7H'TNPFKS3'BN.R83G2+*5*J8W/!6X'CV%LM;3
MU%5B6%52^4-RB![,8_5ZK8_PQO7EZIO6-TA]3:^J;T^'T_=4>B-7#3X-BE'A
MV+X!1XYAN,8`<5IJB/"LP5-77T-13LK*ZS2$.ICE2RO8>KU5@?@*^JCU+]<N
MM'I3PCK-U\S;U3PG-'HQ7.&9,,Q[&Z[$X*[-9]1&9L`_F\Z5+L'K?D::*F\X
M^]Y2*E[#GJ]6VMSU>J@;\>G/77'+F"?AZ9%Z'9DZF8=B'6KKE199S?D[I+G:
MEZ?9RS3A4N2L?KSAM+C6(U5%207FIHY2:B94]SN#;GJ]56M'FS\:7TQ=4_PU
M^EN.]2:V+J7U8SYZI\4Z8=%^L/4"IS0AZ:X'D&AQC`*'J'C60FF7&J[#]M34
M4QA=]LCQJ9`H.WU>I5=?_P#A2=ZCLB=%?1SUFZ6^G[(N9!U2Z591ZE^HGI[,
MV><6Q7"$S+GA\EB&GJL)I(L/PFDD:GDDI:G$*F5Y9&6$0W4/+ZO48RM_'B]0
MO2SUD=?NFGJ%]/F5,G>G'),?6!NB=?25.9Y<Q9Q'3#+]3F&D.&X]14^)9=KZ
MG$HZ&59\/$E//17'F;V39)ZO4:;\&_\`%$]6?K[QC/F">I_TJ)T/HFREE;/O
M2//F&4.-8=A6)8'F=6V44D6/SSS3N@VR4^(0[8*M-Y1$\L[O5ZJ(>HOKA]9%
M!29G:@]46>Z)J?+GXH%13M%F7$T,<_31IERG(MI=&P6P^0/^X6]RW/5ZMSKT
M?Y@QW-GI*]+F:LT8Q4YAS-F;IUDC$,Q8_62O/5UU=6Y9HJFHJ)Y9"6>261V=
MV.I))YZO5I6^M'\1KUY=`/Q"?Q6NEV2^M6<\>RAZAZI.A7HQRA%C%;-29&ZJ
MXO@F3L2I:["HO,_WWO\`(8O72120A29PI_=N/5ZE=E/\?_U;^D7T!^AG$,+P
M[`O5IG&EZ8TV>O4_FG-]3GS'<YU5)C/5;$,G435-?AE-\AA,<D,(\BLQ&KE,
MTA2)8!96E]7J-%^(%^*!Z^,3Z)>NKJ/EJ'".F?1/T:>I[*O2?)DG3JJS/!U7
MS;+@^?,"DJZ:3?4_)&GK\.K7IFA2QEE8+M$=[^KU*+J;_P`*!?6?1=!/1]G7
MHIZ7<J=4^LGJTPKJMG[^H.&T6;<7I,HY.Z=8K_*QE[$O(J:2?^=P2WCQ6O=8
M:2D=')A:,;N>KU!9FG\:CUY=$NL/KRZ[8ED##LY9`S!A'I7P;T\^E>O_`)[7
M8CD7-O6C`:S%*".6/"F5*G8B5O\`-%A(DJJA*2.!XT+%?5ZAV/XU7X@?5G*G
M1?H)EOTTY)Z`^K#J/2]=*GJGCW4+$,R9;RY28!TCPVFJC4X+3TTDU?28C6)7
M"\%7*[43PN90RZKZO5;Q^"-U/ZC=9_PH_1!U2ZMYXQ7J5U(SKDY*S-V>L;K9
M\1Q7$JHXG5Q^;4U-2S22/M4#<Q)L!SU>JU#GJ]7N>KU8*JEIZZEJ:*KB$]+5
MQO%4P-JKQR*493\"#;GJ]0(T/IDZ!89Z>&])M!TJPFF]-[9<GRBW1Y86_DQR
MU4TST<N'F(L287BD9"-W8]^>KU`[UK_#A]"7J-R7TBZ>==/2OD[JCDWH)14V
M&=',#Q?"HZE,O8924D-#%1TCW#K3B*GC0PEBC!5W`D#GJ]2>ZW?A:?AV>H_.
MF"=1.MWHYR)U"SMEO"<.P+`LR5>"01U%+A&$.'H:5#2>4!'36"PBWN)[BV73
MGJ]3C-^&;Z!)_4:WJZ?TH9.7U+/C,.8FZRIAHCQHXY!"T"UOFQLH\XJQWMM]
M\^\UVUYZO4G,O?A._AL93PWK=A&6O13T^P3#?4=2M0]:J.FP&FC3':%\07%C
M32;?\E#\TB3>7#L7>B-:Z*1ZO48?.'I0]-O4'T^T?I3SWT5R]G'TYX=A.'8'
MA_1_$\/BK<%@PO!XHXJ&&.&HWE/EA"GDN"'0J"K`B_/5ZBX0?A)?AH4W2'!N
M@L/HEZ?+TCR_F)<VX7DHX#3M3IF1:<TG\P>1KRR3&%O*)=V!2R$%0!SU>I:9
M?_#:]"65,NUN4LM^E[*N"Y9Q#(>-=+ZK!*>C=*<]/<Q8U/F+$<`51)[M#45U
M3).T2V`9C:PTYZO4G,]?A5?AS]3.HF3>K>>_1WDC,G4SI_0Y>PW)V=I\*48A
M0T>4Q"F#HLL;*6-&E/''"[W81JJ7V`+SU>IQZC_A@?A\]7\O'*O5'TCY*SYE
M]LY9@Z@MAF)X4E4ASCFN<5.,XG>1BWF5[JK5"WV2%5W*=HMZO4B,R_@\?A?Y
MQBR3%F?T0Y!QH=.,`I,L9&EGP@-+AF!4%7)7TM+#('#@02RLT3DETN0K`:<]
M7J4W43\*G\.;JTW5B3J1Z.<C9PEZY9@HLU]5IZS"$>7&,RX?'4PP8E(ZLK)4
MA:R=6DB*EQ(V[=N//5ZE9ZF_0=T,]2'HGSEZ%$P6'I/T?Q?+]#@F08,MT=)1
MKE"3`Y8*S!:K#*94$*'#ZFDAECCL%.S:;`D\]7J45%Z(?3,^;,+ZFYFZ0X%F
M?J_39JPK/V+]3'H13UM;G_"<N+E6+'S'"_EQU(H@85"C:J&P'CSU>H-^H'X6
M?X=W5;(61NF'4CT@9)SID+IIBN/XUD/+6(84M1#A>)9IQ&7%\7E@+MO`K:J=
MYIX]VQW-RN@MZO4[U'X:'H(K,EYRZ=5WI3R?7Y'Z@Y7RGDO.>6*C#OF*2ORQ
MD1=N7J"1)G:R8;8&F9;.A`(:X!YZO4@<;_!]_"^S'DKIKTYQST,].L1R3T?A
MQ>GZ<9=?`*<08;%C\OGX@%VV:0U$GON92QW>\"&UYZO4L\1_##]`&+8U79CQ
M+TI92J\>Q/"<H8%B>+M12?,5.$Y!FH)\O4\SB0&08>V%TIA9KL/*0$D"W/5Z
MGFE_#A]"%%UNZB>I&C]*&2:3KKU8HL7P_J'U/BP6F3%,3I\P4AH,4,DB@!9:
MV%FCJ)D"R2*SAV.]K^KU!GUZ_"Z],_5;H+G;HKTVRS2>GG%,U])GZ%X5U2R[
MA]//C&"=):S$H:ZNRY1"O+QK35"1O'[P)0OO&JCGJ]5@64LK8'D?*N6<E99H
M4PS+>3\/HL+R]AL8"I3T.'TR4D$2A0``D<:J`!X<]7J4'/5Z@PZ==%NE?23+
MF9<H=-LC4&3LLYQQG'LPYHP:CC9(:W&LT5\N*8K62AF-Y*NHG>20^)8]N>KU
M%LS;^&GZ"<^>GC(7I.SEZ4LG9D].G2VJEK>F_2BKPQ9<-P*KGJ:BKEEH26\V
M!I)*J4N4<;MY!N#;GJ]7#/\`^&9^'YU2QWHKF7J#Z/<@9IQCTZX?A^$]$YJG
M+M#Y67L)PF9:BBH::&-%B-+32+NBA=&1"254;C?U>J9B/X<'H7Q?%,9QO$_3
M#E:NQ;,-5U(K<:KY*-VDJ:OK!0?RS.<KDR:MC5/^BJ_\2Z"W/5ZI6:/P[?1%
MG7"<3P+-?IIRQCN#XSE'*.0\4PZ>DD:*?)V0\6@QW+^$L!(/]&P^LI8IH%\&
M47)MSU>INQ?\-3T!Y@ZX9V]2>.^D3(F,]<NI%!B.&YZZCU6`4<]=BE)C&&'!
M:Y9Q*K1L]32,T$TFS>Z,RLQ#-?U>I#]/OPC?PT^E/R7^;CT9Y)R:</Q7+>.T
MS4.'R0G^<Y/Q"?%,%K6(EN\]#/4R-"[7(W6^R`!ZO58QSU>KW/5ZDYG#*.6N
MH&4LTY#SG@T&8\GYVPZNPC-F7JE=]-7X9B5,]'54\J@BZ2Q2,C#V'GJ]078_
MZ9>@>:/3TOI0S!TKPG%?3DF7J'*B=()86.##+F&T\5+2X>(@P(ABC@C51NT"
MC7GJ]00]4?PZ?0YUKHNHF']5_3%E3/M)U9.4&ZAIB.'^<V)OD&CJ,.R\\C[@
MROAU/5310,A4A)'4DAB#ZO4$V/\`X.7X7&:<J9,R-C_H9Z?8GE'IY78MB&2,
MOO@J"FPRHQVHCJZ]8%1AM@J)8E=X/\ENUV:F_J]0U2_A^^B6;U%X#ZMY/2[D
ML^I+*]-2TN7>KXP.D7%J**AH?Y73&%E4(LD%,!#%(%WI&`JL%``]7J&>3H1T
M?EZY0^I>3I[AS]>J?*QR3!U3,1_FRY3.*'&SA8EO;Y?YMC-MM]K6_/5ZA:YZ
MO5[GJ]05YHZ(=)<Z]4^EG6W->0L/QWJQT1@Q^FZ39\J(BV(8#!FBE@HL62D<
M$!15Q4T:2W!N%'/5ZDCU*]*?ITZQ9KS#GGJ?TAP?.V;LV9$QSIEF3'JZ!I)Z
MS(.995GQ3`Y2&`-)5.H,BVN3X\]7J+_BGX5/X<N,]0\K]6L3]'&1JOJ7DJFR
MM294SLV$(,1H(LD_*#`S#*K`K)0K0P)%+]O8@0L4NO/5ZIV1/PN?P[>F68^K
MN;,A>C7I_EG'>O&%XK@G5NJI\OT?EXU@V.3&?$*"6&16B2FJG-Y88T5&TN-!
M;U>H8/3AZ.O2YZ0NG>,])O3+T+R[T4Z>9DK*C$,Q98P*A2EAQ"NJH$I99ZI[
MM)-(8HUC#.Q(10HL`!SU>J!T2]%'I1]-^-9:S%T+Z$X!TQQS)V4?ZA98Q3"Z
M9X9J+)W\_J<U?RF,L[6IOYC635.W_BQR;\]7J-'SU>H+>HO1/I1U;QKI?F+J
M3D2@SCC?17'X\T=*L2K8V>7`LP0T<^'I7TI##;,L-3(@)OHQYZO5`SYZ?^B_
M4_J'TLZL=0.G&&9LZC]$4S#'TFSC60F2MP%,V86,%QA:1PPVBLI!Y,NANNG/
M5ZB>YQ_!]_##Z@X9D#!\[>B/(.9L/Z69<3*73V&KP@2G"LN15L^)14$#E]PC
MBJ*F66.Y)1G8J02>>KU"3EO\-ST%Y0Z\8]ZGLM>DS(^$=>\T18E%F#J9%@=+
M\_5C&:(X;B#R!@8C+60,T=3+LWRJS[V;>U_5ZE?Z8?0WZ0?1;39SI/2EZ=<J
M]!HNHE3#5YW;+N%PT,F)2TRNL"S2"[F*'S'\J('8FYBJ@LU_5ZDK7_AR^AS%
M%J$Q'TS98JUJX.HM+4J])*=]/U;#+G%#^D[8P&(JO\5]+<]7J-ME/*N7<BY6
MRUDG*&$0Y?RGD[#Z/"LKX#3KLIZ'#L/IDI*:GB4DV2**-54>P<]7J+7CGH2]
M'V9LZ8EU%S!Z><M8QGC%\Z8;U$Q+,]11>95RYVPC!7R]1XP79M*F&BD:%6&E
MK&UP"/5Z@+S-^#O^%[G/!LBY?S7Z'>G^8,'Z9Y?GRMD.CJL&2489E^HKJC$V
MHH69MWEK45<TL9)+1N[,A4GGJ]0\5OH8](N)99SSDZOZ!9?JLL]2\]4_4S/V
M#O3R&+%L_4M12U<6.U'Z2[UBR44+;[]T%QSU>H-^I7X6_P"'EUCP?$<`ZI>D
M+).>L&Q7.>.]0Z[#\1PI9XVSGF<0C&,4%VNLE>:>-JI5LDK*&=2VO/5ZGSJ)
M^&WZ"^K.9<YYOZC^DW)&;LP]0LJ4.1LY5]7@E,1794PN:FJ*+#GB0+&L=,]'
M`8"JAH_+0(P"BWJ]28S'^%/^'!F[HSTS]/.9/1AD#%^BW1NOK<3Z8]/9<"IO
MD<'K\38O6SP[;.6JF(-1N8^:0I?<56WJ]1N.CW1WIAZ?^F>3^C?1C)5%TZZ7
M9`I?DLF9)PV-HJ'#J3S7F\J%69B%WR,VI[GGJ]0E<]7J]SU>KW/5ZO<]7J]S
MU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW
M/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO
M<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J
M]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>
MKW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>HL_K(R[B>;?3!UGRW@
MN-5F7<4Q?!WBHL;P^IGHZVF<SQMOAFIG21&`'=6'(4^HW>)[*=Q[^\:)2MIH
MJ!!@@R*+\TW>&;6ZK.2GO1$@D$>1$$>E:>$>5?40^4UH?\[&9_\`/2W45>G!
MR9_7;-HH/YDU;\[\Z&-=YORW\B_WY][[?<O?3G*<]LN8"ZU?FG_R?Y;\QKU'
M5ITQIZ-7?_L?/'94<?\`0L#$_P!V>VQ_=7-O^F]?*@PI.J&9H<7J3BO5+JI7
M9%@RO@N/TO4##L9S+MK*O'^HM9TYI*&/#Y,9EJ%<UE.J[B2"=S>ZH%Q([O;O
M.6AHNR'RZMLMJ=.`;MTW"E%8`3&@DQA&`Q,TG5]--MP>>C_;7.)C^ETT-=9#
MC6#YKRKD[-'6GJMDK$\VXEAV!TE7C&/XW24E-F/%:,5U-@\SKC$CO5LAL33I
M+"K>Z90P(X#FNU3>IVU<?9N2ZEM*ED(=626TG27!@`$3_2*5D8A,4X?IB8!`
M+SPG#^ZN;>C[JBX#-BV9,D4/43"NL/5^;*F99\'INFV(#$\SRKG*;'YW@P],
M">FQ26*HDF,;,T4KQ20H/,G2*/WN.WO:?O7;WAM5W(#J`LN#OC^Q#8!679@I
M`D8@*2H^%!4K"M)^F-@IU!YZ#L_:.8ST>*H%1B&.R24V$Y?ZI]8<UYVGH,T5
ME;T_H<7Q_P#FF$RY.JH*#%J7%/F<7A@I9Z:HJH8V7SFW;PT9=/>X\WVE;T@%
M;MV&V0IL!Q3RM*P\"IM2(!4I*DI49TB((5I.%>_Z%C8F`\\3CAWCG#;_`!44
M?*_5/U5YQSUD"FI<YYWP'!\YX/@&(T60:K-F8#C5748X(W2EC)Q(%I)(G\^"
M:-C"(RHD]_<JRKF6]EQ:6+Q5?.K6TMQ)<"U:`$3XCU`C2I)`5JG3A!.V_IJM
M"F.]>U'9^U<^&JCH=5LN=4>FN*=5:"CZQYWS2_2#`,%Q+,='#G?,<,U1BV;<
M7;!L`PZ)WK"L9JI(F:21P0JLA`.O(@W7[8L]S%JW4JY=;_,N+2DE2B`AI&MU
M9QQT@B`-I!ZJLY],#"9EY["/]=<X[/XJ277/IEZX^A'2GJ/GW%NHF(9PK\O8
M?1SY6GP_/&>*7#4Q>NQZ@P2+#*Y*K$WJ)@WSI=*J'RPVPAHD)%S7<OMT:SO-
M&+9%Y=-I6HA6I0*M"4+65I(A(^V"A6HB<%*QIY_Z7;=L:B\]`V_M5_X5)O$I
M?4-C<WITP[I;U/S+C6,]<<'JZS$J3$L\9O2/"L5?`,5K,/P\O2UP]Z2OP:J@
ME9OLI$Q`N1PPMNT_,&1>KO;M]*+58`*58J3WC86N">"'$*`&TJ`V33*/ICMB
M1^V>QV?M7.O^^ZC0C9?REUTZB)T'HNFO5_-M9C_6'+N+9FQF@Q#.F;`N`4>%
M4J4;PU'RM;[L_P#.*B.A*L1]B<BYC(X'[_MFS7+S=JN[IX-VSB6P4J/[0J,@
MB3]O<@N2.E'!56:^E]A1$//8B?[JY_A4+W2OHGU2ZK].<F]1L%ZYY\HZ#-M%
M'4_(3YNS.DU+.K-!44\@>L4[H9HWC-P-5X%-YOJ"SW*\P=M'+APJ;5$A9@C:
M",=A!!]:NU]+;*TZ@\]!_P""N?X5+[_91ZS_`/;^L\?^IAF7_P`[>$7_`$-!
MG'_'W/\`3J_&G/\`H59O_CSO^JN?X5>_V4>L_P#V_K/'_J89E_\`.WGO^AH,
MX_X^Y_IU?C7O^A5F_P#CSO\`JKG^%7O]E'K/_P!OZSQ_ZF&9?_.WGO\`H:#.
M/^/N?Z=7XU[_`*%6;_X\[_JKG^%7O]E'K/\`]OZSQ_ZF&9?_`#MY[_H:#./^
M/N?Z=7XU[_H59O\`X\[_`*JY_A5[_91ZS_\`;^L\?^IAF7_SMY[_`*&@SC_C
M[G^G5^->_P"A5F_^/._ZJY_A5[_91ZS_`/;^L\?^IAF7_P`[>>_Z&@SC_C[G
M^G5^->_Z%6;_`./._P"JN?X5>_V4>L__`&_K/'_J89E_\[>>_P"AH,X_X^Y_
MIU?C7O\`H59O_CSO^JN?X5>_V4>L_P#V_K/'_J89E_\`.WGO^AH,X_X^Y_IU
M?C7O^A5F_P#CSO\`JKG^%7O]E'K/_P!OZSQ_ZF&9?_.WGO\`H:#./^/N?Z=7
MXU[_`*%6;_X\[_JKG^%7O]E'K/\`]OZSQ_ZF&9?_`#MY[_H:#./^/N?Z=7XU
M[_H59O\`X\[_`*JY_A5[_91ZS_\`;^L\?^IAF7_SMY[_`*&@SC_C[G^G5^->
M_P"A5F_^/._ZJY_A5[_91ZS_`/;^L\?^IAF7_P`[>>_Z&@SC_C[G^G5^->_Z
M%6;_`./._P"JN?X5>_V4>L__`&_K/'_J89E_\[>>_P"AH,X_X^Y_IU?C7O\`
MH59O_CSO^JN?X5>_V4>L_P#V_K/'_J89E_\`.WGO^AH,X_X^Y_IU?C7O^A5F
M_P#CSO\`JKG^%7O]E'K/_P!OZSQ_ZF&9?_.WGO\`H:#./^/N?Z=7XU[_`*%6
M;_X\[_JKG^%7O]E'K/\`]OZSQ_ZF&9?_`#MY[_H:#./^/N?Z=7XU[_H59O\`
MX\[_`*JY_A5[_91ZS_\`;^L\?^IAF7_SMY[_`*&@SC_C[G^G5^->_P"A5F_^
M/._ZJY_A5[_91ZS_`/;^L\?^IAF7_P`[>>_Z&@SC_C[G^G5^->_Z%6;_`./.
M_P"JN?X5>_V4>L__`&_K/'_J89E_\[>>_P"AH,X_X^Y_IU?C7O\`H59O_CSO
M^JN?X5>_V4>L_P#V_K/'_J89E_\`.WGO^AH,X_X^Y_IU?C7O^A5F_P#CSO\`
MJKG^%7O]E'K/_P!OZSQ_ZF&9?_.WGO\`H:#./^/N?Z=7XU[_`*%6;_X\[_JK
MG^%7O]E'K/\`]OZSQ_ZF&9?_`#MY[_H:#./^/N?Z=7XU[_H59O\`X\[_`*JY
M_A5[_91ZS_\`;^L\?^IAF7_SMY[_`*&@SC_C[G^G5^->_P"A5F_^/._ZJY_A
M5[_91ZS_`/;^L\?^IAF7_P`[>>_Z&@SC_C[G^G5^->_Z%6;_`./._P"JN?X5
M>_V4>L__`&_K/'_J89E_\[>>_P"AH,X_X^Y_IU?C7O\`H59O_CSO^JN?X5>_
MV4>L_P#V_K/'_J89E_\`.WGO^AH,X_X^Y_IU?C7O^A5F_P#CSO\`JKG^%7O]
ME'K/_P!OZSQ_ZF&9?_.WGO\`H:#./^/N?Z=7XU[_`*%6;_X\[_JKG^%7O]E'
MK/\`]OZSQ_ZF&9?_`#MY[_H:#./^/N?Z=7XU[_H59O\`X\[_`*JY_A5[_91Z
MS_\`;^L\?^IAF7_SMY[_`*&@SC_C[G^G5^->_P"A5F_^/._ZJY_A5[_91ZS_
M`/;^L\?^IAF7_P`[>>_Z&@SC_C[G^G5^->_Z%6;_`./._P"JN?X5>_V4>L__
M`&_K/'_J89E_\[>>_P"AH,X_X^Y_IU?C7O\`H59O_CSO^JN?X5>_V4>L_P#V
M_K/'_J89E_\`.WGO^AH,X_X^Y_IU?C7O^A5F_P#CSO\`JKG^%7O]E'K/_P!O
MZSQ_ZF&9?_.WGO\`H:#./^/N?Z=7XU[_`*%6;_X\[_JKG^%7O]E'K/\`]OZS
MQ_ZF&9?_`#MY[_H:#./^/N?Z=7XU[_H59O\`X\[_`*JY_A5[_91ZS_\`;^L\
M?^IAF7_SMY[_`*&@SC_C[G^G5^->_P"A5F_^/._ZJY_A5[_91ZS_`/;^L\?^
MIAF7_P`[>>_Z&@SC_C[G^G5^->_Z%6;_`./._P"JN?X5>_V4>L__`&_K/'_J
M89E_\[>>_P"AH,X_X^Y_IU?C7O\`H59O_CSO^JN?X5>_V4>L_P#V_K/'_J89
ME_\`.WGO^AH,X_X^Y_IU?C7O^A5F_P#CSO\`JKG^%7O]E'K/_P!OZSQ_ZF&9
M?_.WGO\`H:#./^/N?Z=7XU[_`*%6;_X\[_JKG^%7O]E'K/\`]OZSQ_ZF&9?_
M`#MY[_H:#./^/N?Z=7XU[_H59O\`X\[_`*JY_A5[_91ZS_\`;^L\?^IAF7_S
MMY[_`*&@SC_C[G^G5^->_P"A5F_^/._ZJY_A5[_91ZS_`/;^L\?^IAF7_P`[
M>>_Z&@SC_C[G^G5^->_Z%6;_`./._P"JN?X5>_V4>L__`&_K/'_J89E_\[>>
M_P"AH,X_X^Y_IU?C7O\`H59O_CSO^JN?X5>_V4>L_P#V_K/'_J89E_\`.WGO
M^AH,X_X^Y_IU?C7O^A5F_P#CSO\`JKG^%7O]E'K/_P!OZSQ_ZF&9?_.WGO\`
MH:#./^/N?Z=7XU[_`*%6;_X\[_JKG^%7O]E'K/\`]OZSQ_ZF&9?_`#MY[_H:
M#./^/N?Z=7XU[_H59O\`X\[_`*JY_A5[_91ZS_\`;^L\?^IAF7_SMY[_`*&@
MSC_C[G^G5^->_P"A5F_^/._ZJY_A5[_91ZS_`/;^L\?^IAF7_P`[>>_Z&@SC
M_C[G^G5^->_Z%6;_`./._P"JN?X57L?A?]/<S]-NA6<L$S7F_%<YXA5YLK*J
M'$\7Q*NQ2ICA?!\-B$2RXA+*X0&,L%!M<DVN3SJ/]$&_MSO%NL_</K4M2;E2
M9423`;:,8^=#'=WL^3NXR;8*4O4=4J45'$`;5$F,-E61\S+H_KW/5ZBK>M[.
MLG3GTG=<\[Q4\E7)EO!)*A*>)'DD<B>);*J`DGWO`<A'ZD<C5F6XU_:IQ+C1
M`]HHISW>A&2VB[Y?VLC4>-:@47J>P:+KM_GZ7`<8_GQPU:23`/Y94BA;$4B^
M1&*$^3N^:^1_T2_;R_CSC@KLUS`Y)_+=/@U3J@ZM,ZN[Z-.OQ_XU1&/K`RW7
MKA4_XJOPHM<.+83283E[!:3,68(Z+",-P##<3WY;D=ZR/+75*7JI1.A#J(3\
MS42T\@L^Y"K#:5(:1%VE^IU;BK<2I3BABK#O+86J@?#CX0%#9!D&09#`^KC*
MP(A7#^%7`ST=-*7.>?J?-_58]3SBN)X;,^?<M]0I8VR?'6XTV(Y9BB@I\-&,
M59:5,+"Q;HZ:.)3'(S-O=2T9+LHR&\M,K_)]P5#\NXQ]ZDHTN$DK[L""[C!6
M2=0`$`@*%E?5WE95J(5,S]IX>E(_&YLH9MJ<R8KF_#X\6QC&JS`,2AIJ7IU1
MX=@%5BV7JRJJ8<2QO`XC)18G6SI62T]1,%I[Q-:-8V"LIK9MYK:I0AAMQ*$I
M<3BZM3@2X$@H:=("VT)*0I*97"A*BH2#5?U;92HR4GA_"8PZHH5.EW5;+G2W
M$L.Q3",)JZ=X<$S9@^*83A.4:?+V%R-F[$J+$:F:EH\-AV4R0_(I'%&QE;:;
MO(["Y#.\NZV99FVI"T*,N-+!6I;BOV25)2%*5BHG42HC2)^U(%7;^KO*T'!*
MAM_A/'TH7^D_J_GZ9=/^GF2JS!ZG-F)].,(I\#P?.)RW/0U;8=1Q_+0);_26
M0B%463;)M=@6VJ#M`4WH[)KC,;]ZX2A3:7EE91)4-1Q)V)G&2)$@828DOM_6
M'EJ0``K##[3^%!QG#U"TF<LX=;)L4RUC296]066<!PS.%724]7!78=BV5*BI
M.'5=*SPMMD"5@=&"D+)""PL1P093N#>6EI:A`_:V;JU(!22E2'0G6E75*8(D
M2E9C955?5YE:@HD*DQ_"KAQV<*A9]]0W4'JUDW,^3NJ'4O'L>I<<AP^##SAV
M43@U+!\ACE!CGS553)+4"JK)'P]8_,#Q1(KMY<*D\>R/<%K*[MM^SL]!05$Z
MEJ63J0M&E*M(TH`63$*42!J6:T]]8&7.""%1_BG\*QY7ZN8!E+-PS=A4>8&J
M(^HF*=0*6AFPNIECICB>#XEA@PB!BEXZ2"3%JFHCMJ&<K8+:ULRW3S&ZM>X6
MT(_+)8)`(G2M"N\.&*U!M"3U"9FFT?5YEB3("ML_:K\.NEQD+U30=)<T]6>H
M&5<L8MCF,Y\F-7@66YL.GIZ?"XUDGQ1\.I9/+]V&JQ*KJ*J1FM9I;=D!X39W
MV97F:6UO:O@H0T(4H`DJ."0M0Z4MI2@1."9XFGV/J_RQ*YA0G^]5A[O6GSHE
MZQ<1Z2=)\C].Y,(Q/%:S+M(W\WQ/^6U:BHQ"MJ9<1K)%"PJ`K5%1(5%NUN(M
M\NR1[-<T=N@@I"S@(."0`E(_TH$UYOZPLM0-*0J!_>J_"A3_`.'"\0_[!G$_
M_'=6_P#4K@9_V!'N@^PU?_H<?+^A7^E5^%>_X<+Q#_L&<3_\=U;_`-2N>_V!
M'N@^PU[_`*''R_H5_I5?A7O^'"\0_P"P9Q/_`,=U;_U*Y[_8$>Z#[#7O^AQ\
MOZ%?Z57X5[_APO$/^P9Q/_QW5O\`U*Y[_8$>Z#[#7O\`H<?+^A7^E5^%>_X<
M+Q#_`+!G$_\`QW5O_4KGO]@1[H/L->_Z''R_H5_I5?A7O^'"\0_[!G$__'=6
M_P#4KGO]@1[H/L->_P"AQ\OZ%?Z57X5[_APO$/\`L&<3_P#'=6_]2N>_V!'N
M@^PU[_H<?+^A7^E5^%>_X<+Q#_L&<3_\=U;_`-2N>_V!'N@^PU[_`*''R_H5
M_I5?A7O^'"\0_P"P9Q/_`,=U;_U*Y[_8$>Z#[#7O^AQ\OZ%?Z57X5[_APO$/
M^P9Q/_QW5O\`U*Y[_8$>Z#[#7O\`H<?+^A7^E5^%>_X<+Q#_`+!G$_\`QW5O
M_4KGO]@1[H/L->_Z''R_H5_I5?A7O^'"\0_[!G$__'=6_P#4KGO]@1[H/L->
M_P"AQ\OZ%?Z57X5[_APO$/\`L&<3_P#'=6_]2N>_V!'N@^PU[_H<?+^A7^E5
M^%>_X<+Q#_L&<3_\=U;_`-2N>_V!'N@^PU[_`*''R_H5_I5?A7O^'"\0_P"P
M9Q/_`,=U;_U*Y[_8$>Z#[#7O^AQ\OZ%?Z57X5[_APO$/^P9Q/_QW5O\`U*Y[
M_8$>Z#[#7O\`H<?+^A7^E5^%>_X<+Q#_`+!G$_\`QW5O_4KGO]@1[H/L->_Z
M''R_H5_I5?A7O^'"\0_[!G$__'=6_P#4KGO]@1[H/L->_P"AQ\OZ%?Z57X5[
M_APO$/\`L&<3_P#'=6_]2N>_V!'N@^PU[_H<?+^A7^E5^%>_X<+Q#_L&<3_\
M=U;_`-2N>_V!'N@^PU[_`*''R_H5_I5?A7O^'"\0_P"P9Q/_`,=U;_U*Y[_8
M$>Z#[#7O^AQ\OZ%?Z57X5[_APO$/^P9Q/_QW5O\`U*Y[_8$>Z#[#7O\`H<?+
M^A7^E5^%>_X<+Q#_`+!G$_\`QW5O_4KGO]@1[H/L->_Z''R_H5_I5?A7O^'"
M\0_[!G$__'=6_P#4KGO]@1[H/L->_P"AQ\OZ%?Z57X5[_APO$/\`L&<3_P#'
M=6_]2N>_V!'N@^PU[_H<?+^A7^E5^%>_X<+Q#_L&<3_\=U;_`-2N>_V!'N@^
MPU[_`*''R_H5_I5?A7O^'"\0_P"P9Q/_`,=U;_U*Y[_8$>Z#[#7O^AQ\OZ%?
MZ57X5[_APO$/^P9Q/_QW5O\`U*Y[_8$>Z#[#7O\`H<?+^A7^E5^%>_X<+Q#_
M`+!G$_\`QW5O_4KGO]@1[H/L->_Z''R_H5_I5?A7O^'"\0_[!G$__'=6_P#4
MKGO]@1[H/L->_P"AQ\OZ%?Z57X5[_APO$/\`L&<3_P#'=6_]2N>_V!'N@^PU
M[_H<?+^A7^E5^%>_X<+Q#_L&<3_\=U;_`-2N>_V!'N@^PU[_`*''R_H5_I5?
MA7O^'"\0_P"P9Q/_`,=U;_U*Y[_8$>Z#[#7O^AQ\OZ%?Z57X5[_APO$/^P9Q
M/_QW5O\`U*Y[_8$>Z#[#7O\`H<?+^A7^E5^%>_X<+Q#_`+!G$_\`QW5O_4KG
MO]@1[H/L->_Z''R_H5_I5?A7O^'"\0_[!G$__'=6_P#4KGO]@1[H/L->_P"A
MQ\OZ%?Z57X5[_APO$/\`L&<3_P#'=6_]2N>_V!'N@^PU[_H<?+^A7^E5^%>_
MX<+Q#_L&<3_\=U;_`-2N>_V!'N@^PU[_`*''R_H5_I5?A7O^'"\0_P"P9Q/_
M`,=U;_U*Y[_8$>Z#[#7O^AQ\OZ%?Z57X5[_APO$/^P9Q/_QW5O\`U*Y[_8$>
MZ#[#7O\`H<?+^A7^E5^%>_X<+Q#_`+!G$_\`QW5O_4KGO]@1[H/L->_Z''R_
MH5_I5?A7O^'"\0_[!G$__'=6_P#4KGO]@1[H/L->_P"AQ\OZ%?Z57X5[_APO
M$/\`L&<3_P#'=6_]2N>_V!'N@^PU[_H<?+^A7^E5^%>_X<+Q#_L&<3_\=U;_
M`-2N>_V!'N@^PU[_`*''R_H5_I5?A7O^'"\0_P"P9Q/_`,=U;_U*Y[_8$>Z#
M[#7O^AQ\OZ%?Z57X5[_APO$/^P9Q/_QW5O\`U*Y[_8$>Z#[#7O\`H<?+^A7^
ME5^%>_X<+Q#_`+!G$_\`QW5O_4KGO]@1[H/L->_Z''R_H5_I5?A7O^'"\0_[
M!G$__'=6_P#4KGO]@1[H/L->_P"AQ\OZ%?Z57X5L"?A0=9INN'I_SOFF>@GP
M]\.SA6X>(:B&6!R(\%PNHW!954D?IN_.JWT+;H*R7=5]E0C5<J5[6VA\JD/=
M+M,9WJMS=-3"%:,01L`5Q_QJL_YFI0IKW/5ZO<]7J]SU>KW/5ZO<]7J]SU>K
MW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5Z
MO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7
MJ]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU
M>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/
M5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZHE?B%!A='48AB=;#AU!2KNJJZ>1(88
MUO:[O(0H'Q)Y1QQ*$RHP!TTV\\AM)4H@`<3@*27^<[IK_P!O"P/_`,>U!_U-
MXA_G%I_QQ/\`IA^-%O\`/K'_`(ZC_3#\:]_G.Z:_]O"P/_Q[4'_4WGOYQ:?\
M<3_IA^->_GUC_P`=1_IA^->_SG=-?^WA8'_X]J#_`*F\]_.+3_CB?],/QKW\
M^L?^.H_TP_&O?YSNFO\`V\+`_P#Q[4'_`%-Y[^<6G_'$_P"F'XU[^?6/_'4?
MZ8?C7O\`.=TU_P"WA8'_`./:@_ZF\]_.+3_CB?\`3#\:]_/K'_CJ/],/QKW^
M<[IK_P!O"P/_`,>U!_U-Y[^<6G_'$_Z8?C7OY]8_\=1_IA^->_SG=-?^WA8'
M_P"/:@_ZF\]_.+3_`(XG_3#\:]_/K'_CJ/\`3#\:]_G.Z:_]O"P/_P`>U!_U
M-Y[^<6G_`!Q/^F'XU[^?6/\`QU'^F'XU[_.=TU_[>%@?_CVH/^IO/?SBT_XX
MG_3#\:]_/K'_`(ZC_3#\:]_G.Z:_]O"P/_Q[4'_4WGOYQ:?\<3_IA^->_GUC
M_P`=1_IA^->_SG=-?^WA8'_X]J#_`*F\]_.+3_CB?],/QKW\^L?^.H_TP_&O
M?YSNFO\`V\+`_P#Q[4'_`%-Y[^<6G_'$_P"F'XU[^?6/_'4?Z8?C7O\`.=TU
M_P"WA8'_`./:@_ZF\]_.+3_CB?\`3#\:]_/K'_CJ/],/QKW^<[IK_P!O"P/_
M`,>U!_U-Y[^<6G_'$_Z8?C7OY]8_\=1_IA^->_SG=-?^WA8'_P"/:@_ZF\]_
M.+3_`(XG_3#\:]_/K'_CJ/\`3#\:]_G.Z:_]O"P/_P`>U!_U-Y[^<6G_`!Q/
M^F'XU[^?6/\`QU'^F'XU[_.=TU_[>%@?_CVH/^IO/?SBT_XXG_3#\:]_/K'_
M`(ZC_3#\:]_G.Z:_]O"P/_Q[4'_4WGOYQ:?\<3_IA^->_GUC_P`=1_IA^->_
MSG=-?^WA8'_X]J#_`*F\]_.+3_CB?],/QKW\^L?^.H_TP_&O?YSNFO\`V\+`
M_P#Q[4'_`%-Y[^<6G_'$_P"F'XU[^?6/_'4?Z8?C7O\`.=TU_P"WA8'_`./:
M@_ZF\]_.+3_CB?\`3#\:]_/K'_CJ/],/QKW^<[IK_P!O"P/_`,>U!_U-Y[^<
M6G_'$_Z8?C7OY]8_\=1_IA^->_SG=-?^WA8'_P"/:@_ZF\]_.+3_`(XG_3#\
M:]_/K'_CJ/\`3#\:]_G.Z:_]O"P/_P`>U!_U-Y[^<6G_`!Q/^F'XU[^?6/\`
MQU'^F'XU[_.=TU_[>%@?_CVH/^IO/?SBT_XXG_3#\:]_/K'_`(ZC_3#\:]_G
M.Z:_]O"P/_Q[4'_4WGOYQ:?\<3_IA^->_GUC_P`=1_IA^->_SG=-?^WA8'_X
M]J#_`*F\]_.+3_CB?],/QKW\^L?^.H_TP_&O?YSNFO\`V\+`_P#Q[4'_`%-Y
M[^<6G_'$_P"F'XU[^?6/_'4?Z8?C7O\`.=TU_P"WA8'_`./:@_ZF\]_.+3_C
MB?\`3#\:]_/K'_CJ/],/QKW^<[IK_P!O"P/_`,>U!_U-Y[^<6G_'$_Z8?C7O
MY]8_\=1_IA^->_SG=-?^WA8'_P"/:@_ZF\]_.+3_`(XG_3#\:]_/K'_CJ/\`
M3#\:]_G.Z:_]O"P/_P`>U!_U-Y[^<6G_`!Q/^F'XU[^?6/\`QU'^F'XU[_.=
MTU_[>%@?_CVH/^IO/?SBT_XXG_3#\:]_/K'_`(ZC_3#\:]_G.Z:_]O"P/_Q[
M4'_4WGOYQ:?\<3_IA^->_GUC_P`=1_IA^->_SG=-?^WA8'_X]J#_`*F\]_.+
M3_CB?],/QKW\^L?^.H_TP_&O?YSNFO\`V\+`_P#Q[4'_`%-Y[^<6G_'$_P"F
M'XU[^?6/_'4?Z8?C7O\`.=TU_P"WA8'_`./:@_ZF\]_.+3_CB?\`3#\:]_/K
M'_CJ/],/QKW^<[IK_P!O"P/_`,>U!_U-Y[^<6G_'$_Z8?C7OY]8_\=1_IA^-
M>_SG=-?^WA8'_P"/:@_ZF\]_.+3_`(XG_3#\:]_/K'_CJ/\`3#\:]_G.Z:_]
MO"P/_P`>U!_U-Y[^<6G_`!Q/^F'XU[^?6/\`QU'^F'XU[_.=TU_[>%@?_CVH
M/^IO/?SBT_XXG_3#\:]_/K'_`(ZC_3#\:]_G.Z:_]O"P/_Q[4'_4WGOYQ:?\
M<3_IA^->_GUC_P`=1_IA^->_SG=-?^WA8'_X]J#_`*F\]_.+3_CB?],/QKW\
M^L?^.H_TP_&O?YSNFO\`V\+`_P#Q[4'_`%-Y[^<6G_'$_P"F'XU[^?6/_'4?
MZ8?C7O\`.=TU_P"WA8'_`./:@_ZF\]_.+3_CB?\`3#\:]_/K'_CJ/],/QKW^
M<[IK_P!O"P/_`,>U!_U-Y[^<6G_'$_Z8?C7OY]8_\=1_IA^->_SG=-?^WA8'
M_P"/:@_ZF\]_.+3_`(XG_3#\:]_/K'_CJ/\`3#\:]_G.Z:_]O"P/_P`>U!_U
M-Y[^<6G_`!Q/^F'XU[^?6/\`QU'^F'XU[_.=TU_[>%@?_CVH/^IO/?SBT_XX
MG_3#\:]_/K'_`(ZC_3#\:]_G.Z:_]O"P/_Q[4'_4WGOYQ:?\<3_IA^->_GUC
M_P`=1_IA^->_SG=-?^WA8'_X]J#_`*F\]_.+3_CB?],/QKW\^L?^.H_TP_&O
M?YSNFO\`V\+`_P#Q[4'_`%-Y[^<6G_'$_P"F'XU[^?6/_'4?Z8?C7O\`.=TU
M_P"WA8'_`./:@_ZF\]_.+3_CB?\`3#\:]_/K'_CJ/],/QKW^<[IK_P!O"P/_
M`,>U!_U-Y[^<6G_'$_Z8?C7OY]8_\=1_IA^->_SG=-?^WA8'_P"/:@_ZF\]_
M.+3_`(XG_3#\:]_/K'_CJ/\`3#\:]_G.Z:_]O"P/_P`>U!_U-Y[^<6G_`!Q/
M^F'XU[^?6/\`QU'^F'XU[_.=TU_[>%@?_CVH/^IO/?SBT_XXG_3#\:]_/K'_
M`(ZC_3#\:]_G.Z:_]O"P/_Q[4'_4WGOYQ:?\<3_IA^->_GUC_P`=1_IA^->_
MSG=-?^WA8'_X]J#_`*F\]_.+3_CB?],/QKW\^L?^.H_TP_&E%@^/8'F&FDK,
M`QFDQRDB<Q2U5'40U,:R!0Q0M"S`,`P-N]B.*F+EMT2A04.HS2ZVO&GDZFU!
M0ZB#\*=N/THKW/5ZBR^LK)-#U']+W6G(^)0+4T.9<&DIZF!MI5E,\;V.[3]W
MD#?4_FJ['<#,+A)A2&B1[12>ZW>9S9LV;PU(=P(/$5H]8UT^R?A6*9X6@S/T
MVS+F_*W4+$LG8'Z5J.C1NH6-4U#F<8`IIS%C\LWS#0$U9<X9Y0126VI=QRGM
M'W76FM35RAIRV2\JZ)_R=!4WKQED#3J\$=]J)(B3X2$5?39NV)'<HU`Q$)G;
M&RALSETY].N7AG6#!.G]9F*HP09RH<DXN(\#APK,V9,DX778GB&$T<DM<LZ2
M(N'S@33PQ02&-Q%*[+;@-RFZSI_NBXXE`5W*ECQE3;;RDI0XH!.D@ZT^%*E+
M&H%20#-65]-.[@G]@GCP3B1M%)7`<F]$6RWE#$<S=+JY<Z9WI\E)A73>DILM
M4TZXIFW)DF<UIUQ+%<;@P]U%-!(ZF6>$W"Q*))6`X9WIS3\PXEEY'<M%Z7"7
M"-+3P9G0EHN#Q$`PE7%1TI$U4?37NY`_8)DQP3Q$^6RA(S#TD]-N5LP/@&-9
M%Q.A3!AEI>HF,S4&%4]-E&HS?+%#A5/BT=55Q50DE,R&3Y:"=8%(>9HT()#U
MAFF>7+'>MN(.KO.[`*B70T"7"V0DI@08UJ05G!`4<*NKZ:-W`8+"<(G!.$[)
MI`81T[Z;YSSST+P#)'IXQN7)W6'-F<,JG/N*1Y8HH$GR=AV-25DU-3C%VJ72
M.JP9U8R0KNB!:,.Q4$]NKF[M+*[=N+ML/6S+3NA/>$P\IO2%'N]()2X(A1A6
M"H`)JB/IJW>40!;I\1(V)X3/PIES1Z8NJ.1C/33=)<&ZBU.)5&<L-P.?#,HX
MSAL=-7875TV'8)-4JV*8COI:F25GF8,GN6*$*&?BS+=\<GO8(?6R$AE2M3J%
M2E04IT)_9HA20`$B#CMQ(%.N?3)D"?\`F'3Q_A'X48S/OI#R/DGIGD[,LF1Z
M*?.6?*W*^!9<P.6.*"%L>S/404JJZ2,LBQ4^^2:1-V_RXV`NW(_R3?\`?O,Q
M<9#A#+275J4,3H;!.!V2J`D'9*APIQSZ8=WTI!+",8&Q/'TH$,?Z'Y?PCH#Z
MD.K<.0L$DQ;HKGW&,I8+2/`XI*FDPW-.&X"DU0JS;_-:.M9FV.%W`6%K@C.Q
MSPNY[96)<7HNK=#JCA(*FEKA.$1*0,03$XTRKZ9]W@A2NX3"3&Q/3'12^Q_I
M5Z5<K4&(8GF+`ZK!:7!*W/E'F:.;#J8SX2.G5_YM/5QPNY6)MT(IF3<9C/"%
M'Z06(K',=X;E:4-%*BM+!3"C"_S']S"20,?NU@QIT+D^&O+^FG=Q(Q83A/!/
M#;PYFDW6=,.A+QXEAM%TVQ'#>H>`U5)%B'2NMI,NRXM,F+9?Q;'L+834>+M1
M0QUJX1.BRM4,8W1HY8T:Y4P:OLU!2M3J%,+!(=27`@:7&T+P+>LE'>))`2-0
M(4E2AMU_T+5N[L[A,]$)X@D?"DGEW)_15\I]/\7S;TIKJ3.G4;#<ES8/TTI8
M,L03C$<VX%B6/QQ+B>)XY#AQ0T^%S2+YT\1`"H/,E?RU-<P_F0NGFV'D%EE3
MP+A[PC2TM""="6BY.I:0=*5#:KPI&HU_Z%KW<@?L$R8X)X@GRX48BE](603U
M/R5D;$^GPP>AZFY7KL=R@M71I2XC35N"5%(F(T-?&S.J2"'$8)(P/\,H)(`/
M`"[O_<_RUVY0Z%*8=2A<&4D+"M"DGB)0H'S3LDTI_P"A8=W]03W"<1.Q/#TZ
MZ&+_`(;RZ<_]@S3?\@4_]'`E_LR7?]+XT]_T*UD'_&$>Q->_X;RZ<_\`8,TW
M_(%/_1SW^S)=_P!+XU[_`*%:R#_C"/8FO?\`#>73G_L&:;_D"G_HY[_9DN_Z
M7QKW_0K60?\`&$>Q->_X;RZ<_P#8,TW_`"!3_P!'/?[,EW_2^->_Z%:R#_C"
M/8FO?\-Y=.?^P9IO^0*?^CGO]F2[_I?&O?\`0K60?\81[$U[_AO+IS_V#--_
MR!3_`-'/?[,EW_2^->_Z%:R#_C"/8FO?\-Y=.?\`L&:;_D"G_HY[_9DN_P"E
M\:]_T*UD'_&$>Q->_P"&\NG/_8,TW_(%/_1SW^S)=_TOC7O^A6L@_P",(]B:
M]_PWETY_[!FF_P"0*?\`HY[_`&9+O^E\:]_T*UD'_&$>Q->_X;RZ<_\`8,TW
M_(%/_1SW^S)=_P!+XU[_`*%:R#_C"/8FO?\`#>73C_L&:?\`Y!IOZ.>_V9+O
M^E\:]_T*UD'_`!A'L37O^&\NG'_8,T__`"#3?T<]_LR7?]+XU[_H5K(/^,(]
MB:]_PWETX_[!FG_Y!IOZ.>_V9+O^E\:]_P!"M9!_QA'L37O^&\NG'_8,T_\`
MR#3?T<]_LR7?]+XU[_H5K(/^,(]B:]_PWETX_P"P9I_^0:;^CGO]F2[_`*7Q
MKW_0K60?\81[$U[_`(;RZ<?]@S3_`/(--_1SW^S)=_TOC7O^A6L@_P",(]B:
M]_PWETX_[!FG_P"0:;^CGO\`9DN_Z7QKW_0K60?\81[$U[_AO+IQ_P!@S3_\
M@TW]'/?[,EW_`$OC7O\`H5K(/^,(]B:]_P`-Y=./^P9I_P#D&F_HY[_9DN_Z
M7QKW_0K60?\`&$>Q->_X;RZ<?]@S3_\`(--_1SW^S)=_TOC7O^A6L@_XPCV)
MKW_#>73C_L&:?_D&F_HY[_9DN_Z7QKW_`$*UD'_&$>Q->_X;RZ<?]@S3_P#(
M--_1SW^S)=_TOC7O^A6L@_XPCV)KW_#>73C_`+!FG_Y!IOZ.>_V9+O\`I?&O
M?]"M9!_QA'L37O\`AO+IQ_V#-/\`\@TW]'/?[,EW_2^->_Z%:R#_`(PCV)KW
M_#>73C_L&:?_`)!IOZ.>_P!F2[_I?&O?]"M9!_QA'L37O^&\NG'_`&#-/_R#
M3?T<]_LR7?\`2^->_P"A6L@_XPCV)KW_``WETX_[!FG_`.0:;^CGO]F2[_I?
M&O?]"M9!_P`81[$U[_AO+IQ_V#-/_P`@TW]'/?[,EW_2^->_Z%:R#_C"/8FO
M?\-Y=./^P9I_^0:;^CGO]F2[_I?&O?\`0K60?\81[$U[_AO+IQ_V#-/_`,@T
MW]'/?[,EW_2^->_Z%:R#_C"/8FO?\-Y=./\`L&:?_D&F_HY[_9DN_P"E\:]_
MT*UD'_&$>Q->_P"&\NG'_8,T_P#R#3?T<]_LR7?]+XU[_H5K(/\`C"/8FO?\
M-Y=./^P9I_\`D&F_HY[_`&9+O^E\:]_T*UD'_&$>Q->_X;RZ<?\`8,T__(--
M_1SW^S)=_P!+XU[_`*%:R#_C"/8FO?\`#>73C_L&:?\`Y!IOZ.>_V9+O^E\:
M]_T*UD'_`!A'L37O^&\NG'_8,T__`"#3?T<]_LR7?]+XU[_H5K(/^,(]B:]_
MPWETX_[!FG_Y!IOZ.>_V9+O^E\:]_P!"M9!_QA'L37O^&\NG'_8,T_\`R#3?
MT<]_LR7?]+XU[_H5K(/^,(]B:]_PWETX_P"P9I_^0:;^CGO]F2[_`*7QKW_0
MK60?\81[$U[_`(;RZ<?]@S3_`/(--_1SW^S)=_TOC7O^A6L@_P",(]B:]_PW
METX_[!FG_P"0:;^CGO\`9DN_Z7QKW_0K60?\81[$U[_AO+IQ_P!@S3_\@TW]
M'/?[,EW_`$OC7O\`H5K(/^,(]B:]_P`-Y=./^P9I_P#D&F_HY[_9DN_Z7QKW
M_0K60?\`&$>Q->_X;RZ<?]@S3_\`(--_1SW^S)=_TOC7O^A6L@_XPCV)KW_#
M>73C_L&:?_D&F_HY[_9DN_Z7QKW_`$*UD'_&$>Q->_X;RZ<?]@S3_P#(--_1
MSW^S)=_TOC7O^A6L@_XPCV)KW_#>73C_`+!FG_Y!IOZ.>_V9+O\`I?&O?]"M
M9!_QA'L35Z_X8'1C!.AW0K.65L!H$P^DQ'-E9B$L*!`#))@^&TY/Z.P[0CG7
M/Z`]YG,UW1N'5F2+I0_]!-'YT<9=N!9[N(_+VR`A*CJ($#$X</(59%S.6E]>
MYZO45CUMYGQ7)GI1ZY9IP/"JG&\7P7!))J#":.GFJJJ>3SXE"QQ4ZN[G7L`>
M0O\`43D"\UW)OK1`)4ZUI`'6111GV\AR>S7>`%7="8`))\@,:TUL=S9GG&,M
M5.%473G/^7<UTF=L4S_D?J71Y2Q48QEW,&*XO)BLQI"]"4>!UFDII8904FA=
MED!O<<I++LQSAJX"U6Y6T6$L+;(5H<;2@)&KB%"`M*A!2L`IBH7/U7#_`)EW
MML_W)S;_`*6DI0455AN:\T9AHNAF9:"AS/-FFKGP^DZ:QTF*)6YQIJJGQ)Y,
M<BPG^8SPWK99(())2L;MJ755531_<O>)RU;:4VX5-AH25.E,,E)1#1/=I/A2
M%*`D@;`22:#ZJD`S^6=X_P"M+X_YM9<-Q/JGA&3L7RG3Y5SCBPS!A^5,+QYL
M;Z6PX]A>(4&4,!&7:2*JPK$L.>"0/`J,Q#*1(H8&UUY6X[/<R=NTOFT6G0IU
M2="W4*2IU?>**7$D*$*D#;X3'75A]5PB/R[T8?ZTOAA_1I)8-D>/+E?ENIP;
MHQF]Z;":?+L&-S8IT\./8Q7_`-5W5J,T^+XSA515X<KHHBG2E95:,!5V$;N&
MEYN_O+<(6'&ERHN%.DN(0GO?NEM!"7(/B25R0K$ZME-I^JAL?\PSO^I+X?YM
M"=EK-74'*5!T6I<%R%U`CJ>A^:<U9HR_7RY.Q.4UDF<FQ@8C25$9H@HC*8U*
MD;I9EVJVIOP-YCV99M=+NE.6QBZ:::4`%".Y[O0H'IEM)(.!DBG4_5<!$6[V
M$D?LG..W^'KHS@]9G6@=NC6<1X?\PMC_`&[?\HG(X_Z%HO?^-+_TII__`*&W
M5_QA[_4G/\&@HZP>HCK5U$RW@4%%T9S6F8LD9BP'-.4I9\JX]Y7\RP&O6I5'
M)HSM$\+2P%K';YFX:C@HW2[![W+[A94TONW6UM+A)G2M,3_FG2J.,1QK7_0V
M041J8>@&?[DY_@T'&/YIZBX\<ZX`V1L_4?2;J9F%,U]0^E*Y+Q-XL1QL5E)B
M,K+B#4GS,$$\]##)-`FC$,`RJQ'!!8]F6:L=T[^6)NF&^Z;=A4I1"DCP?:I2
M4J4$J.S"02!3)^JX%)'Y=Z"9/[)S_!ILS,U7G/.OJ"SAF?HOGO%8/4=EU<N9
MPRNV5,4%#0Q30P0U]717P]F6HKA0T1G,FY2::+W2+@J<MW$WBL[.S89:*39.
M=XA6E6I1!)0E7]ZC4YIB".\5CLJB_JK2HDFW>\6W]DY_@U&RK-F?+)@F'2C-
M:5B8M1XI4_R;IHF5J&84&#8C@D47R.`87!"KM'B<KS3V+N^TZ*`H<S/<//+F
M1W*XT%(UJ==4-2T+)U.$F)0`E.P"=I,U8?58D'"W='^Y+_P:Q85B?5?!\FU6
M4HLM9QQGY_!\KX!BDF-=+(<<PNOPC*5-64-%!5X5B.'202_H:L!F#*=\:OXL
MIM==GN8NW8?-HM,+<<&A;J%)6Z4J44N)(4,4X#'`D<`:V/JN`$?EWHP']R7P
M_P`VE7T^ZC=4^GF8>D$.$=),\39-Z#93Q;`,B+5Y?S!4UE35YBK*:6MGG+47
MNK##1)'"JG:!(R@!57A9GW9+F5_;W)6RH/7;R5KA!``;"@D#I)*B5':2D$F2
M:NGZKTI2(8>D3_K3F`_TM&1_VR.LO_;E\X?^HKC_`/YR<CS_`*%JOO\`C2_]
M*:O_`-#;J_XP]_J3G^#7O]LCK+_VY?.'_J*X_P#^<G/?]"U7W_&E_P"E->_Z
M&W5_QA[_`%)S_!KW^V1UE_[<OG#_`-17'_\`SDY[_H6J^_XTO_2FO?\`0VZO
M^,/?ZDY_@U[_`&R.LO\`VY?.'_J*X_\`^<G/?]"U7W_&E_Z4U[_H;=7_`!A[
M_4G/\&O?[9'67_MR^</_`%%<?_\`.3GO^A:K[_C2_P#2FO?]#;J_XP]_J3G^
M#7O]LCK+_P!N7SA_ZBN/_P#G)SW_`$+5??\`&E_Z4U[_`*&W5_QA[_4G/\&O
M?[9'67_MR^</_45Q_P#\Y.>_Z%JOO^-+_P!*:]_T-NK_`(P]_J3G^#7O]LCK
M+_VY?.'_`*BN/_\`G)SW_0M5]_QI?^E->_Z&W5_QA[_4G/\`!KW^V1UE_P"W
M+YP_]17'_P#SDY[_`*%JOO\`C2_]*:]_T-NK_C#W^I.?X->_VR.LO_;E\X?^
MHKC_`/YR<]_T+5??\:7_`*4U[_H;=7_&'O\`4G/\&O?[9'67_MR^</\`U%<?
M_P#.3GO^A:K[_C2_]*:]_P!#;J_XP]_J3G^#7O\`;(ZR_P#;E\X?^HKC_P#Y
MR<]_T+5??\:7_I37O^AMU?\`&'O]2<_P:]_MD=9?^W+YP_\`45Q__P`Y.>_Z
M%JOO^-+_`-*:]_T-NK_C#W^I.?X->_VR.LO_`&Y?.'_J*X__`.<G/?\`0M5]
M_P`:7_I37O\`H;=7_&'O]2<_P:]_MD=9?^W+YP_]17'_`/SDY[_H6J^_XTO_
M`$IKW_0VZO\`C#W^I.?X->_VR.LO_;E\X?\`J*X__P"<G/?]"U7W_&E_Z4U[
M_H;=7_&'O]2<_P`&O?[9'67_`+<OG#_U%<?_`/.3GO\`H6J^_P"-+_TIKW_0
MVZO^,/?ZDY_@U[_;(ZR_]N7SA_ZBN/\`_G)SW_0M5]_QI?\`I37O^AMU?\8>
M_P!2<_P:]_MD=9?^W+YP_P#45Q__`,Y.>_Z%JOO^-+_TIKW_`$-NK_C#W^I.
M?X->_P!LCK+_`-N7SA_ZBN/_`/G)SW_0M5]_QI?^E->_Z&W5_P`8>_U)S_!K
MW^V1UE_[<OG#_P!17'__`#DY[_H6J^_XTO\`TIKW_0VZO^,/?ZDY_@U[_;(Z
MR_\`;E\X?^HKC_\`YR<]_P!"U7W_`!I?^E->_P"AMU?\8>_U)S_!KW^V1UE_
M[<OG#_U%<?\`_.3GO^A:K[_C2_\`2FO?]#;J_P",/?ZDY_@U[_;(ZR_]N7SA
M_P"HKC__`)R<]_T+5??\:7_I37O^AMU?\8>_U)S_``:]_MD=9?\`MR^</_45
MQ_\`\Y.>_P"A:K[_`(TO_2FO?]#;J_XP]_J3G^#7O]LCK+_VY?.'_J*X_P#^
M<G/?]"U7W_&E_P"E->_Z&W5_QA[_`%)S_!KW^V1UE_[<OG#_`-17'_\`SDY[
M_H6J^_XTO_2FO?\`0VZO^,/?ZDY_@U[_`&R.LO\`VY?.'_J*X_\`^<G/?]"U
M7W_&E_Z4U[_H;=7_`!A[_4G/\&O?[9'67_MR^</_`%%<?_\`.3GO^A:K[_C2
M_P#2FO?]#;J_XP]_J3G^#7O]LCK+_P!N7SA_ZBN/_P#G)SW_`$+5??\`&E_Z
M4U[_`*&W5_QA[_4G/\&O?[9'67_MR^</_45Q_P#\Y.>_Z%JOO^-+_P!*:]_T
M-NK_`(P]_J3G^#7O]LCK+_VY?.'_`*BN/_\`G)SW_0M5]_QI?^E->_Z&W5_Q
MA[_4G/\`!KW^V1UE_P"W+YP_]17'_P#SDY[_`*%JOO\`C2_]*:]_T-NK_C#W
M^I.?X->_VR.LO_;E\X?^HKC_`/YR<]_T+5??\:7_`*4U[_H;=7_&'O\`4G/\
M&O?[9'67_MR^</\`U%<?_P#.3GO^A:K[_C2_]*:]_P!#;J_XP]_J3G^#7O\`
M;(ZR_P#;E\X?^HKC_P#YR<]_T+5??\:7_I37O^AMU?\`&'O]2<_P:]_MD=9?
M^W+YP_\`45Q__P`Y.>_Z%JOO^-+_`-*:]_T-NK_C#W^I.?X->_VR.LO_`&Y?
M.'_J*X__`.<G/?\`0M5]_P`:7_I37O\`H;=7_&'O]2<_P:]_MD=9?^W+YP_]
M17'_`/SDY[_H6J^_XTO_`$IKW_0VZO\`C#W^I.?X->_VR.LO_;E\X?\`J*X_
M_P"<G/?]"U7W_&E_Z4U[_H;=7_&'O]2<_P`&O?[9'67_`+<OG#_U%<?_`/.3
MGO\`H6J^_P"-+_TIKW_0VZO^,/?ZDY_@U[_;(ZR_]N7SA_ZBN/\`_G)SW_0M
M5]_QI?\`I37O^AMU?\8>_P!2<_P:]_MD=9?^W+YP_P#45Q__`,Y.>_Z%JOO^
M-+_TIKW_`$-NK_C#W^I.?X->_P!LCK+_`-N7SA_ZBN/_`/G)SW_0M5]_QI?^
ME->_Z&W5_P`8>_U)S_!KW^V1UE_[<OG#_P!17'__`#DY[_H6J^_XTO\`TIKW
M_0VZO^,/?ZDY_@U[_;(ZR_\`;E\X?^HKC_\`YR<]_P!"U7W_`!I?^E->_P"A
MMU?\8>_U)S_!KW^V1UE_[<OG#_U%<?\`_.3GO^A:K[_C2_\`2FO?]#;J_P",
M/?ZDY_@UL`?A1]3,S]5.@&=L?S5E?$LIXA19PK:.##\4P^LPV=X4P7"YA(L=
M;'$Q0M*0&`M<$7N#SJ!]$NXSN0;KOV[B2DJN5*Q$;6VA\JDO<SM&.\]LJY*%
M(T*T0I)2<`#,*`,>+;5GG,QZ%U>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[
MGJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7
MN>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU
M>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO
M5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ
M]7N>KU>YZO5[GJ]7N>KU>YZO4U8WCN"99PFNQ[,F,4N7\#PM/-Q/&JZHAI*2
MGC!`WRS3LB(MSW8@<8N;EME!6XH)2-I)@#S)IBYN6V6RMQ02D;23`'F306_[
M1_IX_P"W]9+_`/4IP/\`\ZN$/]L\G_YF6O\`5$?C1+_:[*?^9AK_`$Z?QKW^
MT?Z>/^W]9+_]2G`__.KGO[9Y/_S,M?ZHC\:]_:[*?^9AK_3I_&O?[1_IX_[?
MUDO_`-2G`_\`SJY[^V>3_P#,RU_JB/QKW]KLI_YF&O\`3I_&O?[1_IX_[?UD
MO_U*<#_\ZN>_MGD__,RU_JB/QKW]KLI_YF&O].G\:]_M'^GC_M_62_\`U*<#
M_P#.KGO[9Y/_`,S+7^J(_&O?VNRG_F8:_P!.G\:]_M'^GC_M_62__4IP/_SJ
MY[^V>3_\S+7^J(_&O?VNRG_F8:_TZ?QKW^T?Z>/^W]9+_P#4IP/_`,ZN>_MG
MD_\`S,M?ZHC\:]_:[*?^9AK_`$Z?QKW^T?Z>/^W]9+_]2G`__.KGO[9Y/_S,
MM?ZHC\:]_:[*?^9AK_3I_&O?[1_IX_[?UDO_`-2G`_\`SJY[^V>3_P#,RU_J
MB/QKW]KLI_YF&O\`3I_&O?[1_IX_[?UDO_U*<#_\ZN>_MGD__,RU_JB/QKW]
MKLI_YF&O].G\:]_M'^GC_M_62_\`U*<#_P#.KGO[9Y/_`,S+7^J(_&O?VNRG
M_F8:_P!.G\:]_M'^GC_M_62__4IP/_SJY[^V>3_\S+7^J(_&O?VNRG_F8:_T
MZ?QKW^T?Z>/^W]9+_P#4IP/_`,ZN>_MGD_\`S,M?ZHC\:]_:[*?^9AK_`$Z?
MQKW^T?Z>/^W]9+_]2G`__.KGO[9Y/_S,M?ZHC\:]_:[*?^9AK_3I_&O?[1_I
MX_[?UDO_`-2G`_\`SJY[^V>3_P#,RU_JB/QKW]KLI_YF&O\`3I_&O?[1_IX_
M[?UDO_U*<#_\ZN>_MGD__,RU_JB/QKW]KLI_YF&O].G\:]_M'^GC_M_62_\`
MU*<#_P#.KGO[9Y/_`,S+7^J(_&O?VNRG_F8:_P!.G\:]_M'^GC_M_62__4IP
M/_SJY[^V>3_\S+7^J(_&O?VNRG_F8:_TZ?QKW^T?Z>/^W]9+_P#4IP/_`,ZN
M>_MGD_\`S,M?ZHC\:]_:[*?^9AK_`$Z?QKW^T?Z>/^W]9+_]2G`__.KGO[9Y
M/_S,M?ZHC\:]_:[*?^9AK_3I_&O?[1_IX_[?UDO_`-2G`_\`SJY[^V>3_P#,
MRU_JB/QKW]KLI_YF&O\`3I_&O?[1_IX_[?UDO_U*<#_\ZN>_MGD__,RU_JB/
MQKW]KLI_YF&O].G\:]_M'^GC_M_62_\`U*<#_P#.KGO[9Y/_`,S+7^J(_&O?
MVNRG_F8:_P!.G\:]_M'^GC_M_62__4IP/_SJY[^V>3_\S+7^J(_&O?VNRG_F
M8:_TZ?QKW^T?Z>/^W]9+_P#4IP/_`,ZN>_MGD_\`S,M?ZHC\:]_:[*?^9AK_
M`$Z?QKW^T?Z>/^W]9+_]2G`__.KGO[9Y/_S,M?ZHC\:]_:[*?^9AK_3I_&O?
M[1_IX_[?UDO_`-2G`_\`SJY[^V>3_P#,RU_JB/QKW]KLI_YF&O\`3I_&O?[1
M_IX_[?UDO_U*<#_\ZN>_MGD__,RU_JB/QKW]KLI_YF&O].G\:]_M'^GC_M_6
M2_\`U*<#_P#.KGO[9Y/_`,S+7^J(_&O?VNRG_F8:_P!.G\:]_M'^GC_M_62_
M_4IP/_SJY[^V>3_\S+7^J(_&O?VNRG_F8:_TZ?QKW^T?Z>/^W]9+_P#4IP/_
M`,ZN>_MGD_\`S,M?ZHC\:]_:[*?^9AK_`$Z?QKW^T?Z>/^W]9+_]2G`__.KG
MO[9Y/_S,M?ZHC\:]_:[*?^9AK_3I_&O?[1_IX_[?UDO_`-2G`_\`SJY[^V>3
M_P#,RU_JB/QKW]KLI_YF&O\`3I_&O?[1_IX_[?UDO_U*<#_\ZN>_MGD__,RU
M_JB/QKW]KLI_YF&O].G\:]_M'^GC_M_62_\`U*<#_P#.KGO[9Y/_`,S+7^J(
M_&O?VNRG_F8:_P!.G\:]_M'^GC_M_62__4IP/_SJY[^V>3_\S+7^J(_&O?VN
MRG_F8:_TZ?QKW^T?Z>/^W]9+_P#4IP/_`,ZN>_MGD_\`S,M?ZHC\:]_:[*?^
M9AK_`$Z?QKW^T?Z>/^W]9+_]2G`__.KGO[9Y/_S,M?ZHC\:]_:[*?^9AK_3I
M_&O?[1_IX_[?UDO_`-2G`_\`SJY[^V>3_P#,RU_JB/QKW]KLI_YF&O\`3I_&
MO?[1_IX_[?UDO_U*<#_\ZN>_MGD__,RU_JB/QKW]KLI_YF&O].G\:]_M'^GC
M_M_62_\`U*<#_P#.KGO[9Y/_`,S+7^J(_&O?VNRG_F8:_P!.G\:]_M'^GC_M
M_62__4IP/_SJY[^V>3_\S+7^J(_&O?VNRG_F8:_TZ?QKW^T?Z>/^W]9+_P#4
MIP/_`,ZN>_MGD_\`S,M?ZHC\:]_:[*?^9AK_`$Z?QKW^T?Z>/^W]9+_]2G`_
M_.KGO[9Y/_S,M?ZHC\:]_:[*?^9AK_3I_&O?[1_IX_[?UDO_`-2G`_\`SJY[
M^V>3_P#,RU_JB/QKW]KLI_YF&O\`3I_&O?[1_IX_[?UDO_U*<#_\ZN>_MGD_
M_,RU_JB/QKW]KLI_YF&O].G\:Z/J1].X!)Z]Y+`&I)S3@>G_`)%<\-\\G_YF
M6O\`5$_C6CO?E/\`S,-?Z=/XT,-+54M=2TU;15,=915D:2TE7$ZR12Q2*'1T
M="0RL"""#8C@B;<2I(4DR#0@0L*`(,@UGY>K5[GJ]7N>KU>YZO5[GJ]7N>KU
M>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]1;_`%>Y.P[J!Z:.L>3,6C67
M#<PX1)3UD;@%2AFC;6_T<@+ZI,S79=GV8OH^Y#)(]HK2LC9S(?E71*',"#T5
MHWT,V!8/U[]<W2[.>1\"EP7HQ!(OII:EI&@JL?QC#Z3!J>KPNKDDE=9IVK,S
M8;Y?EJEHY&T)%^<K'LF#V1Y5>6ZUZ[D_Y3)!"$*+A2M(`$`(9=F9Q2*)?]@K
M(0XM):3X=F`QV8>\5@Z?]2O3Y@_1OIWF/K?E*EJL^4F2J'.7J$Q+`C@&'83E
MO#<0S)B.7HIZ>CQK$XZNM)_ELT[4U$L\J1(7(]Y`U\]W'S=[-WFLN5#!?4S;
MA86I;BDMH<(*D(*$?>E(4YH25$`;"11/8?N\$`J:3LDX#`3'KLX4J^H];TNH
M<X9`CZ?=*JJHZ-XQF#JG@6.]:IJ+!:R@Q6;IGD/',PURX-`F)15`*5V%>5%+
M4Q)#4!)`C`6?A7N]D5VNT>-T\D7:6[9:605A21<OM-I[PZ"G%#DD()4@E)(G
M"G%]A60`B&1IDB8'\(),>RLN,U73#%:?HW6],.D=;CV3LR]0<E9'ZB=6ZZAP
M:'":>NQO+:YEQ&@BI8L1-4E5#%/%'YZQO3I.6B#O;=RMGDEVTJY3>/H0\BW>
M>;:25%12ASNT+*BC24DA1TR%E$*@3%>_V"L@,0R""0)@;2)YX4I,Q9N])V7N
MFG3'J<>E&8<7P_JQD3#,_97P&EI,#.(##L7S;A&3:>CE$M<D8JS58S"Q`<IL
M#'?<`$NR_=3>&XS%^S[YI*K>X4PI1*].I#3CQ4(03ITMJ&R9(PB37E]AF[P0
M%=T,1.P=('SKCUS],?7C)U?F/'.FO2BFQ.CH\NY5QC"NE=5E*+%ZM,5Q'.$>
M"8KA#XQ@.)302RP4"/5!H@0F]6:\:W-MR]\-W+M"&[M[2HN.H+H=T#2EHK;<
M#:T!0"ED(@Q,$#Q&GW_I_P`E2,&`<!P'3$848'TL^DZHZL9&Q[,O6/I5%TQQ
M^JS-BL.4<IU>%RX;5PY9<4]3A1JDJF<O4>3/MG=;+YBLNT%2.`3M,WZMLKO4
M,V#W?H#22M04%`N8AS3`P3(E(Q.D@R9IZU^GO(W$R64CT%%;RGTTFZRYN],&
M'9'DR]T]REZG%ZK8UEW%:C+:8W74V6\CUM)0X0626OI8_.KD=ZB5KV5750/=
M),EYI>6V46E\NY2MYVQ_*H4`YH27'@I3F(0HP@PD=)!)VP$S/8+D*RF&DPJ>
M`X?C009EQF;)?6SHGTPQ[)N5JC`\(Z@YWR-ZGLRPX?/$KT.!8CE'",,QS"Q)
M4M\HC/G&DEJH'\[;:15:P#<%67;NVUYDUU>-+<"U6[+ULDD'Q+3<+6TYX?&0
M+=80H:9E)(DQ2=SL,R%+@26D[2#@.$8^\5`S+C$[9\ZLX3A.!8%EOI_AO5#I
MSE#IIF2'*6)9HQ5\L9IJ<PX56XD</PN=I:^:6HP%I:58(](W'NOWXHR[=ZV%
MC;K65K?5:W#KB2ZEI/>-!E24:U"$`)=`65'[AM&RO'L-R#4?V28!`V=,X^ZC
MA9@Z&Y,Z=],LO]5J_%4ZB93IL]9:R]U`FQ/IQC?3S$*?",T8C2Y;2:DH<P"&
M9VI:S$()VEV%'C$B"S"XB>QSYS,,R79);#+IMW'&]-PW<)*VDJ<(4IN0-2$*
M2!,A6E6PTL<[`L@2C5W28D#[8VF.(H[\GH(Z5Q221/A-)NC8JWN1=P;>SD,)
M[6KPB:6_]"ZY%_QM/L%</]@SI3_TRJ3_`*)Q?T<M_LL7M>_Z%UR+_C:?8*]_
ML&=*?^F52?\`1.+^CGO]EB]KW_0NN1?\;3[!7O\`8,Z4_P#3*I/^B<7]'/?[
M+%[7O^A=<B_XVGV"O?[!G2G_`*95)_T3B_HY[_98O:]_T+KD7_&T^P5[_8,Z
M4_\`3*I/^B<7]'/?[+%[7O\`H77(O^-I]@KW^P9TI_Z95)_T3B_HY[_98O:]
M_P!"ZY%_QM/L%>_V#.E/_3*I/^B<7]'/?[+%[7O^A=<B_P"-I]@KW^P9TI_Z
M95)_T3B_HY[_`&6+VO?]"ZY%_P`;3[!7O]@SI3_TRJ3_`*)Q?T<]_LL7M>_Z
M%UR+_C:?8*]_L&=*?^F52?\`1.+^CGO]EB]KW_0NN1?\;3[!7O\`8,Z4_P#3
M*I/^B<7]'/?[+%[7O^A=<B_XVGV"O?[!G2G_`*95)_T3B_HY[_98O:]_T+KD
M7_&T^P5[_8,Z4_\`3*I/^B<7]'/?[+%[7O\`H77(O^-I]@KW^P9TI_Z95)_T
M3B_HY[_98O:]_P!"ZY%_QM/L%>_V#.E/_3*I/^B<7]'/?[+%[7O^A=<B_P"-
MI]@KW^P9TI_Z95)_T3B_HY[_`&6+VO?]"ZY%_P`;3[!7O]@SI3_TRJ3_`*)Q
M?T<]_LL7M>_Z%UR+_C:?8*]_L&=*?^F52?\`1.+^CGO]EB]KW_0NN1?\;3[!
M7O\`8,Z4_P#3*I/^B<7]'/?[+%[7O^A=<B_XVGV"O?[!G2G_`*95)_T3B_HY
M[_98O:]_T+KD7_&T^P5[_8,Z4_\`3*I/^B<7]'/?[+%[7O\`H77(O^-I]@KW
M^P9TI_Z95)_T3B_HY[_98O:]_P!"ZY%_QM/L%>_V#.E/_3*I/^B<7]'/?[+%
M[7O^A=<B_P"-I]@KW^P9TI_Z95)_T3B_HY[_`&6+VO?]"ZY%_P`;3[!7O]@S
MI3_TRJ3_`*)Q?T<]_LL7M>_Z%UR+_C:?8*]_L&=*?^F52?\`1.+^CGO]EB]K
MW_0NN1?\;3[!7O\`8,Z4_P#3*I/^B<7]'/?[+%[7O^A=<B_XVGV"O?[!G2G_
M`*95)_T3B_HY[_98O:]_T+KD7_&T^P5[_8,Z4_\`3*I/^B<7]'/?[+%[7O\`
MH77(O^-I]@KW^P9TI_Z95)_T3B_HY[_98O:]_P!"ZY%_QM/L%>_V#.E/_3*I
M/^B<7]'/?[+%[7O^A=<B_P"-I]@KW^P9TI_Z95)_T3B_HY[_`&6+VO?]"ZY%
M_P`;3[!7O]@SI3_TRJ3_`*)Q?T<]_LL7M>_Z%UR+_C:?8*]_L&=*?^F52?\`
M1.+^CGO]EB]KW_0NN1?\;3[!6&H]!72AJ>=3A5)9D8']'%XJ?AQI_M;ODH)$
MR!7O^A=,A.'=I]@K:;Z<X=#@_3W(>$4X"T^%X-A=-`H[!(*&*);?4O/I&W!>
M+F16JSM++9]J$T[^52Q^S3L3@/(84L^"RO5[GJ]7N>KU>YZO5[GJ]7N>KU>Y
MZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]19?65!GZI]+W6FGZ6Y:J\X]09
M<&D7*N6:%4:KK*HSQVCB#L@)M<ZGPY%';GNJ]GFZ5Y8-)*EO-Z0!QQ%$V\.:
MW5C9+?MD%QU`E*1M)Z!6G16^@_UG8GU0PWJ[B7I`ZC5F;,)ZA2=2:(E,)6#^
M>28!0X#\LX20,]&/Y92U(B9B?/B1RQ"A><]F>Q??-O+56*+4AI5L+<^$SH#B
MG-0Q@+\:T2!]BB(QFH0/;+O>3/\`+7YV[!MZ?NI&T7X;_K-PFCP.CP+TN=3\
M$%!@%#EG'Z^&DRL]?BV#X9CE9CU,IJZB&2>BGCDQ">+YBA>"0Q/M+7"D&[O9
M=OFZM:G+,*EQ3B00O2A:D)0KPA82M)"$G2X%IU"8Q(.T]LF]P_YMCWL'^%3I
MB_X??KIQ;%8&'IUZLX;DO#<4SYC>7NF%-'EM,&P[%>I&`XA@&-S0EXVJ2KIB
ME1-#&\S)%(Y*C:2O$UIV0[VM-$?D$J>4AA"G2E>M2;=:'&@?'IP*$I40D%20
M),XUO_9FWOB/Y:_QX#CM_BK)AOH`]=6"U&4*/!_3GU8P[(^4LSX#G0]-43+I
MPG$,T8#@<.7EKJEG0U/^DP0*\\4<RQF6\BJI)Y2X['M[7DN*<L4EYQI;/>:5
MZTM+67-*?%I\*B0E122$^$DBO#MFWO"8_EK^V=@_PJ2,'X9_K<&#Y;RYB/0'
MK!C.7,CY=PS*>0L%G3*ZQ8/@&#YOP_.E-3Q-!!&\CBJPV&-I9B[M$+$[@&!L
MOLUWO[U;J,O0EQUQ3KB@E<K<6TME1,K(`TK40E,`*QV85H]LN]T`?RQ_##8/
M\*K`'P3\35W9SZ0L[7<DG_1J+N3?_E+Y!(^C7.P/^)5^RG/]FS?/_G'/^Q/^
M%7<>"_B:Q2)(OI"SKNC(9;TU$1<&_P#RE<\KZ-<[(C\JOV5[_9LWS_YQS_L3
M_A42C)?HC_$KRE1]'X\%]/W4;)F*^G1\Z8;TAQO#,/RS6[LLYOKDK#35E/CD
M55'YL"(L*E`-$#7UL)CSGL.SVZ7<ERP+J;T,J=2K6G]HTDB4E"TF%&58],<*
M=5VS[UITZ,M?P'$#`\8A6(KV-?AX>LC,6%U%!CGI/ZGXG6XOA'4+#LV9CE.#
M_P`QQFNZF2X9/B^+U,J%0M<DF$4S4K1*D<015"650-6?9+OI;NA3=II"5VZD
M)"3I0FV"PVVD:OL(<4%ZB5*DDF292GMEWO.W+7\>H<=O\5=U/X?7K?B;!:C+
M7IDZH91Q'+,O3B?+=?2T^7*DTD_2^BK:#"'\O$$GCD,BU\C5'F*V]K$;=;^;
M[(=[SJ#UD'$K%P%`A8D7*DJ<$I4"(*`$Q$##&K)[9M[Q_P`VQ_V#AL_BX4(7
M47TY_BL=2<H8)T^SCT$S]GK+M1FG+F.9MK\0PG+.'U*X?EK$X<?BHZ9,"CI(
MV,]91P!VD%U3?8]APBW>^FG,LNNUW3&7J:<#+B$!.M0U.)+94HK6HC2A2H`V
MF*5?[-6]JTJUY;<;,``,3/&5;!MZS1DY,$_$UE=Y'](>=B\A+,?EJ+N3<_\`
M(UR.D_1KG8$?E5^RF/\`9LWS_P"<<_[$_P"%7'^0_B9_]PA9V_\`&:B_\ZN;
M_P"A-L\_YE5^RO?[-F^?_..?]B?\*O?R'\3/_N$+.W_C-1?^=7/?]";9Y_S*
MK]E>_P!FS?/_`)QS_L3_`(5>_D/XF?\`W"%G;_QFHO\`SJY[_H3;//\`F57[
M*]_LV;Y_\XY_V)_PJ]_(?Q,_^X0L[?\`C-1?^=7/?]";9Y_S*K]E>_V;-\_^
M<<_[$_X5>_D/XF?_`'"%G;_QFHO_`#JY[_H3;//^95?LKW^S9OG_`,XY_P!B
M?\*O?R'\3/\`[A"SM_XS47_G5SW_`$)MGG_,JOV5[_9LWS_YQS_L3_A5[^0_
MB9_]PA9V_P#&:B_\ZN>_Z$VSS_F57[*]_LV;Y_\`..?]B?\`"KW\A_$S_P"X
M0L[?^,U%_P"=7/?]";9Y_P`RJ_97O]FS?/\`YQS_`+$_X5>_D/XF?_<(6=O_
M`!FHO_.KGO\`H3;//^95?LKW^S9OG_SCG_8G_"KW\A_$S_[A"SM_XS47_G5S
MW_0FV>?\RJ_97O\`9LWS_P"<<_[$_P"%7OY#^)G_`-PA9V_\9J+_`,ZN>_Z$
MVSS_`)E5^RO?[-F^?_..?]B?\*O?R'\3/_N$+.W_`(S47_G5SW_0FV>?\RJ_
M97O]FS?/_G'/^Q/^%7OY#^)G_P!PA9V_\9J+_P`ZN>_Z$VSS_F57[*]_LV;Y
M_P#..?\`8G_"KW\A_$S_`.X0L[?^,U%_YU<]_P!";9Y_S*K]E>_V;-\_^<<_
M[$_X5>_D/XF?_<(6=O\`QFHO_.KGO^A-L\_YE5^RO?[-F^?_`#CG_8G_``J]
M_(?Q,_\`N$+.W_C-1?\`G5SW_0FV>?\`,JOV5[_9LWS_`.<<_P"Q/^%7OY#^
M)G_W"%G;_P`9J+_SJY[_`*$VSS_F57[*]_LV;Y_\XY_V)_PJ]_(?Q,_^X0L[
M?^,U%_YU<]_T)MGG_,JOV5[_`&;-\_\`G'/^Q/\`A5[^0_B9_P#<(6=O_&:B
M_P#.KGO^A-L\_P"95?LKW^S9OG_SCG_8G_"KW\A_$S_[A"SM_P",U%_YU<]_
MT)MGG_,JOV5[_9LWS_YQS_L3_A5[^0_B9_\`<(6=O_&:B_\`.KGO^A-L\_YE
M5^RO?[-F^?\`SCG_`&)_PJ]_(?Q,_P#N$+.W_C-1?^=7/?\`0FV>?\RJ_97O
M]FS?/_G'/^Q/^%7OY#^)G_W"%G;_`,9J+_SJY[_H3;//^95?LKW^S9OG_P`X
MY_V)_P`*O?R'\3/_`+A"SM_XS47_`)U<]_T)MGG_`#*K]E>_V;-\_P#G'/\`
ML3_A5[^0_B9_]PA9V_\`&:B_\ZN>_P"A-L\_YE5^RO?[-F^?_..?]B?\*O?R
M'\3/_N$+.W_C-1?^=7/?]";9Y_S*K]E>_P!FS?/_`)QS_L3_`(5>_D/XF?\`
MW"%G;_QFHO\`SJY[_H3;//\`F57[*]_LV;Y_\XY_V)_PJ]_(?Q,_^X0L[?\`
MC-1?^=7/?]";9Y_S*K]E>_V;-\_^<<_[$_X5>_D/XF?_`'"%G;_QFHO_`#JY
M[_H3;//^95?LKW^S9OG_`,XY_P!B?\*O?R'\3/\`[A"SM_XS47_G5SW_`$)M
MGG_,JOV5[_9LWS_YQS_L3_A5[^0_B9_]PA9V_P#&:B_\ZN>_Z$VSS_F57[*]
M_LV;Y_\`..?]B?\`"KW\A_$S_P"X0L[?^,U%_P"=7/?]";9Y_P`RJ_97O]FS
M?/\`YQS_`+$_X5>_D/XF?_<(6=O_`!FHO_.KGO\`H3;//^95?LKW^S9OG_SC
MG_8G_"KW\A_$S_[A"SM_XS47_G5SW_0FV>?\RJ_97O\`9LWS_P"<<_[$_P"%
M6&HP#\39J>=8_2%G8NR,$'RU%W*FW_(URJ_HSSQ0(_*KQZJ]_LV;Y_\`..?]
MB?\`"K;+Z:+BR=..GZ8]0R89CJX)A0QK#90!+3U8H(A-$X!(W(]P=>XYV6W3
ML56N5,,J$%#2$D=!"0(J>K*X<=92M8TJ4`2#M!(D@^5+;@@I37N>KU>YZO5[
MGJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7
MN>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU
M>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO
M5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ
M]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>
MKU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU,>9<SY:R7@.)YISC
MF&ARGEC!(C-C.8\2JZ>@H*2$$*9)JBJ=(XUN0+LP'$M[>LVS1==4$(3M*B`!
MYDX"DUW>,V[9<=4$(3M)(`'F3@*`[_;#](__`'%+TY_]3?+/_G;P*_[)&[O_
M`#.,?ZJW_A4'O[=9)_S-,_ZHC\:]_MA^D?\`[BEZ<_\`J;Y9_P#.WGO]DC=W
M_F<8_P!5;_PJ]_;K)/\`F:9_U1'XU[_;#](__<4O3G_U-\L_^=O/?[)&[O\`
MS.,?ZJW_`(5>_MUDG_,TS_JB/QKW^V'Z1_\`N*7IS_ZF^6?_`#MY[_9(W=_Y
MG&/]5;_PJ]_;K)/^9IG_`%1'XU[_`&P_2/\`]Q2].?\`U-\L_P#G;SW^R1N[
M_P`SC'^JM_X5>_MUDG_,TS_JB/QKW^V'Z1_^XI>G/_J;Y9_\[>>_V2-W?^9Q
MC_56_P#"KW]NLD_YFF?]41^->_VP_2/_`-Q2].?_`%-\L_\`G;SW^R1N[_S.
M,?ZJW_A5[^W62?\`,TS_`*HC\:]_MA^D?_N*7IS_`.IOEG_SMY[_`&2-W?\`
MF<8_U5O_``J]_;K)/^9IG_5$?C7O]L/TC_\`<4O3G_U-\L_^=O/?[)&[O_,X
MQ_JK?^%7O[=9)_S-,_ZHC\:]_MA^D?\`[BEZ<_\`J;Y9_P#.WGO]DC=W_F<8
M_P!5;_PJ]_;K)/\`F:9_U1'XU[_;#](__<4O3G_U-\L_^=O/?[)&[O\`S.,?
MZJW_`(5>_MUDG_,TS_JB/QKW^V'Z1_\`N*7IS_ZF^6?_`#MY[_9(W=_YG&/]
M5;_PJ]_;K)/^9IG_`%1'XU[_`&P_2/\`]Q2].?\`U-\L_P#G;SW^R1N[_P`S
MC'^JM_X5>_MUDG_,TS_JB/QKW^V'Z1_^XI>G/_J;Y9_\[>>_V2-W?^9QC_56
M_P#"KW]NLD_YFF?]41^->_VP_2/_`-Q2].?_`%-\L_\`G;SW^R1N[_S.,?ZJ
MW_A5[^W62?\`,TS_`*HC\:]_MA^D?_N*7IS_`.IOEG_SMY[_`&2-W?\`F<8_
MU5O_``J]_;K)/^9IG_5$?C7O]L/TC_\`<4O3G_U-\L_^=O/?[)&[O_,XQ_JK
M?^%7O[=9)_S-,_ZHC\:]_MA^D?\`[BEZ<_\`J;Y9_P#.WGO]DC=W_F<8_P!5
M;_PJ]_;K)/\`F:9_U1'XU[_;#](__<4O3G_U-\L_^=O/?[)&[O\`S.,?ZJW_
M`(5>_MUDG_,TS_JB/QKW^V'Z1_\`N*7IS_ZF^6?_`#MY[_9(W=_YG&/]5;_P
MJ]_;K)/^9IG_`%1'XU[_`&P_2/\`]Q2].?\`U-\L_P#G;SW^R1N[_P`SC'^J
MM_X5>_MUDG_,TS_JB/QKW^V'Z1_^XI>G/_J;Y9_\[>>_V2-W?^9QC_56_P#"
MKW]NLD_YFF?]41^->_VP_2/_`-Q2].?_`%-\L_\`G;SW^R1N[_S.,?ZJW_A5
M[^W62?\`,TS_`*HC\:]_MA^D?_N*7IS_`.IOEG_SMY[_`&2-W?\`F<8_U5O_
M``J]_;K)/^9IG_5$?C7O]L/TC_\`<4O3G_U-\L_^=O/?[)&[O_,XQ_JK?^%7
MO[=9)_S-,_ZHC\:]_MA^D?\`[BEZ<_\`J;Y9_P#.WGO]DC=W_F<8_P!5;_PJ
M]_;K)/\`F:9_U1'XU[_;#](__<4O3G_U-\L_^=O/?[)&[O\`S.,?ZJW_`(5>
M_MUDG_,TS_JB/QKW^V'Z1_\`N*7IS_ZF^6?_`#MY[_9(W=_YG&/]5;_PJ]_;
MK)/^9IG_`%1'XU[_`&P_2/\`]Q2].?\`U-\L_P#G;SW^R1N[_P`SC'^JM_X5
M>_MUDG_,TS_JB/QKW^V'Z1_^XI>G/_J;Y9_\[>>_V2-W?^9QC_56_P#"KW]N
MLD_YFF?]41^->_VP_2/_`-Q2].?_`%-\L_\`G;SW^R1N[_S.,?ZJW_A5[^W6
M2?\`,TS_`*HC\:]_MA^D?_N*7IS_`.IOEG_SMY[_`&2-W?\`F<8_U5O_``J]
M_;K)/^9IG_5$?C7O]L/TC_\`<4O3G_U-\L_^=O/?[)&[O_,XQ_JK?^%7O[=9
M)_S-,_ZHC\:]_MA^D?\`[BEZ<_\`J;Y9_P#.WGO]DC=W_F<8_P!5;_PJ]_;K
M)/\`F:9_U1'XU[_;#](__<4O3G_U-\L_^=O/?[)&[O\`S.,?ZJW_`(5>_MUD
MG_,TS_JB/QKW^V'Z1_\`N*7IS_ZF^6?_`#MY[_9(W=_YG&/]5;_PJ]_;K)/^
M9IG_`%1'XU[_`&P_2/\`]Q2].?\`U-\L_P#G;SW^R1N[_P`SC'^JM_X5>_MU
MDG_,TS_JB/QKW^V'Z1_^XI>G/_J;Y9_\[>>_V2-W?^9QC_56_P#"KW]NLD_Y
MFF?]41^->_VP_2/_`-Q2].?_`%-\L_\`G;SW^R1N[_S.,?ZJW_A5[^W62?\`
M,TS_`*HC\:]_MA^D?_N*7IS_`.IOEG_SMY[_`&2-W?\`F<8_U5O_``J]_;K)
M/^9IG_5$?C7O]L/TC_\`<4O3G_U-\L_^=O/?[)&[O_,XQ_JK?^%7O[=9)_S-
M,_ZHC\:]_MA^D?\`[BEZ<_\`J;Y9_P#.WGO]DC=W_F<8_P!5;_PJ]_;K)/\`
MF:9_U1'XU[_;#](__<4O3G_U-\L_^=O/?[)&[O\`S.,?ZJW_`(5>_MUDG_,T
MS_JB/QH?<)Q;"\>PO#<<P/$J?&<%QFGAJ\'QBDFCJ*6KI:B,3130RPEDDCD1
M@RLI((((-N"ZWN&WFPM!"DJ`((,@@X@@C`@C8:$K+R'$!:""E0D$8@@["#Q!
MIPX]3M>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>
MKU>YZO5[GJ]7N>KU>YZO5[GJ]1?/59EG"<Y>G?JQE?'463",:PMH:]'MM,9F
MC.M_HYC[]5E^Y:]G69.M_<EDD>T4\QE;-ZL,/"4+P/E6AMECI;5X8</ZIXQE
M[&X\CT/J=Q;).:^K:Y[JL2IOZJ3]0JG*=-A0RA6L:?R&DGIZ7S8OTD*GSE!*
M6YS,S'.6')LFU-]\<J0\EKN$I/>BW2ZIS\P/%J@*7"O"H^`[:O\`[&.3%.+2
M-.K3,)F)CHGWT(&%YMS-B72'HYG6/(V3,4SQUQP_/>8L!R-@&5\SY@Q#",OY
M(GGH"U32+C-''+%--Y)J*^6LI8J8-L6*H9@5(+G=RQ;S6YMRZ\EFU4PVI:W&
MFTK<>`5X5=VH@@:M+8;<4N)*FP,4X[+,ET)/=)E4X`3LYVS[:%'TSSQ^K.IA
MQW(V1\F]/<EY5RETJS%U$PC'$Q>KQ:NEZDY1.;*A,*JZ*6*&GCHHY(XH'FIY
MA42!P3$%OP-]HN6M[K)+=RX\\\X]=-ME&@(2+=WN@7$J!*BL@E02I.@1@J8I
MZS[*<D>Q#:``$G'K$^ZBN]%\U9RR-Z=N@N.Y\RSECJU4X]T8I.K.,XFL.,IC
MRY>P'-V%X/F"&LJ*FNG6LK_Y7B+UL,Z1QJ)83$8I`P?DE;X;O9?>Y_=MVRW+
M<(O3:@>#N^\6TM;)2`D:&^]0&U))4=*@H*2013`[+\F*`HM(Q3JP$1B)'LQH
M;<1Z68WU_P`5P;JCT>R+AO63HC38GGZBRUT)RIU`/3[/&:<MX9BM)@>$YPI:
MN6H@2LA>II*Z..$U%/3E)8GW,Z[2#K;.;3(FE6=^XJVO2E@J?=MQ<,M.*2I;
MENI,$H.E39*M*U@I4(`,A6UV5Y-]R&D*$G#"8'$3ATT&>"U/3C.>9_3/E_(>
M(XW5Y8Q[$>B#XQF[,32X?FRN3'NH6:,JXQA6-45!(F'!X6P;RIG@@!F()9Y$
MV6$=YEMW:6U\[<I;#B$WL(;`4TG0PPZVXTI0+D$.:DA2O#,`),TTGLRR)1`#
M28,;0)Q)!]D48;J/^&;U<I\9Q#%NAO46FP9I\U9HF@I,<SCF+$J3^J6+X'08
M3A\?D8B:Q4GH:B6MK(U0"TB1#?9AL`6[_;]DJF0WF+&J&6A*&6TGO4+6M9E.
MDE*TAMLD\"HQAB8/=D64D0EMO;T#9[*$'J_Z;\-Z+^D3I;@.(XG%+UCS%6=,
M>GV9,^I5-73TN(YHQW"\L8EBJ54J(TLR)/-)'*R@F0JQ%^$.ZF^8SC>NX=0C
M_)$"YN$MQI!2TA;J&](V`D)!2#]LBFKCLCR1"`HMHU$@;!&)^%/W0_H#D+$:
M;UT5.*AL<I.DW47-&&9,AJYZB9:;#,+R5@V(PTR2;MZ1^;,[>ZP-V+7W&_$.
M^F]ERVK*@@!!N+9I2X`$J4\XDJ(V$P!M$0`-E;;[),B7JEM/A)&P=$T5#H]U
M)RSF*HZ+]+L:Z98#2]3.IV'=.\VY=H(6QBKB?I=C?3>7.6.XH7Q"KGJ):K#Z
MO#*O#EDDF(:5X&<,2Q:4-[=T'+=-U>-O+-LPJX:43H!_,HN`RTB$I"0EQ*T.
MD!(A(6$D0(0-=E^1K(!:3*H.S@1)]FSV4@_\^6,S=)LN]2:7H-@T1ZL93R_F
MCIS48GEK-^!83@M1CV>,"RU'AM958M+#_.T^4Q^.85V&B*(2Q.A3:\3,=?['
MMH,T7:*NE_Y.\XTYI<96I80RZX5I2@'N3K:*>[=U*TJ!!D*`9_V,<ET!7=)Q
M`.R(D@1U[=HH]/J*].&7LMU/I+Z98EF&BP)NM/4&+*_6#/\`EV*7!1\I3Y8Q
MK'8Z;#VJIZV:A_F-5AT%,&\]I0'98Y`[*PA;<#?-5PG,+Q#97^5MRZTVY"\2
MXV@J7`2%]VE:EQI"20"I,`BC5WLBR-M2!W:#)@X#H)^5(WJKT5Z:>G+%:;(7
M3;-\?57-_4[..!X5EKI1B=/BV><R92IJ[`:_%*I:.CI*N'$<2$ZX:]1'%75]
M.D$9D?S]BI&QONSO'>;PM&YNVOR[3#*U*=24,-NE*TI3J44EMO25A)+;:RM6
ME.C42H5O>R?(DD0A!)($`#X#]**!@?6_,&<^F.8.I^7ND^1L"I.F'27&^I'4
M++N*T^,R5N*8AEKJ=C^0*O"Z%J/$1'1+40X$U0DDIJ3"[!")E]X2M>]GUG9Y
MDBS=??67[Q%NVI)0`E+ELT^E:I1*])="2!W>H"1H.%%B>S#)5(*@TG!,[.@D
M1[IHQ>8<5H,+Z?>K+U$8?T^RG4=%?2_C.<LO/TZJ(L8BSEC%;E;"J66.K%="
M\M)%'45E38TYH]RTP$PE9B(^`"PR=+M_E^5*==%Y?(9<[P:"R@.J4"G20%$I
M0G[M<%SP:0/%2E795D@0M?=)A)(CB8Y]E(H8QG%LWY*Z3MTQRSA&<<ZYXR)E
MR@ZCXWDS.F7<'&&9ORGF+':MUP''*^FQ%YZ&IP'9'*:A8:F*4,NQE8*<?R;+
M_P`H[>AYU3+3#[A;0\RXO4TZRA([U"%-A*TNR1I*FU)(,@@F@[*LE*@GNDXD
M"2(V@G8<<(]:-OT&Z$=/<1ZS>K#H[F1H<=I^D>-Y9K\KXW)N<I0YSRW'C,U`
M&E,C;*6KCG,"LQ*0R(ER%'(LWWWHNF\HR^_9&@W#;B5)P^YEPH"\(Q4@IU&`
M"H$QB:,&NR+(E.*26T^&.`XBC5_[)'1;_E`I?N3^CD8_[(N9])I1_L-9!_03
M[J]_LD=%O^4"E^Y/Z.>_V1<SZ37O]AK(/Z"?=7O]DCHM_P`H%+]R?T<]_LBY
MGTFO?[#60?T$^ZO?[)'1;_E`I?N3^CGO]D7,^DU[_8:R#^@GW5[_`&2.BW_*
M!2_<G]'/?[(N9])KW^PUD']!/NKW^R1T6_Y0*7[D_HY[_9%S/I->_P!AK(/Z
M"?=7O]DCHM_R@4OW)_1SW^R+F?2:]_L-9!_03[J]_LD=%O\`E`I?N3^CGO\`
M9%S/I->_V&L@_H)]U>_V2.BW_*!2_<G]'/?[(N9])KW^PUD']!/NKW^R1T6_
MY0*7[D_HY[_9%S/I->_V&L@_H)]U>_V2.BW_`"@4OW)_1SW^R+F?2:]_L-9!
M_03[J]_LD=%O^4"E^Y/Z.>_V1<SZ37O]AK(/Z"?=7O\`9(Z+?\H%+]R?T<]_
MLBYGTFO?[#60?T$^ZO?[)'1;_E`I?N3^CGO]D7,^DU[_`&&L@_H)]U>_V2.B
MW_*!2_<G]'/?[(N9])KW^PUD']!/NKW^R1T6_P"4"E^Y/Z.>_P!D7,^DU[_8
M:R#^@GW5[_9(Z+?\H%+]R?T<]_LBYGTFO?[#60?T$^ZO?[)'1;_E`I?N3^CG
MO]D7,^DU[_8:R#^@GW5[_9(Z+?\`*!2_<G]'/?[(N9])KW^PUD']!/NKW^R1
MT6_Y0*7[D_HY[_9%S/I->_V&L@_H)]U>_P!DCHM_R@4OW)_1SW^R+F?2:]_L
M-9!_03[J]_LD=%O^4"E^Y/Z.>_V1<SZ37O\`8:R#^@GW5[_9(Z+?\H%+]R?T
M<]_LBYGTFO?[#60?T$^ZO?[)'1;_`)0*7[D_HY[_`&1<SZ37O]AK(/Z"?=7O
M]DCHM_R@4OW)_1SW^R+F?2:]_L-9!_03[JXOZ2.BQ5A\A2Z@^">SZ.55VBYG
M&TU[_8:R#^@GW5LE]&L+H\#Z0=*<%P]0M!@^6L"I:%5["&GPN")`/AM4<^CK
ML=N%.[HY<M6U5JP3YEI)HG<M$6ZBTC[48#R&`H2>2/5*]SU>KW/5ZO<]7J]S
MU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW
M/5Z@%]4/3K//5OT_]4^F_33&*'+^?,WX8])EC&L2>HCH*:I:6-P\S4D4T@6R
MG[*$_#@![4=S3O#N_<9<"!WZ-,G9M!Q@'HZ*)\_;OEV:Q9E*7R/"53I!ZX!/
ML%:V>%?@/>JC`\S#.6$YEZ2T69!BU1CZ5XK\Z/$F.U<SU$V(I2RX:U,E6\DC
M.9EB#AB2"#KS#*Z^DK>A^V_+N7C1;T!N/%.@``(*@WJ*0`!I)B!$5#_\M[1/
M^/6W^F<_^9UPQ3\!GU0XWE[*F4L5QKH[699R-'70Y/P3SLV1P8?3XHYDK8(Q
M#A2$P5+&\T+$QR?O*=.6MOI,WJ9N''T7J`XZ4E:I7*BG!),H^Y/\*A!3P(K7
M\L[1/^/6W^F<_P#F=<8?P%O4[3U>3ZZGQ7HU!4]/Z+#,.R84;-*1T%!@A9L-
MIUB7"1')'1%R:82JWDDWCVGGE_2;O4I#J3?((>4I2_$OQ*7]YG1(*_XX(U?Q
M37OY9VB?\>MO],Y_\SJ3-^!GZUZ'+]%@V1^IW23(-;@.6:S)V3<;I8\QU+8+
MEK$)(Y*G#Z:&?"0GD2&)3L:XW`$WM8U:^D#/%W!<N;AMY*W0\M)6X-;B0=*U
M$(F1)Q'"1QFGK?+^T%*P5.6R@.&MP3Z]W3/1_@$^J*ER;TRR++FSI16X-T>P
MB+`^G=4:[-]-B&&X:D"4\D,59A^%4\RI,(PTR!PCM[Q4GBI[Z5-Z57C]R+MH
M+N5E;@\12I4D@E*D$2F828D#`&J*R[M$U2';8?YSG_S.E0GX&_JXCK\"Q.',
MW1VGQ#*\>"19;J8OZRQ&@CRU4SUN$K`(\&54%'-4RR0@#W6=CX\+#]'V\A0M
M!O$%+FLJ!4LZBX`')E&.L)`5T@"J?RSM$_X];?Z9S_YG0I?\-3_B.?\`;]>F
M_P#XW9I_\\W`S_T(5>_\=8_WO_`K?\M[1/\`CUM_IG/_`)G2%ZE?@R^O[JGD
MG&<C9CZZ=.DP_%32S4U=%79G^8H:_#ZN+$:*L@+8,0)::H@CE0G2ZZZ</-V_
MHIS3*[U-RTZP5)D$'7"DJ!2I)\.Q224GJ-.-6':&E0)=MB!PU.8_^@Z3!_`H
M]7+YGQ?.TV>>EO\`6_,=7_,,SXU#BV>Z5<2Q%J>.E>IJ::GH5IY'>.)5;?&;
MJ`#<#AC_`-"B[R"V3;BZ9[I`TI203I3)(2%%O4`"21!&)D53^7=HG!ZV_P!,
MY_\`,Z>\$_!(]8^6\;R?F7+^<ND.#YBZ?8`,J9&QRG?,R56$Y:#1.,,II/Y/
M=*8&!+)X6^FZ*\^C;>&X9<9=NVU-O.=ZM)4N%.8^-0T8JQ./75?Y9VB?\>MO
M],Y_\SI*TGX"'J7H(\:AH\0Z,4\&86I3B\"G-'ER"BQ<8_!&B-A!6&*.O450
MBB")YOOE=VO#1WZ4-['"DJOD$HF/$O\`B1W9)\&)*/!*I.G"8KW\L[0_^/6W
M^F<_^9T)6<_P=/7=U%P"NRKGWJCTKSAEO$GBDKL%KZC,\\#RP2K412@'!KK)
M'(H>.12&5@"I!UX',G^B+.,O?#UM<--N)D`I*P8(@C[,01@0<","*V<M[1/^
M/6W^F<_^9T';_@,>J*7+Z96?'^D)P5,4;'!'\WG$59QIJ=J1J]JT88*MJDPN
M8C*TQ8QG83MTX($_2;O2+COA>MZ]&C:J-$SHTZ-`3(F`F)QVXU[^6=HG_'K;
M_3.?_,ZZPK\!7U-X#@&*Y4P3$>B^$98QS!:G+F+Y?IAF:&CJ,`K,2J<9GPYH
MDP<+\O)5UDT[(+#?(Q\>;NOI.WK??2^Y?(4XA8<"BI9(<"4H"YT?<$)2F>@`
M5K^6=H?_`!ZV_P!,Y_\`,Z<*O\"SU78AFS$<]8AF#HYB&;<726/%L8J#F:?Y
MD3X?_*)7E@EP=H'E>D_T=I3'YAB]PMMTXG:^D/>9NU3;(O4!I,0`I8B%:Q!"
M-0`7X@)@*\437OY9VB?\>MO],Y_\SK!EK\"+U49.7"EROC_1[!C@>*TF.81/
M'-FMYZ?%Z##Y<(I:I9I\)>3?3TL\D$(+%8XV*J`#QS,OI(WHO"KOKUM6M!0<
M5P4*4%J3`0!"E`*5A*B`236_Y9VB?\>MO],Y_P#,Z4N2OP9?Q`\DXCG_`!RC
MZ]].Z_'^IF,OC6;,9FK,RK+-*E)#AU)`-F#:0TM+3QPQ#4V!8ZL>%V=?13F5
MZVRVIQA+;"-"$@K@"2I1^W:M1*CYQL`IUVQ[0U'!VV&`_B<]O]SXTO?^&I_Q
M'/\`M^O3?_QNS3_YYN$7_0A5[_QUC_>_\"FOY;VB?\>MO],Y_P#,Z]_PU/\`
MB.?]OUZ;_P#C=FG_`,\W/?\`0A5[_P`=8_WO_`KW\M[1/^/6W^F<_P#F=>_X
M:G_$<_[?KTW_`/&[-/\`YYN>_P"A"KW_`(ZQ_O?^!7OY;VB?\>MO],Y_\SKW
M_#4_XCG_`&_7IO\`^-V:?_/-SW_0A5[_`,=8_P![_P`"O?RWM$_X];?Z9S_Y
MG7O^&I_Q'/\`M^O3?_QNS3_YYN>_Z$*O?^.L?[W_`(%>_EO:)_QZV_TSG_S.
MO?\`#4_XCG_;]>F__C=FG_SS<]_T(5>_\=8_WO\`P*]_+>T3_CUM_IG/_F=>
M_P"&I_Q'/^WZ]-__`!NS3_YYN>_Z$*O?^.L?[W_@5[^6]HG_`!ZV_P!,Y_\`
M,Z]_PU/^(Y_V_7IO_P"-V:?_`#S<]_T(5>_\=8_WO_`KW\M[1/\`CUM_IG/_
M`)G7O^&I_P`1S_M^O3?_`,;LT_\`GFY[_H0J]_XZQ_O?^!7OY;VB?\>MO],Y
M_P#,Z]_PU/\`B.?]OUZ;_P#C=FG_`,\W/?\`0A5[_P`=8_WO_`KW\M[1/^/6
MW^F<_P#F=>_X:G_$<_[?KTW_`/&[-/\`YYN>_P"A"KW_`(ZQ_O?^!7OY;VB?
M\>MO],Y_\SKW_#4_XCG_`&_7IO\`^-V:?_/-SW_0A5[_`,=8_P![_P`"O?RW
MM$_X];?Z9S_YG7O^&I_Q'/\`M^O3?_QNS3_YYN>_Z$*O?^.L?[W_`(%>_EO:
M)_QZV_TSG_S.O?\`#4_XCG_;]>F__C=FG_SS<]_T(5>_\=8_WO\`P*]_+>T3
M_CUM_IG/_F=>_P"&I_Q'/^WZ]-__`!NS3_YYN>_Z$*O?^.L?[W_@5[^6]HG_
M`!ZV_P!,Y_\`,Z]_PU/^(Y_V_7IO_P"-V:?_`#S<]_T(5>_\=8_WO_`KW\M[
M1/\`CUM_IG/_`)G7O^&I_P`1S_M^O3?_`,;LT_\`GFY[_H0J]_XZQ_O?^!7O
MY;VB?\>MO],Y_P#,Z]_PU/\`B.?]OUZ;_P#C=FG_`,\W/?\`0A5[_P`=8_WO
M_`KW\M[1/^/6W^F<_P#F=>_X:G_$<_[?KTW_`/&[-/\`YYN>_P"A"KW_`(ZQ
M_O?^!7OY;VB?\>MO],Y_\SKW_#4_XCG_`&_7IO\`^-V:?_/-SW_0A5[_`,=8
M_P![_P`"O?RWM$_X];?Z9S_YG7O^&I_Q'/\`M^O3?_QNS3_YYN>_Z$*O?^.L
M?[W_`(%>_EO:)_QZV_TSG_S.O?\`#4_XCG_;]>F__C=FG_SS<]_T(5>_\=8_
MWO\`P*]_+>T3_CUM_IG/_F=>_P"&I_Q'/^WZ]-__`!NS3_YYN>_Z$*O?^.L?
M[W_@5[^6]HG_`!ZV_P!,Y_\`,Z]_PU/^(Y_V_7IO_P"-V:?_`#S<]_T(5>_\
M=8_WO_`KW\M[1/\`CUM_IG/_`)G7O^&I_P`1S_M^O3?_`,;LT_\`GFY[_H0J
M]_XZQ_O?^!7OY;VB?\>MO],Y_P#,ZXM^%-^(X58#KMTWN0;?Z=FG_P`\W/?]
M"$WO_'6/][_P*\<M[1/^/6W^F<_^9UL/=(<LY@R5TGZ89-S96T^)9IREEW!,
M,S+B-(TK4M1B%!AL-+420F9(W,;R1L4+*#8BX!TYT7W/R0Y9E%O9D@EEI",-
MG@2$X=6&%37EJ;@6R`^07=(U$;-48Q,&)F)`H1.".EM>YZO5[GJ]7N>KU>YZ
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MTRRT7=7*M#+8E2L3`]`3[J19CF+-HPIYTPA(DF"?<`2?042H_BJ^@P+N/7.0
M+_B_JGG:W_EGY$?_`$,IN1_S.)_TCG^!0,_V4<D_XXK_`%-W_`KA_P`.L^@C
M_M^S?^HIG;_SS\W_`-#);D_\SB?](Y_@5[_90R3_`(XK_4W?\"N_^'6?01_V
M_9O_`%%,[?\`GGY[_H9+<G_F<3_I'/\``KW^RADG_'%?ZF[_`(%>/XK'H)!(
M/75P1W']5,[?^>?GO^AD]R/^9Q/^D<_P*]_LHY)_QQ7^IN_X%=K^*MZ"G-DZ
MZ.Q]@RGG8_PP?FC]2>Y`_P"8Q/\`I'/\"O?[*.2?\<5_J;O^!7O^'5_05:_^
M?1["]S_5/.WAW_YP_/?]#)[D?\SB?](Y_@5[_91R3_CBO]3=_P`"N1_%4]!B
MBYZY2`'Q.4\[?^>?FO\`H93<C_F<3_I'/\"O?[*.2?\`'%?ZF[_@5P_X=8]!
M(.T]=7OVM_53.U__`"S\W_T,GN1_S.)_TCG^!7O]E')/^.*_U-W_``*Y_P##
MJGH,V[O\^4FW_%_5/.]O_+/S7_0RFY'_`#.)_P!(Y_@5[_91R3_CBO\`4W?\
M"L?_``ZSZ"/^W[-_ZBF=O_//RW_0R6Y/_,XG_2.?X%>_V4,D_P".*_U-W_`K
MW_#K/H(_[?LW_J*9V_\`//SW_0R6Y/\`S.)_TCG^!7O]E#)/^.*_U-W_``*]
M_P`.L^@C_M^S?^HIG;_SS\]_T,EN3_S.)_TCG^!7O]E#)/\`CBO]3=_P*]_P
MZSZ"/^W[-_ZBF=O_`#S\]_T,EN3_`,SB?](Y_@5[_90R3_CBO]3=_P`"N0_%
M7]!)[==7/_B*9V_\\_-?]#)[D?\`,XG_`$CG^!7O]E')/^.*_P!3=_P*X_\`
M#K/H(_[?LW_J*9V_\\_-_P#0R6Y/_,XG_2.?X%>_V4,D_P".*_U-W_`KD/Q5
MO04P++UT<JO<C*>=K#_R3\U_T,GN1_S.)_TCG^!7O]E')/\`CBO]3=_P*X_\
M.L^@C_M^S?\`J*9V_P#//S?_`$,EN3_S.)_TCG^!7O\`90R3_CBO]3=_P*]_
MPZSZ"/\`M^S?^HIG;_SS\]_T,EN3_P`SB?\`2.?X%>_V4,D_XXK_`%-W_`KW
M_#K/H(_[?LW_`*BF=O\`SS\]_P!#);D_\SB?](Y_@5[_`&4,D_XXK_4W?\"N
M_P#AUCT$'MUU8V[_`/&4SM_YY^>_Z&3W(_YG$_Z1S_`KW^RCDG_'%?ZF[_@5
MU_PZSZ"/^W[-_P"HIG;_`,\_/?\`0R6Y/_,XG_2.?X%>_P!E#)/^.*_U-W_`
MKW_#K/H(_P"W[-_ZBF=O_//SW_0R6Y/_`#.)_P!(Y_@5[_90R3_CBO\`4W?\
M"O?\.L^@C_M^S?\`J*9V_P#//SW_`$,EN3_S.)_TCG^!7O\`90R3_CBO]3=_
MP*]_PZSZ"/\`M^S?^HIG;_SS\]_T,EN3_P`SB?\`2.?X%>_V4,D_XXK_`%-W
M_`KW_#K/H(_[?LW_`*BF=O\`SS\]_P!#);D_\SB?](Y_@5[_`&4,D_XXK_4W
M?\"O?\.L^@C_`+?LW_J*9V_\\_/?]#);D_\`,XG_`$CG^!7O]E#)/^.*_P!3
M=_P*]_PZSZ"/^W[-_P"HIG;_`,\_/?\`0R6Y/_,XG_2.?X%>_P!E#)/^.*_U
M-W_`KW_#K/H(_P"W[-_ZBF=O_//SW_0R6Y/_`#.)_P!(Y_@5[_90R3_CBO\`
M4W?\"O?\.L^@C_M^S?\`J*9V_P#//SW_`$,EN3_S.)_TCG^!7O\`90R3_CBO
M]3=_P*]_PZSZ"/\`M^S?^HIG;_SS\]_T,EN3_P`SB?\`2.?X%>_V4,D_XXK_
M`%-W_`KW_#K/H(_[?LW_`*BF=O\`SS\]_P!#);D_\SB?](Y_@5[_`&4,D_XX
MK_4W?\"E9D3\2'T7]2\YY8Z>Y)ZQMC6;\Y5D5!EO"3EO-M-\S5S7"1^;687%
M$E[?:=P/CPRR;MZW1S"[1;6]T%NN$)2-*Q).P8I`]II58]HF47+R6FUJ*U&!
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MIN0`<R,TN4O!5@E8[PY2AQ+18;"`Z+=+A<[]*N\"\%*$H`4N$J5!H\3E.6\4
MIC7ZQ/1'SH1\+]1'47$>CW1O-4=-D_&NHO6S#.H&:*?*6!9,K*RHP#+^1YYJ
M!3,F*YCP^DDIWE:!JNMFKH6BOMA@FW%D#USV>Y8WFURR2\FWM5L-:UO`!;CP
M"L"EE:@H#4$-I;6%1*UHB%5&5Y=W8.E$F>&R/7Y^E"CZ:NN-=ZI:FES'AU+D
M;H[D[*>4.D>/YYRQB^&5^(5V.U'4G*;9DK5PZO3$:1:.*G9TIZ%V@G\V17#6
ML!P-=HFY#.[*2TLOW+KCUVVA2%)2E`MW>[3K1H5K*H*G`%(TI(BGK;*LL<,E
M*$@`;1MD28\ME%;Z$]<>IW33TW^GR?'ERUUCGQ#HG2=5,5^8PG%?Y\F$9:S?
MA>&X]A\];-BD[5U;-@]?+40U)B0BHBVF-T?22]]MR,JS'>&\#?>VP%\;40I/
M=ZW&EJ:6$A`T(#J`E2),H5.H$8IF<LR\(!*4$Z9V=8D>SWT,^)?S#U.X_E;J
MATPP?*'67I;-6=01T\]*T6>\4Z;9CS7DJCQ6BP/",XT^(4+RK52>?15@C681
M4PBJ8VW"1;D(6R&=VV'+.\4];7(2QWET6$W#;3Q2I;EN4*`TC2I$Z=3FI"A&
MDX*/Y1EI.I*4$2<-A(X&:#/!.JW3[.N:?2Y@F27QRCRC5XCT(FQ'',T5DASM
M5?S#J+FK+>+X9C<V&SIA]5%'_*@ADB@_3CWWDE5EL([S=6\L[:_<N`V70F^`
M2V/V(TV[#C:V@H=XDGO)@J\!P"4D&J#+,J)2`D1X=L3B3,T8CJ/Z!\S_`,\Q
M''>A'5O#^G]75YLS96HE?F3-M?3G*F8,`H,#I:-J>J^;C$U"[UU9`%LJS&(A
M[$[`%N_VWV?<I:S*W4\`RTGPMM)/>MN+6I4C286.[0J<2G5(V2H?W>RT_;H&
M)]F'5YT)G6/)6"=%_1ITJR"V88JCJ9BU5TNZ<9KZD05=35U4!S#CN%97Q7%(
MJRK6.=I_)FF:.>0!_,97(W<#>Z6:KSC>ZXNM$6Z1<W"6R``>[0MUM!2)2$R$
M@I&&D$#"KO9)E*61`258`^W$T5>'HU4=4<]>M[+G2[)N-+U"RYU;I\(Z-]?)
M\]K0Y>R7A]'@F7*S9)A,V,FHJH8%:9WITPZ1)S(4+C<S+)R][&\LL<K=O'6_
MRZ[,K>8#&IQY16\)#@;TI)\("BZDHB0,`"G.39:HK2E*=N!P@##U]U-/4GUJ
M8UD_,.:<3P3(.6\?R!B]-UZAZ;8P^!34>%R5_23+N(8I12T]=/C"5F(K)58<
MT&(+_+:>&-F*P3R!5>13N]V-6UW;MH<=<0^DV)<&L%03=.(2H%(;*&R$K"FO
MVJU$"5H220EES+\M"C"$D>+AT##CC/'`=1H3ZCKKG'+^:L'Z/XW#D3%L[=0<
M6Z%T66^IU-EW$Z3",!AZLX=CM?B(JL,EQ:5ZMJ!L!,-(PJH?.>>,.%*V8-M[
MC6+]JJ_;[]++*+TJ;+B2M9M5-)1I6&P$:^]U+&A6D(5!,X.?RO+0=.E$G3C&
M`F9PGA'OKKK/UPSOT5QOK;!/+T\ZA8=Z=>F.7\V8ZN%Y=Q2`YGS!F7-6,Y7A
MA21\9F_E]-1"BAGJTM,]UD0,H(9/;H;D6&<,VI`N&57MTXTG4XD]VVVTVZ21
MW8[Q2]2DH/A&*20=A\_E66H)A*#`G9M))'3A&TUPDZ_YOH\?K>C\^2\-J^I-
M3G#`\(REC(R9\IC^*X+79-K,T8B\64I\RM'!-0O1W::NQ6GA>DD69`[_`*,[
M3N%8K8%^'%"V#*UK'?2A*TO):1-P&94%A7VMLK4'`4'2GQ5[^699LT)F1C'"
M.B>!Z3LHMN$>HC,'4/+L?77%4P"EH<1Z092K,2Z.I1UXP5<PR=?:O(-77Q5&
M'8PDBM)#1F=0DCC:5BWR(I:21+KL^M;"X_EJ.\*DWCH#TIU]W^12^E!"FX@%
M6DR!C*H2H@)91EN7$:M*?M&$<=4'W8U9?Z8\=AZW_P`RZHYJKLEY=Z:8YCV?
M<$RUTB7":R#->&G*.:ZC+U/+/B,F(O%42R1T;RUD(HX_*:1%5B%);'3M'RY.
M3:;-D/+N4ML+4[J!:5WK0<("`@%(!4`A6LZ@DDC&`86N394LZE!`&.$8X'#'
M]*!S!NF?0WJY-ZU\X];.J^(](\<Z,9WQ7!,F9CP_,53@E-T]RMA&%X;B.$XG
M'2+,E%,:[SFJI9*R&59@YA^RH4"Z[W@S?*AE=OE]NFX1<L)6M*FPLW#JU+2X
M@JC6-$!`"%)*8U[3->:R/*%!>H)&.&S9P-!=G#U8R8#U=@H<`RG@.:>C^+9U
MSED3!<QC`I::DDJ\L9#Q',2U$>)U6*4U14UJ5M`$K*6'"Q31QN52I9Q<B3*>
MRIM_*BIUQQN[2PR^I.L$@.OH;@H""E*"A<MK4]K4H26P#%)',MRP.0$)*9(V
M=6V?/JCKIDP[U19YP?)61CFO!\@XUG+K/DGH9F3*F/TF!8IAV$95Q'JYG),I
MUL5?3RXK425M-AJ2K/&XF@:1_<;:"&"RX[,<O>O'>X5<)9MG[UM22M*ENIM6
M2ZDH(0`A3A!21I6$C$21%53EN7!.*420GAL),'SC;0F]<^KV=^DF<<5Z38'A
M^5>H6;\@]/\`,O4#'\\83DVLJ,)Q4X=C\V%T&#UD$V8X%P18XH"<3KGJ)UA9
MXR(PI/`YN5NAE^:VB;UPNLM/7#;"4+>`4G4@*6XDAD]])/[)L)05`*!43%.7
M&598@Z0E)@$S&W'`;<.LXTCLU=3L>SUT$]:'73YC+_3Z@],N*P5?23(%#0U'
M\WDK<`P#+F=9(<5Q2'$I*:MBJ4Q&IPV2".F$;AED#747-\KW8M;+/,LRV''E
M7R"'5J4-$+6\R"V@H"D%)0AT**M0@I(@FM'*<L*%JTI$;!&/`[?:*MVAR3T1
MJ8*:J3#Z6G6KBCE6G?:7C$J"38V@U6]CS%1>:YJE13),&/91N,CR7^BFLG]0
M^B?_`"BT?W+_`$<K_.,UZ36_Y%DO0FO?U#Z)_P#*+1_<O]'/?SC->DU[^19+
MT)KW]0^B?_*+1_<O]'/?SC->DU[^19+T)KW]0^B?_*+1_<O]'/?SC->DU[^1
M9+T)KW]0^B?_`"BT?W+_`$<]_.,UZ37OY%DO0FO?U#Z)_P#*+1_<O]'/?SC-
M>DU[^19+T)KW]0^B?_*+1_<O]'/?SC->DU[^19+T)KW]0^B?_*+1_<O]'/?S
MC->DU[^19+T)KW]0^B?_`"BT?W+_`$<]_.,UZ37OY%DO0FO?U#Z)_P#*+1_<
MO]'/?SC->DU[^19+T)H8/3[DSI)1=<NE%7A%/2KBM-C=(^'L@7<)03:VG?DU
M?3AFF9+W_P`L2LG2;A$^6-)+[)\I0RI383K`P\ZOWY]%5`BO<]7J]SU>KW/5
MZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]
M7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]S
MU>H!_4]TPS9UHZ`]4NEF1<R4V4,W9VPQZ+`<S5<<TM-1SM*CB21*<AR+*1[I
MOP#]I.YXS_(G\N)`#Z=,G9M!^5$N\5K>/V+B+58;>(\*C)`/28QK7*PK_A/Y
MUNP/-C9[P;JOTRPO.;5U1BAS-!E;$XZS^9U;.\U8'5M*B1I&+2CWR23>YYB+
M=?29G;]K^6<OM3.D)TDKC2-B8C[1`@;,-E0U_9#?N(_/-?Z5?XUSQ;_A/_UO
MQ[`<LY6QKJKTPQ7+63&J&RC@$^4\0DH\,-6Q><4T3';&LQ8F15%G_>!YJU^D
MK.V'UO-WVEQV-:@I<JC9J,8QP.T<*U_8_?O_`)GFO]*O\:]_RS_=;?GLH8E_
MG3Z7?/\`3ZFI:+(U5_5&NWX11T)9J6"E_P"*HX"Q,*KI&3=;<]_T*7G>AQ'Y
M[PO$J6-2_&5?<5=)5_$>/&:]_8_?O_F>:_TJ_P`:RU7X"OJAAP&GP;*7J1R'
MD&JPK`:G+&5L=PO*U6M3@V`5KH\]#1+.KQQP2&-28]NRX#6N!RK/T@7QN"Y<
M7"7@IP.J2HN0MP3"E1!*A.V9B1,&GK?=/?E#@4J\94!P*7`#[%`TT_\`+/;U
MJER5D#I[B75_ISCF5>EU!#AF0J"ORWBM4^&T<-,E+LADD;<F]$'F;2-YU-^*
MO^A4\\%Z]=(O0AVX45.%)6-1)G$1!@G#HX516Z6_943^=9$_WB_QI4G\"#U%
MFNPG$O\`/9TW&(8`F$Q8%6#*^(K)11X!-+488D#*1Y:T<D\CP!;>6S,5L2>%
MG_0G>::%(_.#2O65"5^(N`!<X8ZP`%3]P`G95/['[]_\SK7^E7^-+W_AG3UM
M?]Q893_\=6._]3>$7_0B:O\`CK7L5^%:_L=OU_S.M?Z5?XTCNH/X'7J[ZEY.
MQK).9O55E63"<96%O.CPO&UGI:JDJ(ZVEJH&9V"S4\\22QM;1E'#C(/HON<M
MO$7++S6I,[0J"""%).&(4DE)'0:=8W2WZ0L*_.LF.!0N#U;:=<%_!0]7F7IL
M;J\&]3&2,,Q#-%8<2S5B%-@.+TTN)XFT$=,]74F%U\R9DA12YULH'8#B2]^B
M2XN`E+EPA26TZ4`ZB$IDD)3(P`))CI)/&FU;G[]$_P#%K7^E7^-!M5_\)ZNK
M=?C.*YBKNHO2FMQ['3B)QC&)<G5LE14_S>GFI*_>[W)^;BJ)$G_XL#-OO<\$
M37TJ9^VREI.8$-HTP`IR!H(*(']Z0"G^C`B*]_9#?O\`YGFO]*O\:4V,?@.^
MHK,%-C5%CO6SIQC%)F.DPN@QZ"IRQB4RUE%@;O)AL$N\G<E&TC&G!_R9)*V)
MX76GT>9I;J2IJ\"2@J4F"L0I<:R,-JX&K^E&,UX;G[]_\SS7^E7^-<,"_`9]
M0N6*2NH,N=9NFN!T.)X6N"8I14N5<0ABJL'2:IJ!13(EA)!YE9.YC:X+2.2+
MLQ.[WZ/LVN5A3MX%J2O6"5+)"X2-0Z%0E(D8PD#@*]_8_?O_`)G6O]*O\:3R
M?\)[.KT>68LF)U)Z6)E2&O&*0X`,HUXIEQ(4_P`I\T%O_EO*_1[[WV>[]G3A
M@?I4S\W/Y@WY[TITZM2YTS.G9LG&.G';6_[(;]S/YYK_`$J_QK-'_P`)\^LD
M-'A&'P]2^E<.'X!22T&!T"9/K4@I*&?$QC4E-#&ME2)JP"H*`;?-]^V[7E%?
M2AGI6I9OR5+(4HZER5!.@$GB='AG;IPV5K^Q^_?_`#/-?Z5?XTH,+_`@]1N!
MYSQCJ+@O6[ISA.?LP>=_.\YT^6<3BQ.J-24,QDJ$(<F4Q)YAO=]HW7MPONOH
M[S1^S3:.7@4PB-*"5E(B8@1&$F.B3%>_L?OW_P`SK7^E7^-1,S_@(]?\ZYCP
M_-^<.L737-.:L+6G2AS#B&5L1JZM$I)C40*9)BQ812'?&&OM.HL>.Y;](6;V
M=N6+>]#;2IE*2L#$0<`.(P,;1MKW]C]^_P#F>:_TJ_QIOK_^$_?6S%,TUF>,
M3ZI]+\0SE7U$E76YHFRE7R5TE7-3FCDG,SDMYLD1,;O?<RZ,2.*&/I+SMJU%
MLB^AD"`D*7I`!D".@'$#8#B*]_9#?O\`YGFO]*O\:=9_P%_4)589-@M3UFZ:
MU&#U&"4F69L+?*V(O3MEV@D\VEPPQL2ORD#G=%#;:AU`!XE1]'^;)<#@O`%A
MPN3*Y[Q6"ES'WJ&!5M(VU[^Q^_?_`#.M?Z5?XTQ57_">_K!6X+@67*WJ3TKJ
M\!RS/4U.`81+D^M>GI:BMD6:ID1&N-T[HK2DWWD`M<@<7-_2EGR'ENIOR''`
M`HA2Y(3@D'_%$A/1)B*]_8_?O_F>:_TJ_P`:<,U_@)>IS-V`X]EBL]2>2\-P
M+..-46/9^H*/`\5@&/UM%-33?Z>0;RB4T4"RM]IDC"7VZ<8RGZ0LPM'T/)N&
MU+;;4VV5:SW84%#P881J44\`23$T\QNIOT@D_G&3@1BA>$\?NVCA0I-^#MZW
M'9G?U8Y39G)+,<*QW4G7_BS@8'T)$?ZZU[%?A3']CM^_^9UK_2K_`!KC_P`,
MZ>MK_N+#*?\`XZL=_P"IO-_]")J_XZU[%?A7O[';]?\`,ZU_I5_C7O\`AG3U
MM?\`<6&4_P#QU8[_`-3>>_Z$35_QUKV*_"O?V.WZ_P"9UK_2K_&O?\,Z>MK_
M`+BPRG_XZL=_ZF\]_P!")J_XZU[%?A7O[';]?\SK7^E7^->_X9T];7_<6&4_
M_'5CO_4WGO\`H1-7_'6O8K\*]_8[?K_F=:_TJ_QKW_#.GK:_[BPRG_XZL=_Z
MF\]_T(FK_CK7L5^%>_L=OU_S.M?Z5?XU[_AG3UM?]Q893_\`'5CO_4WGO^A$
MU?\`'6O8K\*]_8[?K_F=:_TJ_P`:]_PSIZVO^XL,I_\`CJQW_J;SW_0B:O\`
MCK7L5^%>_L=OU_S.M?Z5?XU[_AG3UM?]Q893_P#'5CO_`%-Y[_H1-7_'6O8K
M\*]_8[?K_F=:_P!*O\:]_P`,Z>MK_N+#*?\`XZL=_P"IO/?]")J_XZU[%?A7
MO[';]?\`,ZU_I5_C7O\`AG3UM?\`<6&4_P#QU8[_`-3>>_Z$35_QUKV*_"O?
MV.WZ_P"9UK_2K_&A@]/OX6?JWZ4]<>E/4O-_J4RUF;*V1L;I,2Q_+U+AV,1U
M%;2P$EXHWFD*!FOH6TX+MP?HY.2YU;W_`'K9[AQ*X`,X>E&N1[K;XM7C:[B[
M:6R%`J2$J!(X@28J_7F=M397N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO
M5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ
M]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>
MKU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>Y
MZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[
MGJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7
MN>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU
M>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO4%?6_J[EWH+TGSSUAS9AF(XSESI_
M1-7XOAF$P05.(S0K(L96"*IFIT9[N-&D4?'@?WJWEMLGRYR]N)[IH2J-L>I`
M]]%.>YNFPLUW"DJ6$"82`5'R!($^HJJ.+\>#TDS5;X?#TPZF38A$"9*!,&RP
MTZA>]XUS`6%O'3F/ROJXW7"-10^$].A,>W7%1+_LYV__`#)7?^D;_P#FM28_
MQT_2M,BRP](^J4T3WV2I@&7&4V-C8KCY'<6XTKZOMU$F"EX'_%3_`(=:_P!G
M2V_YD[K_`$C?_P`UKA_P^QZ4?FTH/\U/4\5\B&5*#^1Y:\]HQ^^(_P"L&XKI
MWM;EO^AN]U=&K2]IV3H3$^>N*]_LZ6W_`#)77^D;_P#FM=#\=GTH-M*]*>I[
M;B`ML#RT;DL4`%LP>)!`^.G/'ZN]U?Z+W^D3_AU[_9TMO^9*Z_TC?_S6I'_#
MYWI;_P"W/=5/_4>R[_Y_N4_Z'`W3Z'O]*G_#KW^SI;?\R=U_I&__`)K7O^'S
MO2W_`-N>ZJ?^H]EW_P`_W/?]#@;I=#W^E3_AU[_9TMO^9.Z_TC?_`,UH/:W_
M`(45>@/#<4Q/`\1P_..'XU@N[^<X//'DF&JH]A"MY\4F95>.Q-CN`UX(&?J3
MRAQI+B+:[4A6PAF0?(A4'TI4GMF24@BPO(/_``-'_P`UI7TOX]/I!K<3Q?!*
M+IMU*K,:R^*8X_@\6#Y7EJZ$5D9FI_F84S"7B\Y%+1[P-P!(N!PH=^K/=E#2
M7%(?"%SI)0D!6G`Z3K@P<#&P[:3GMP8`!-E=P=G@;Q_]"USJ_P`>7TBT#(E?
MTTZE4+R7$:3X/E>$L0=IL),PB]CIRK7U;;L+^U#Y\D)/^CK0[<[<_P#,%=_Z
M1O\`^:TX'\<[TMC0]'NJG_J/9=_\_P!Q/_T.!NET/?Z5/^'6O]G2V_YD[K_2
M-_\`S6L2_CK>E1YI:=.DW5%ZB`(9Z<8#ELR1B0$J648_<!K:7&O+GZO=U`)T
MO0?[Q/\`AU[_`&=+;_F3NO\`2-__`#6LO_#YWI;_`.W/=5/_`%'LN_\`G^Y7
M_H<#=/H>_P!*G_#KW^SI;?\`,G=?Z1O_`.:U[_A\[TM_]N>ZJ?\`J/9=_P#/
M]SW_`$.!NGT/?Z5/^'7O]G2V_P"9.Z_TC?\`\UKBWXZ/I80`OTAZIH"0%+8!
MEP7)-@-<?[D]AS8^K_=,[`]_I4_X=>_V=+;_`)D[K_2-_P#S6N7_``^=Z6_^
MW/\`53_U'\N_^?\`YK_H<#=/H>_TJ?\`#KW^SI;?\R=U_I&__FM>_P"'SO2W
M_P!N>ZJ?^H]EW_S_`'/?]#@;I]#W^E3_`(=>_P!G2V_YD[K_`$C?_P`UKC_P
M^CZ6=VS_`#0]4]]K[/Y!EW=:]KV_G][<]_T-_NG$P]_I4_X=>_V=+;_F3NO]
M(W_\UJ(GX\'I)EK&PZ+IAU,EQ",$OAZX-EAIU`%R3&,P;A;Z..J^KC=<(UE#
M^GIT)CVZXK?^SG;_`/,E=_Z1O_YK4W_A\[TM_P#;GNJG_J/9=_\`/]QK_H<#
M=/H>_P!*G_#K7^SI;?\`,G=?Z1O_`.:U[_A\[TM_]N>ZJ?\`J/9=_P#/]SW_
M`$.!NGT/?Z5/^'7O]G2V_P"9.Z_TC?\`\UKBWXZ'I912S](.J:*NK,<OY=``
M^)./\\/J_P!TSP>_TJ?\.O?[.EM_S)W7^D;_`/FM<O\`A\[TMC0]'NJEQ_W;
MV7?_`#_<]_T.!NET/?Z5/^'7O]G2V_YD[K_2-_\`S6O?\/G>EO\`[<]U4_\`
M4>R[_P"?[GO^AP-T^A[_`$J?\.O?[.EM_P`R=U_I&_\`YK7O^'SO2W_VY[JI
M_P"H]EW_`,_W/?\`0X&Z?0]_I4_X=>_V=+;_`)D[K_2-_P#S6O?\/G>EO_MS
MW53_`-1[+O\`Y_N>_P"AP-T^A[_2I_PZ]_LZ6W_,G=?Z1O\`^:U[_A\[TM_]
MN>ZJ?^H]EW_S_<]_T.!NGT/?Z5/^'7O]G2V_YD[K_2-__-:]_P`/G>EO_MSW
M53_U'LN_^?[GO^AP-T^A[_2I_P`.O?[.EM_S)W7^D;_^:U[_`(?.]+?_`&Y[
MJI_ZCV7?_/\`<]_T.!NGT/?Z5/\`AU[_`&=+;_F3NO\`2-__`#6O?\/G>EO_
M`+<]U4_]1[+O_G^Y[_H<#=/H>_TJ?\.O?[.EM_S)W7^D;_\`FM>_X?.]+?\`
MVY[JI_ZCV7?_`#_<]_T.!NGT/?Z5/^'7O]G2V_YD[K_2-_\`S6O?\/G>EO\`
M[<]U4_\`4>R[_P"?[GO^AP-T^A[_`$J?\.O?[.EM_P`R=U_I&_\`YK3_`)3_
M`!K/3/G'-F5<GX=TFZG4F(YNQ/#\*PZJJ<!P!*:*HQ&KCHHWE:/''98U:0%B
M%)`O8'MQ=EGU8;K7=RAA`=U.*"1*4Q*C`_CZ32FS[:[9YY+?Y2Z&H@24-P),
M28<.'3A5PG,F:FBO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]
M7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]S
MU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>H"O4U189B/07JA0XT%.%U.&.M:'^QL
M\U#K?F._U9NN([.,S4C[@R8]HI?EC+3EPE+GVDXUHX9`R?TW@S)!BV#8ETPS
M#CV'>IK,46)=.<+PKY7JW-A,_56NPR21\4I,7DD-'3PS_-U$4F'K&])&T;.`
MV_G+C/LSOU6Y0X+I#:LK;(<4J;0*%JA0`;+8&M1&A)#A4'%!0!(BA,G*K(C'
M21JB.,3'3'7LV4[9;ZK58Z2YAS!B&?J+)F;<B9*./]#,E4V%Y?BI^IF99<ZY
MGP^7#VHTHO-J5`P^DI/EJ`Q2@R^<S$F_$F8[J-?S5#265.M.OZ'UE3A-LV&6
M%!>K5"3XUKUN:DD)T`84R,IR\H)($@2-F)D_I0J9@R5TERYUGQ/'<&K>G?7>
M@Q;J7@SY@Z5U]-7Y<ZU95KY\6P_#YUP?$(IUDQ##,/<_,)#)3Q0R4V\"9U^V
M&;'-<RN,G2TX+FT*;5>EU)2Y9NI"%J'>((AMQP>$J"E*2N"4`[%:LHR])PTJ
M3.S81\C[/6@\R'78%4=5\&Q]_P"65V,8Q1]/,-K43#L+BAJ*:3K?GG"VC2)*
M<11,\$$:^:BJX/O!MQ))_G=JXG*U->((2JX4/$HD'\E:JDF9("B3!)'"(PIA
M&56!.('#XD'W`4MLM9^P*MZ+=)\V8EU]@/4+JK5Y+B]2>6329:5ND-%C6(2T
M^-U<,:T(?#A12A:(+B9F$1_3/<7X2YCN\XC.+AA%F>XMP\;=4N?Y64)!:23J
MAS6)<_9:2K[!%;1DV6]VDG3)B=F'3^%-&$9@QKJ!U#QW(6!]:ZK"\@Y/R[UJ
MKLD]4</PS*\]5G%<EUV5EP/$I)JC#9::6*"7$JRDE>FB2.J$18;2=P5W666U
MA8(N7+4*?<=LTK:4IT!GODO]Z@`+"@5!"%I"R5-E48C"FTY+EQ64X0`K&!C$
M1\_.C49A],^0_49TIK,1Q[$,$HZ?KGD7IY!CN'F*=$BEIL33,6*;1&K[5FAG
M:*&Q)5K7(&O(SR_M"N]W\T"&@LFTN+@I,C&4EM'J"`5=(V48)R'+2D$:08'H
M>-)3I!Z4I/3OEOU*=4LVYNP#J/U/SME6@J8JO#::NC6;&\HTN8A2'9B)D;RW
MI*F@B5=['?'(=`5N9[V=IC>?W%C9,-N,VS3JA"BG!#I9U8IC$*2X28&"D\0:
M;1D&7I0=6DF,//']*+FW3#+474'"\3Z8=$,@^I^;!?3GT^QL8'FVK6AJ\7KZ
M_'<PUU1+AI;!<5B>JKG9W=)'@#,57?<W601O$^;!2+RZN+`*S)]&IH2$)2AE
M("_VK9"4"`"`N!)C#%K^6623X`"-(.V)./52&FZA5>1\C9`RYTAS;A^8<KY4
MZ6Y8QOI/FZNKL%P&ES;FBMQ?$J6OP^OPG&J/$L7JXJ!J>"B;#,/85D.[WBS@
M<.4[NM7MZ\[?-J0ZY=N(=0E*UEII*$%"TN(4AI!7*G`ZX.Z5&$`TE<RFPCPA
M)\(,X"3QD;?08T(O3S*_3S*75/JQAV8NK4O2?)G43JEU3.=NLM4F6164M3E;
M#,OO@F#)B6(X88(H66MJ66.=7:18?+A*,7W$&?W][=Y9;J:MQ</,VEMH9'>0
M0ZIWO7-"5R3X4`E)`25:ER(A2C)LN*M*H"95T81$?.F?*V=>H6?LC=6<]XKG
M^3I[FO)^5^CSY;RE!@^!)AJXAG?$&H\0Q&IIL0H):@M/`D=1%`956(N18]@J
MS/(LML;VWMD,AYIQV[U+*UZM+*90A*DK"?"J4J5!*HF12=O)\O4DD@`@)C`<
M=M"S78;C^2LW9CH:+K'B&>Z;"NIV:LB98P'$,*RR7GP5>F5;FNBDJ'P_#:=Y
ML0AQ&%!%,FQ#'^C>)C[Y"S#EK>6B%*MDM%5JT^I25.8+_,I:4`%+(#:FR929
M(5X@H;*>.1Y<"8@^(C8-D3\:"?%.HF1>J&&^G+")LY8;FR9<*],N/]1:2EBH
M7-/F[&>J4-'BWGFBB7RJG;3[):8$>61;8I.HIMMW+O+7+UP-*;&O,FVR2K%I
M%L2W$G%.,A?\4_<151E.7>&`-B9]3C[J`[JKU5EZ@].^J.6!U#5\-ZD=&L\Y
MTJ:*EKL`./9>Q3+>:L$I*6'Y+"\-;^3"2CQ"45-!55=34)MNS1E22,]V-U&[
M#,+=[N?$Q>L,@E+FAQ+C3I4=2E_MH6@:'$(;09P"I@)UY581@!]I/"9D1Y8<
M,:-!6]3<UP]:LR85EDX?F<81G/%L`RID.IQK+#Q9@R=09;J,0H,3APF@PXXM
M)4UKHE4,269*&1;Q*$N.1LSNO9G)T+>U(U,(6I80Y+;RG`E2"XI?=!*!*.Z*
M2Z#XC-/JRC+]9A*=I'#$1Y3Z[*$'TN472K.7J#I\4J^L%/U<Q/&>B^5,5SC3
MR4V%PC+V8,1S)6RUV'(F&T].:98GNHHZC?406M(Y)'"+M*5F-GD)0FV-NE-\
MZE&*CWC:6TA*Y43J)'\:80N92!%*+;),L*X,$:0>&WC0.TN4_3++TD]2U/EU
MLJ2>J=>M&=8>E='0MAO]=_YD,_1+AIM1?[\!2"/68O\`HOE]^_W+\%SN8[PC
M-+$N]]_+/R+)=*M7<Z>X.O;^SU3]L>+7$8UXY7EQ:4,)D@#UPH2\M9GP[",R
M]/<[9WZL)%D3-/J&ZFY$S?2XC3Y>H<OX3D_+S9QI,$I_/%%%)$TE31449GDG
MW2.(TO=F#AO,<H+MN];V]O\`MV\NMGT%)<4XIUS\N73&H@PE3ATA,)!4=@$-
MHR7+=0)`@K(.S8)CY46O'NNM77>G3J'U'Q#KC!TUS)E?I]B.9.BE6E!EL#.^
M,29VS'A+(T.(4$OGBCI:&CA6"`(R&3SI-PY(=CN*TC>!FT3:E]MRX2V\-3G[
M%'<LJVI6-.M2EJ*E2#&A,4E_E.7ELF$@@2,!B9/RBCE9/_J1C/J/S-THZC9V
MH\]93S\<UT6'X)@>)94Q#!,+PVCIEE2GQG"10T^-81500JR&J>>>GJ97L"A*
M`1)FS=TSN^B]M&BTZSW2BI:74K4HF);<U%EU*C!T!*%H2),PHTO:R3+`[!`@
MSLCW\0:'OTFX3D_._IHZ)9JSY30)FW&,!IFQ>29+33^2\E-#42;]=\\,:2L3
MJ2U_'@&[47KBSWBNF;8GNDN&(V"8)`ZDDD#RIZTR/*U-`J"9HPG^;_I#_P`5
M4?\`R"O`'_.<SZ32C^091T)KW^;_`*0_\54?_(*\]_.<SZ37OY!E'0FO?YO^
MD/\`Q51_\@KSW\YS/I->_D&4=":]_F_Z0_\`%5'_`,@KSW\YS/I->_D&4=":
M]_F_Z0_\54?_`""O/?SG,^DU[^091T)KW^;_`*0_\54?_(*\]_.<SZ37OY!E
M'0FO?YO^D/\`Q51_\@KSW\YS/I->_D&4=":]_F_Z0_\`%5'_`,@KSW\YS/I-
M>_D&4=":]_F_Z0_\54?_`""O/?SG,^DU[^091T)I5Y"R)TH@SYD6>ECI/FH<
M;PAZ4A5OYBXC"R6^-P.#'LZS?,3O%9`DQ^99_P"544U<9'E26R4A,@&/.MA_
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M'7F&JOH=:*-)N@4]&@Q[-45#']@=\_\`F?;_`-25_P#-*S'\$_U(,U,S>L;`
MF:C8O1L<EUQ,+L+%HR<8]TGQ(MR@^AED3_E0QV^`X^?BQKW]@=\_^<@W_J2O
M_FE='\$WU'FK6O/K%P(UZ)Y:5YR77>>L?^`2?SC<%U[7MSW_`$(TSIT_FAIZ
M-!CV:HKW]@=\_P#G(-_ZDK_YI7(?@H^I,$$>LG`P1:Q&3*\'0EA_SF/`DGZ>
M:_Z$88_YF1_I/^2KW]@=\_\`G(-_ZDK_`.:5Q'X)OJ/"UBCUBX$%Q$DXBO\`
M4NNM4%EVDRC^<>_<:'=?3F_^A&F</\J&&SP'#R\6'I7O[`[Y_P#,^W_J2O\`
MYI7)/P4?4G&L:1^LG`XTA3RX47)E>`D8`&Q0,8T70:#3FC]##!,FY&/]Y_R5
M:_L!OG_S/M_ZDK_YI60?@K>I@``>L[!@!H`,G8B``/\`O\\U_P!"+6__`#,I
M_P!)_P`E6_[`[Y_\Y!O_`%)7_P`TKL?@L>ID$'_;/P;3_NSL1(_/&>:/T*VW
M_,RG_2?\E7O[`[Y_\Y!O_4E?_-*9<O\`X&_J"RMA5%@F!>L3!J'"\.5HZ"E_
MJCBC^3$TK3"-&DQHL$4N0BWLHT&@XLO_`*)$73I<=NDE2MI[O:8B?NVGB>.T
MU96X>^9,_GV_]25_\TIS/X)OJ/8P,WK%P)FI9&EI6.2ZXF*5K[G3_?Q[K&^I
M&O$P^AIG'_*AC@?`<1T'Q;*K_8'?/_F?;_U)7_S2O2_@G>H^>)X)_6+@4\$C
M!Y(7R77.C.IW!BK8P06!%P>_/)^AEE)D70!_Q#_A5[^P.^?_`#/M_P"I*_\`
MFE96_!4]2SL[OZS,%=I;&5CDW$"6([7)QG6WA?E1]"UN/^8D?Z3_`)*O?V!W
MS_YR#?\`J2O_`)I77_#*GJ6W;O\`;,P7<&W!OZFXA?=:VZ_\Y[VTOSW_`$(O
M;_\`,R/])_R5>_L#OG_SD&_]25_\TK%'^";ZCH=PA]8F`Q!W,C[,E5JWD+;R
MQVXP+M?6_>^O+J^AID[;H'_,/^%7O[`[Y_\`,^W_`*DK_P":5Y/P3/4;&9C'
MZP\!C-2SO4%<E5JF1Y``[-;&/>+``,3W\>>/T-,F)NAA_>'T_BX5[^P.^?\`
MSD&_]25_\TKM/P3O4A%,M1%ZQL"CJ$B$"5"Y+KED$*G<(PPQBX0'4+VYH_0R
MR1!NA$S]AV]/W;>NO?V!WS_YGV_]25_\TKN+\$_U(0-*T'K&P*!YV9YW3)=<
MA=W-V9BN,"Y)[D\\KZ&6%;;H&/[P_P"%7O[`[Y_\S[?^I*_^:5B3\$CU$Q5;
MXA%ZO\OQ8A("LE>N2*Q9V!T(,@Q?<;_3RQ^AQHHTFZ&GHT&/9JBO?V!WS_YG
MV_\`4E?_`#2LDOX)_J0FA>GF]8V!34\IW2T[Y+KFC9MV^Y5L8()W"]_;KRJ?
MH99!D70!_P`0_P"%7O[`[Y_\S[?^I*_^:4'V<?\`A/\`]9,_54,V:?6)0XA1
M+%Y%=EY<OX[%A-=`)#+Y=511XZ()5N3>ZW8&S$C3A_D_T?N6"2&+I`,R%=T"
MM)V2E1.H>W#:(-/M[D[Z)20+]K_452/(]YA2SQ3\#WU#8S28S1UWK%P4IF"F
MDH\8J8LGXC!4S4\L9B9#-#C*R#W38$'3PMPGM?HB;96E2;H>`R`6Y`(QF"J*
M93N%OF#/Y]O_`%)7_P`TJ91_@E^H[#J.CP[#_6-@=%A^'0Q4]!119-Q!(H8(
M4$4<:*N,V"JJ@`#L!QE[Z&V7%E:KH%2B2248DG$D^+C6O[`[Y_\`.0;_`-25
M_P#-*D_\,K^IG_N,_!__`%#\1_\`/SQO_H16V_YF4_ZG_P`E7O[`[Y_\Y!O_
M`%)7_P`TKW_#*_J9_P"XS\'_`/4/Q'_S\\]_T(K;?\S*?]3_`.2KW]@=\_\`
MG(-_ZDK_`.:5[_AE?U,_]QGX/_ZA^(_^?GGO^A%;;_F93_J?_)5[^P.^?_.0
M;_U)7_S2O?\`#*_J9_[C/P?_`-0_$?\`S\\]_P!"*VW_`#,I_P!3_P"2KW]@
M=\_^<@W_`*DK_P":5[_AE?U,_P#<9^#_`/J'XC_Y^>>_Z$5MO^9E/^I_\E7O
M[`[Y_P#.0;_U)7_S2O?\,K^IG_N,_!__`%#\1_\`/SSW_0BMM_S,I_U/_DJ]
M_8'?/_G(-_ZDK_YI7O\`AE?U,_\`<9^#_P#J'XC_`.?GGO\`H16V_P"9E/\`
MJ?\`R5>_L#OG_P`Y!O\`U)7_`,TKW_#*_J9_[C/P?_U#\1_\_//?]"*VW_,R
MG_4_^2KW]@=\_P#G(-_ZDK_YI7O^&5_4S_W&?@__`*A^(_\`GYY[_H16V_YF
M4_ZG_P`E7O[`[Y_\Y!O_`%)7_P`TI59#_!W]1N4\]Y'S9B/K`PG%L/RKC.%8
MG7X4F4\0B>JAP^OBK'A5VQ=PID6,KN*FU[V/#3(_HGMK.^:N/S`/=+2N-']%
M05_2ZJ56.XV]Z'T*<OFU("@2`VH2`<1/><1A6P=S.^IVKW/5ZO<]7J]SU>KW
M/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO
M<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J
M]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>
MKW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5
MZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]
M7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]S
MU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J";KKU;
MPSH/TBS[U@QK`:_-&%Y`H6KZW`,+6G;$*I%D2/9`*N6&,M[]_><#X\#6^&]-
MODF6.WS\EMI.HQMB8XQ13GN:&RM%OA"G"@3I3&H]0D@3YD54;'^.]T&F@Q&J
MAZ!9_FI<'>6/&*I'R<\5')3C=*E0ZXV5B:,:N'(*^-N8XJ^L'=X*2DLO@J@@
M:4R0=A'BQGA&WA45_P"S`]_S(7'_`*#_`,.ID/XYG1BIAAJ:;TX=2*FFJ$62
MFJ8HLJ21R1NH971TQDAE8&X(-B.,K^LK=I)(+3P(X$)D?[U7O]F%W_F0N/\`
MT'_AU@JOQU^AU!85_I[ZAT!9))5$_P#5&$F*';YCCS<;7W4W#<W87%^XY=KZ
MQ=W5_:R\>&`2<3L&"MIX=->_V8'O^9"X_P#0?^'6:3\<WHO%)!#+Z<>H\4U4
MS+2PO'E17E95+E45L:!8A020+Z"_;E$_63NT02&GB!MP3AY^+"O?[,+O_,A<
M?^@_\.LP_'%Z0$@#TT]2R3V'R^5O_/SRO_0YN[/_`!MWV(_PJU_LPN_\R%Q_
MZ#_PZ">D_P"%'OHUKL6AP&EZ?9MDQJHQ"GPFGPHU63DGDQ6K8I!1JKXT"9Y2
MIV1CWF\!P4N_4K9(:+JK.YT!)7.A,:1M5]WVCB=@I6KM2O`).77,1.QO9_IZ
M7^#_`(]'I_S%'B<V`=!>H&-PX+656'8Q+2_U1G6EQ"B;944TICQHA)8B;.AU
M4]^$-W]7N06Y2'6'T%20H2$B4JV*$JQ!X'C2=?:\^G;87`G_`&O_``ZY5GX\
MWI^PZ;"J?$>A6>\.J,>;9@-/439,@DKW-O=IEEQQ3,?>&B`]QS3/U?9`X%%#
M#Z@C[H2DZ?\`&A6'K%:':^\?^8"X_P#0?^'4^?\`'1Z*4I45?IUZBTA=XXT$
MJY2C+23/Y<:#?C0NSM[JCN3H+GC"/K(W;5]K3QXX!)P&T_=PX]%:_P!F![_F
M0N/_`$'_`(=2/^'QNC__`'#3U+_\9\K?^?GE/^AS=V?^-N^Q'^%6O]F%W_F0
MN/\`T'_AU[_A\;H__P!PT]2__&?*W_GYY[_H<W=G_C;OL1_A5[_9A=_YD+C_
M`-!_X=))_P#A0+Z8(\7&7I.E&;8\PM,M,N7FQ+(8KS4LVP0_+''_`#?,)-@F
MW=?2W#0?5?DY:[T6MSW<3J[OPQTZIB.N8J_^RZ_$_P`ON(_W/_#I6_\`#XW1
M_P#[AIZE_P#C/E;_`,_/"O\`Z'-W9_XV[[$?X54_V87?^9"X_P#0?^'6.7\<
MOHU!%+/4>F_J13T\"L\]1)%E1(XT0%F9F;&0%4`7))L!RR?K*W:48#;Q)ZD?
MX5;_`-F%W_F0N/\`T'_ATPX3^/MZ;LP4]?5Y?Z-9TQ^DPD;L6JZ"MR/6Q4B[
M2UYWIL>=8Q92;N1H#[.+KKZMLD84$NV]P@JV!2`DGR!4)]*L>UY\;;"X_P#0
M?^'3]'^.5T;FCCFA]-W4F:&95>&9(<JNCHPW*RLN,D$$&X([\0*^LO=H&"VZ
M".I'^%5?]F%W_F0N/_0?^'7/_A\;H_\`]PT]2_\`HAE;_P`_/-?]#F[L_P#&
MW?8C_"K7^S"[_P`R%Q_Z#_PZ]_P^-T?_`.X:>I?_`$0RM_Y^>>_Z'-W9_P"-
MN^Q'^%7O]F%W_F0N/_0?^'7O^'QNC_\`W#3U+_Z(96_\_//?]#F[L_\`&W?8
MC_"KW^S"[_S(7'_H/_#K@_XY?1J-HED]-_4B)IVV0*T65%,C[2VU0V,BYL";
M#6PYL?65NT=C;V'4C_"K?^S"[_S(7'_H/_#KG_P^-T?_`.X:>I?_`$0RM_Y^
M>:_Z'-W9_P"-N^Q'^%6O]F%W_F0N/_0?^'7O^'QNC_\`W#3U+_Z(96_\_//?
M]#F[L_\`&W?8C_"KW^S"[_S(7'_H/_#KW_#XW1__`+AIZE_]$,K?^?GGO^AS
M=V?^-N^Q'^%7O]F%W_F0N/\`T'_AU[_A\;H__P!PT]2_^B&5O_/SSW_0YN[/
M_&W?8C_"KW^S"[_S(7'_`*#_`,.O?\/C='_^X:>I?_1#*W_GYY[_`*'-W9_X
MV[[$?X5>_P!F%W_F0N/_`$'_`(=>_P"'QNC_`/W#3U+_`.B&5O\`S\\]_P!#
MF[L_\;=]B/\`"KW^S"[_`,R%Q_Z#_P`.O?\`#XW1_P#[AIZE_P#1#*W_`)^>
M>_Z'-W9_XV[[$?X5>_V87?\`F0N/_0?^'7O^'QNC_P#W#3U+_P"B&5O_`#\\
M]_T.;NS_`,;=]B/\*O?[,+O_`#(7'_H/_#KW_#XW1_\`[AIZE_\`1#*W_GYY
M[_H<W=G_`(V[[$?X5>_V87?^9"X_]!_X=>_X?&Z/_P#<-/4O_HAE;_S\\]_T
M.;NS_P`;=]B/\*O?[,+O_,A<?^@_\.O?\/C='_\`N&GJ7_T0RM_Y^>>_Z'-W
M9_XV[[$?X5>_V87?^9"X_P#0?^'2ARA^-)TFSAF[*>4*7TZ]1</JLVXIAV%4
MN(5$&613P2XC61T222^7B[ML0R!FVJ38&P)XORKZO=V[NZ;82AT*<4E(D)B5
M$`?Q=)I1:=K3KKJ4?D7QJ($GNX$F)/CV#::N:YE94QU[GJ]7N>KU>YZO5[GJ
M]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>
MKU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU`9
MZF$PN3H/U.3&MO\`*FPUQ7;[;=GFIWOS'?ZLRX.S?,]'W=R8]HHPRI+1N$AS
M[)QK1OZ?94R;A^-=?NFE-@7F93]6V<^K-9F2M2G_`-&HSD3/V--BIF<M9?YI
MA$M'31>[[Q5FN;6YRXS[,[EQFSNRO]KES%J$B<3W[#?=QT]VZ'%G'"0,*$J&
MLOU$&,2?2"?B(BGK(?4W..%8ITARAA]7A>6XL(POH;0]+LHU68)**#'LNXIE
MK`VS'.V7:/+E?/B;B26MA-0M;&M"84D<1IN:1%GF[5BZU<OJ"UE2[U3JPV%%
M#B7'>Y'?%Y"6Q`;5I+:B]J*1J,!-4HL2?X?X>/E.$'KXX4E<=SQ@V)Y@Z=YV
MK^I=9B?72@Z9]:ZOJ?D"2.BJ*3(V8UQ;+L$%%2TXHP*58XT,<,4A?SXU$_O[
MMY-++)%MV[UNEA*;(W5F&W`2"^WI>)4HZO%)Q4H1H)T81I'BW80#(D@R,,#A
M%+WJ9FFAQO.&7*VAZAXA)ZA,$Q7KHE'T8IX::2FR]%A62LRT^5:JEI/(9H7G
MC2FDAJ78K6M(2`=NU"/=S*RS:+2IE/Y!:+*7B3+A4\R7TJ5.(22H*2`"T!C$
MR;.-9?$B)\6&$;#'RI19AZUX-U$S!TYRWT^ZNU<&`XZW0##,[YBP'Y198*K,
MV(9A@S,D54U-(D=2Z4L*5&WWH&4"R.".(+#<Q>7L//75LDK1^>4A*Y@AM+)9
M)3J!*05**9P6"=HJSC>7$@"/X9V=<T9_KCZ2<F]5L(FH,&ZH4&"XE0YPPS-^
M6L;Q&GJ*Z:"LP3(59E>A,[02PF25:^:&LD=2NY$9!9F!$;;E]J5SE;H4XPI2
M2RII020D%*WTNJB08&@*0`9@D'$"*5.V.6$>%21^[\<:1F<^D62_3WZ.>JF7
MJ?-5!CN.X[B6%56<<X440PMDI,P8G@F%YHQ%1(\IC?RFKJP>\=H8+<E;DWRC
M>FYS_>VW=+:D(0E00@G5BVEQ3".$B>[1UQ.$U5RVRU+1Q258?*?F:=<0C]'6
M4,^>J3!?4/AV!0569*Z&+ISAN)4,=0^+9%CRU24M%AN7U\IWJ'AJ4JD>EI-T
MRS-O*^^C%.P=Z[NQL',J+A"$DN%*HT/]XHJ6[B`D%.@A:X24B)\)`=;1E0*I
MT[</**)=FO(F#QXATWP'J!G;%\+ZJ8Z/2PF,X4V)12STA@S_`"4V)5E/#)&Z
M_-4@$2SU`W!)78MJXY+V5YTLMONVK2%6J/YG!TP#+`*$D@CPKQ*4X2D"-E%W
MY?+X&(GPS[?%[J6&9.KF;<#J\>R?59R\C(^2LS=6<&P/J?BN9Z?*V)5M9E[%
MJ"/+M)5XC'EW&17R)35$K+2B*-ZXK;=(RE24Y?NG9/)0^EJ7W6K5:FDMEU*0
MXE??*2COF]`*@`5RH-3,)!D>+=A,>&!JQV>7`S\Z-OZ5\1&>.HG6G%^KV:9?
MG,E?U)PW"LC4Z?(Y<@GQ?IW@>/8I-'255+#4-(<0J)MAF(:($H5&H$5]IEJF
MRR^U;L6Q#O?**SXG"$7#J$`J"BF-`3.G!1A4G;2NT9RPJ)7IX>6P3[Z`;TQX
MET$PSJ#U2PS,_7/I5EVKFZR]1Q3=)L5R[A?]=ZB.HSE5BE%/B<^88)5>?<K4
M[##VL"`H;1N#CM'M<Z=L&%LVEVL"RM_VJ7%=R(93JE`9((3B%#O1QF-E;MFL
MN).I28DX1PG#&?E2-S;U:ZGT.&9_RK@F(2S8KZ8,0P;*'5S-U1+3X=_/(,T9
MS@GBQ_YP8;B,<;TV6(HII9TIG$$E4\ACLHVFV5[J96MQEYQ(";]*W6D`%6@M
M,D%K3K02%7)*0DK&M+82%8XHUHL8@:<,.&,G;[/>:'K+6-X-G3T8>KFKS=B.
M&9E6BP?J11=+,;I,5FS))68''D]VIP^,2X7A"8HZ54DT:U<$&R10J[G=6)!&
M8V*[/>_+DL)4V2NW4ZDI#<+[X3#8<<+0*0DE"E2#)@`@4J0UEO=*G3JQCV88
MP.-!!FO,'0G%NGO0S,?IFQO+>(YLZ<=.,XU76#&\M'":I,/PY.E-8E)38B:)
M9(VG?'%HW@IY;OOC9MNU7/!9EF7YRU?W36;H=2T_<M!E+FH:E?FDZE(U0=(9
M[P*4G"%`3)%:N$9<4ITZ9@S[/QBHF&=8\9RQBU7%A.:%ZX9_S/E2MGZ>Y"PO
M$Z*G7`\9AZ9G':*BS!E6KPJ*1*5J^E.W&:6KVRRSQP%-NG'+G="WN6@5M_E6
M$/`..*23K0;G0I3+X<(*M"L6%HE*4*6#.-,Z+!./A42,-FV-A$=/$&F#+'6_
M&!D_'9JO/E'B.5<3CZ=4V+YT&;TQ.7`<=QJOK%QPXAF"7*V%4N7Z4T\,7FTH
MAFGHI"%VQB9&5=F6Y5O^;0`R4NI_,$([K2%H0E/=:&>_<4^K43"]24.I!,JT
M$&J6[",=.,<?;C`@>V*9*3KS6CIO3YMQ_K!!6TF1,P]2,(H\H8=C2Y=S;FBD
MP#,T<&#UN&5N/X)54N.U`HMT2X=40Q-6%DE!L;\6N[C-?S`L-6Q!=;MUE:D=
MXTT5MDN)6E#J5,)UP2ZE2@T`4[<*T&[#3)TX$X;#MP.(Q\CMH8X.J>;,2Z^X
MO@AQO#<GRG.&.X?'E"NQ:>N>DZ?PX!55-!B7]4:'+KR+()%AJCB+8D8W?=2W
MW%8P$5[KV;>1I<T*<'<H5K2D)E\N)"T?F%/`1&I'=!K4!#NP%5.=W8%?\($G
MV>4?/JI*19^PG$?3?ZBT&:?\Z74WI=392QO('4"BS'A^;<N5V;/GHU@APN>/
M#<+K*&IFJ8E%3A-1YGDI*JJVV1APT5D*V]X;+]GW%L^74.-J;4TXEK29*P5K
M0M(2?`\F-1221*0:]W67AI0\.H`1L(/P/I5OT^'=&UGE58Z-5#&R@QL!KV!\
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MGJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU`EZC^D5;UZZ&]2NCN&YO;(5=
MU`PYZ"FSBE'_`#!L/9I4D\T4_GTWF?8M;S%[]^!'?W=)O/LG>R]:M*7DZ28F
M,0=DB=G31+O'EK]Y8N,LN=TXL0%QJTGIB1/M%4H_\,:]2>W^W94VTT_J%[.W
M_/1^',/?^A&K'_F;_P#00_\`FE0M_L3;Q_\`.3_]`_\`W6O?\,:]2K$?[=E5
M9K[A_4/O?O\`\]'SW_0C5A_S-?\`H(?_`#2O?[$V\?\`SD__`$#_`/=:[_X8
MVZEV`_V[:JPM8?U#/AV_YZ/GO^A&;#_F:_\`00_^:5[_`&)MX_\`G)_^@?\`
M[K77_#&O4JVW_;LJ=O\`A_J'II_XD?/?]"-6'_,U_P"@A_\`-*]_L3[Q_P#.
M3_\`0/\`]UKL_@;=2SW]=M4>_P#SP9\>_P#ST?/?]"-6'_,U_P"@A_\`-*]_
ML3[Q_P#.3_\`0/\`]UK'_P`,9=1_^XZ:C_U`O_>CY;_H1RQ_YF__`$$/_FE>
M_P!B?>/_`)R?_H'_`.ZU$Q#\"+/.+4%=A6)^M^6NPW$X9:?$**7(`:.:"9#&
MZ,#F/4,K$'CMO]$=HTX%HO(4D@@AH8$8@_W2MI[*-Y`9_F?_`*!_^ZUGI/P+
M.HE#2TU%2^NNKCIJ.-(J=#D5W(2-0B@L^9"Q(`&I))\>4=^AZR6HJ5=XDS_<
M1Q_SZ\KLHWD)G^9_^@?_`+K6<?@:]20+#UV5(&NG]0O:+'_GH^4_Z$:L?^9O
M_P!!#_YI6O\`8FWC_P"<G_Z!_P#NM>'X&W4H=O7;5#0#_F`_`=O^>CYK_H1J
MP_YFO_00_P#FE>_V)MX_^<G_`.@?_NM='\#/J0;`^NNI(';_`(P7;Q_["/F_
M^A&['_F;_P#00_\`FE>_V)]X_P#G)_\`H'_[K7+_`(8VZEV`_P!NVI(&@']0
M]+>S_F(^:_Z$9L/^9K_T$/\`YI7O]B;>/_G)_P#H'_[K2>P#\`S-N6/YH<%]
M;U533XY5R5^-5TF2)ZFIJZN55C,DL]3F:21RJ(L:`M9$544!5`!A?_1=;W6G
MO+R0A(2D=RD``<``L`8DDX8DDF22:<=[+-Y5F3F?_H&/@[3^?P-.I)8,?774
MEAV;^H6NG_B1\0?]"-V/_,W_`.@A_P#-*;_V)MX_^<G_`.@?_NM=G\#;J4;$
M^NVJ)!N/^,'X_P#J1\T/H:L/^9K_`-!#_P":5[_8FWC_`.<G_P"@?_NM>/X&
MW4HBQ]=M41[/ZA_&_P#V$?/?]"-6'_,U_P"@A_\`-*]_L3;Q_P#.3_\`0/\`
M]UKQ_`VZEDW/KMJB?;_4,^/_`(D?/?\`0C5A_P`S7_H(?_-*]_L3[Q_\Y/\`
M]`__`'6N_P#AC?J7W_V[JJ^FO]0SX?\`B1\]_P!",V'_`#-?^@A_\TKW^Q/O
M'_SD_P#T#_\`=:Z_X8UZE6M_MV5-AV']0M/;_P!A'SW_`$(U8_\`,U_Z"'_S
M2O?[$V\?_.3_`/0/_P!UIJQ?\!G.F/KA\>,^MZ?$8L*JZ>OH89,AL42LI&\R
M&4J,R`,8V]Y=P(#`'N`0JM/HGMF"HMWFDJ24F&1L.T??Q&!CAAL-63V4[R#9
MF>W_`(#_`/=:<O\`AC+J/_W'34?^H%_[T?$__0CEC_S-_P#H(?\`S2J_[$V\
M?_.3_P#0/_W6O?\`#&74?_N.FH_]0+_WH^>_Z$<L?^9O_P!!#_YI7O\`8GWC
M_P"<G_Z!_P#NM>_X8RZC_P#<=-1_Z@7_`+T?/?\`0CEC_P`S?_H(?_-*]_L3
M[Q_\Y/\`]`__`'6O?\,9=1_^XZ:C_P!0+_WH^>_Z$<L?^9O_`-!#_P":5[_8
MGWC_`.<G_P"@?_NM>_X8RZC_`/<=-1_Z@7_O1\]_T(Y8_P#,W_Z"'_S2O?[$
M^\?_`#D__0/_`-UKW_#&74?_`+CIJ/\`U`O_`'H^>_Z$<L?^9O\`]!#_`.:5
M[_8GWC_YR?\`Z!_^ZU[_`(8RZC_]QTU'_J!?^]'SW_0CEC_S-_\`H(?_`#2O
M?[$^\?\`SD__`$#_`/=:]_PQEU'_`.XZ:C_U`O\`WH^>_P"A'+'_`)F__00_
M^:5[_8GWC_YR?_H'_P"ZU[_AC+J/_P!QTU'_`*@7_O1\]_T(Y8_\S?\`Z"'_
M`,TKW^Q/O'_SD_\`T#_]UKW_``QEU'_[CIJ/_4"_]Z/GO^A'+'_F;_\`00_^
M:5[_`&)]X_\`G)_^@?\`[K7O^&,NH_\`W'34?^H%_P"]'SW_`$(Y8_\`,W_Z
M"'_S2O?[$^\?_.3_`/0/_P!UI4Y&_!4Z@9/SQDG.%3ZUZC&:?*.,87BL^#_U
M'\@5:8;7Q5I@,G]8)-@D$>W=M-KWL>W#/)/HNL;.]:N/S6KNUI5'=`24D$8Z
M^JE5CV6[P-/H6O,M24J!([J)`,D3WIB=DP:OUYFW4\U[GJ]7N>KU>YZO5[GJ
M]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>
MKU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>Y
MZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[
MGJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7
MN>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU
M>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO
M5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU`IZC>J..
M=%.A_4GJKEK*J9XQW)&'/6X9E.6K:ACKY%E2/RC.D,YCN&O<1MV[<!7:+OBC
M=_)'\Q6G4EA.HB8G$#;CTT59Y=7+%HM=N@..@>%),`GHF#'L-:_^%?\`"@K-
M&.9FER;A/INP&LS)#B-7@[4/];\:CA.+4,KT]11)539;2F>HCDB=#$LI;<I`
M!(YBI=?5W?,6WYA=A#92%SWHG0H`A6D)U!)!!DB((-1@=[=[0)_((_U4_P#S
M.A@'XQ/J39E5?1+0EG!95&<JZY`TN/\`?%VX$O\`H?>T_P"99/\`JO\`R%5_
MMAO9_P`R"/\`55?_`#.L?_#Q_J-\N2;_`&*L/\F'_+2_USKMJ_2?Y%IRW_0^
MEK,?EDR?^"?\A7O[8[V?\R"/]55_\SIJP'\:OKKFC`L(S/EST>X3C67<P4ZU
M>!XU3YUKGIZNF<766-C@0NI]O%-]]<[=J^IEVT"7$&%)+F(/0?!MKQWPWL'_
M`#`(_P!5/_S.D]G+\=CJCT]3#WSIZ4L'P%\6\TX52-G'%:FJJ4@VB5XJ>BR]
M-,Z1[U\QPFU;C<1<<,,H^M)R_*OR]D%Z8D]Z`!.P$J2`"8,"9,&*VG>_>T[+
M!'^JG_YG6"J_'BZCT>&8?C<_I=P%L%Q=*%\'QB'.V(U-)6C$WDCI!334V7Y$
MF>9HF")&68V[:B]VOK->6X6Q8^-.J07((TQJU`I!`$B28'7@:\-[][3_`,P"
M/]5/_P`SI,Y8_P"%">8,Y8Q@>7\M>G+`<0QS,]17TF6\*DS=CE%/7U6%0&IK
M8J=<0RU!YCT\:EI0OV+:V.G#+,OJVO[-E;KV7Z4-A)4>]"@D*,))T@P%'`=/
M"K*WMWM&VP1_JI_^9TILO?CQ]1,VY#HNJ66/3'EW'>G&)1RRX?G:FSW6/A\\
M<-8^'N4D_D0O:>-HM!<L+"YMPMS#ZS7[2^-D]8Z+A)`*"YXA(U"1H_HD'RQJ
MIWOWLF/R"/\`53_\SJ*_X]^?(\VKD27TRY?BS;)4BBBPA\[8D@>O*%_DTJ&R
M^*=JJRDFG60RZ'W=#QQ/UD7)M/S(L/V4:I[S^'^E&G4$_P!]&GKKW]K][8G\
M@B/]M/\`\SH2&_&.]1RK&S>BG#U67_),<YUP#?1_OBUX'A]>MJ?^89/^J?\`
M(5K^V.]G_,@C_55?_,ZY_P##Q7J2\PQ?[$U!YJBYB_KE7;@+7O;^17YK_H?:
MTB?RR8_VW_D*]_;#>S_F01_JJO\`YG7$?C&^H\H9!Z*</,:_:D_KG7;1K;O_
M`"+FS]>MI,?ED_ZI_P`A7O[8[V?\R"/]55_\SIDK/QL>N&'8W@.6J_T@X11Y
M@S3#75&6\'DSM7+/7089Y/S<D(_D7O+#\Q'O/AN'%C/UR(<96\FT!;;*0H]Y
M@DJG2#X.,&/(U[^V&]G_`#((_P!5/_S.GW_AXKU);_*_V)J'S;7\O^N5=NL?
MA_(N(O\`H?:TB?RR8_VW_D*]_;#>S_F01_JJO_F=8S^,AZC5W;O17APV&SWS
MI6Z'X_[XN6'UZ6O_`#+)_P!4_P"0K7]L=[/^9!'^JJ_^9TQ8?^-OUKQ>FQBL
MPKTAX1B5+E^JK*'&Y8,ZU\ORU;A]A4P.$P$GS(K^\H!/LXNN/KA2TI*5V@25
M@*3+D2E7VG[-AX&M_P!L-[/^9!'^JG_YG3Q#^,KZB*B&&HA]%N'M#41K+"QS
ME7J3&ZA@VU\!!&A\0"/'B-?UXVR20;9,@Q_=?^0KW]L=[/\`F01_JJO_`)G4
M@_C&>I`%%/HGH`T@O&O]<JZ[#VC_`'Q:CC?_`$/M:?\`,LG_`%7_`)"O?VQW
ML_YD$?ZJK_YG2;S1^-YUFR3A<N-9N])&#9>PN&1(6JZG.]<NZ>4[4AC1<"9Y
M)7(LL:*68]@>&.6_6^+QT-L686HB8#G`;23H@`<22`.)KPWPWL)_X@1_JI_^
M9UQRC^-]UES[A:8UDOTC81F3#6DDA:>FSIB&^.>*V^*6*3`$EBE2XW1R*K"X
MN->;S7ZWA8N]W<680J)Q<V@[""$P0>!!(/37COAO8#'Y!'^JG_YG2E'XQGJ0
M*NP]%%`5COO;^N==9=O>_P#OBTMPN_Z'UM/^99/^J?\`(5[^V.]G_,@C_55?
M_,ZZ/XQWJ."+*?13AXC<V23^N==M)]@/\BY[_H?6UF/RR9_VS_D*]_;'>S_F
M01_JJO\`YG63_AXGU)F3R?\`8EH?-%B8OZY5VZQ^'\BYK_H?>TB?RR8_VW_D
M*]_;'>S_`)D$?ZJK_P"9TSX9^-3UVQJD^?PCT>83B-%YL\!J8L[5C*)Z6=Z:
M:,_[XKAHY$9&!U!!'%5S]=#3*]*[0),`XN<")!^S8001U5X[X[V?\R"/]5/_
M`,SIP_X>3]1/_<%V&_\`J:UG_GCXQ_T/E;?\RJ?]4_Y"M?VQWL_YD$?ZJK_Y
MG7O^'D_43_W!=AO_`*FM9_YX^>_Z'RMO^95/^J?\A7O[8[V?\R"/]55_\SKW
M_#R?J)_[@NPW_P!36L_\\?/?]#Y6W_,JG_5/^0KW]L=[/^9!'^JJ_P#F=>_X
M>3]1/_<%V&_^IK6?^>/GO^A\K;_F53_JG_(5[^V.]G_,@C_55?\`S.O?\/)^
MHG_N"[#?_4UK/_/'SW_0^5M_S*I_U3_D*]_;'>S_`)D$?ZJK_P"9U[_AY/U$
M_P#<%V&_^IK6?^>/GO\`H?*V_P"95/\`JG_(5[^V.]G_`#((_P!55_\`,Z]_
MP\GZB?\`N"[#?_4UK/\`SQ\]_P!#Y6W_`#*I_P!4_P"0KW]L=[/^9!'^JJ_^
M9TJ,C_BZ]?\`-6=\E95K_1[A^$T.:,8PO#:[%ESC63-2PXA7Q4CS",X*@<QK
M(6V[A>UKCOPUR+ZX+:]OFK?\L!WJTHGO)C4H)'\/73]KO=O2IU*5V*`DD`GO
M#@)Q/]SX#&KZN9ZU,%>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU
M>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO
M5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]0$^IO$<-PGH)U0Q+&+?RRCPQWK-
MVHV"5._,>/JR8<<[.,S2C[BR8]HI?EEPVU<)6Y]H.-:5N3:@#$XL(P_&,]/F
MG!?41C6;HNDF-932#IP^6)NI]7B,F(G%:K+L)8IAE0];2,F*N?F5BVQG[`Y.
M9OI[KO%)M^Z5EJ&N]0[-QW@MDI".[#QVN`-KED#052H;:$*<^R\8ZL=4QA$3
MY3LZ]M-$<,%'T8Z'8!F/)^9Y\5SK#U%Q'K%C4]'FW,=;)F6/$I:7+4-3AV&U
M5/+!,U-+>DJYYHZ.!([2#<\;HJ+^O-[IQIUH):-NED`M-I[LI!>*5J20H:AX
MT)2IU9/A,!0-1GN7:`)$XS\J$3H!F^EK,?R#F7U1Y7SMF#J$V4>EIZ38G24^
M98:?",1@RL(,SQ8N<+FAHZ:I;$S-)7K7&T\1C5!+MV`AWZR[0P\SDSC"+?OK
MGO02V2M)=E@MZ@5J2&](;+?V*"BK3,T[:[PY=M<()@1[,??MH/<C9+J\F=/.
ME6#9'BQS(>-0]&:['<XXC65F+)2GJ9E'-.`8U@D.(&LF\J%Y*>*KI7BLB-3,
MZNI118]SK/&[R_N'+DMO(-ZE"``F?RSK3J'2B!)`44+"L2%@$$$XL(SS+PD`
M$`Z?]Z!$?,4(^"YSREG?+?3OKSF#&.I_0GJCU13,F:,$ZC9.PM,WKEG"\T5E
M))095Q3`6P[%C-#'14E'-_O&$65''GHS'>'[S++BSN'LL:3:W=M;]VTIMY7=
M=XIH*"GT.ZVX)6I:?O)*2GP$#!3_`#_+58E6E6.R,.J#SUTUX'C&>:_/O2&O
MSYE'Y08-#T/GS!1X'A4N&Y;AKL%ZBYKJ\4JX</IFEIZ.8T,M'/61HQ\K>JEB
MH4\4WK%@W8W*;9R=1O0DK5J<*5V[`0DK,*6-86ELF-4$@233:=XK`J!41_#[
MB9]T4/76#H=D+J;@66*7!^K4.3<T9,Q/.F*Y6S9_)3724=5G''*:OD*1M5PZ
MQT:5%(2'!;SMXVE;$#[I[\7>6ON*<MRXTZEE*D:],AE"DC'2=JRE>S#3&,S3
MK^>98H8*`./#I/(K%7X7TFZ'=&?3ATNPW$!BN0\A=4\,KLS5,$#TL<>!XGG#
M%<;HHYT\R0F"CJ\0HXY26(<1EB!?:+L7V99UF][>+&E]ZT4E()F5I:;0HC`>
M):4+*<,-43A-73G^6)0E((,&?22:0Z8]A&6.J$$G1.3-V`T^+=1_YQU*].^=
M<LTV,]/WI,0S#YN,YBP7,!H9!03LC/B5+%#B+GSF*&F1F(4Y5:KN<M/\P[E9
M3;:&[AEPH?E+<-LN,ZAK3,-+*F@-(D.*`$M_VART*E"L)Q!@CK(XCI^5%BRQ
M/Z@H<B9M6FQ/$:3JQ49(QJFZROA^!9HPJHQ_,DN8,,D$L&,9DQ^HHZBN^1CK
MUPR7"($B1)564PD1QB2,R.[YO6Y2DVH?06=2VU!ML-K$%MMH+2C66RZ'U%1*
M24A<J52-.?V81]PDC'SD=?G$4:+,68/3R^/9#AP3IKG]?2U14N<CBF2HJ'/L
M==_7"I;"9,*JQA\T_P#-4I%1*M8"T20QU),I"J1*8VR^TSP,.EQ^W_F9+,+*
MF-/=#O.\3K`[HKG0502I3<)$D::7JW@RG4`/MQPZ\(YZ:"7+BYZ/\_SUGVES
M'7=7LLXOZ=!EG$TJL0FB2ECJZ"ESH88:1_DYPU)),F)NJ,I(+$Z`\%&8.V'@
MMK8M"T<1F&H0D&86;:21K3XPDM`D'$`;8I*C/[#:2-7A]WW4DZJKKJ+%\F9B
MP_I]G3%NO."Y"ZR476G-X;'Z.@K\S8SB.#QX=+AF(3-)!^D@ADDH?D3N6!!"
M"DH`4T:#2VG6E/,)L57%H64>`J2VA+FL+0(5@H@.=Y@5DK,H,GW\_P`O$&1J
MA4^9B*SY$HZK%NJE'D_&<(S'7^G>LZF99Q%L.&$9LRI@TN`OTEQU,5VTN*5L
M]?!0R8Y'2M(E3*&,Y6Z@L"S>=W+;66%]M30OQ:N)G6TZL+_--:/$E(;4L,E<
M%((T3!P,:1GV7ZX)&F1[(,^^*-)Z=LXX=3=<L]Y&S-B-55=/O2S%BN!9`Q:H
MK*JH_GO]>:ZGS11O4L]1*9Y<)PM8:*\X+J69A8."8UW_`,M4K)6KED`/WY2M
MP``:.X26E:<!I#KNISPX$``X@TKM]XLN2OQ$:1,=<GY;*GY/ZS]/\!RGZH^F
MTV6\RT.>\V9JZF8AD>JBREFOY"HAQ2C:7#YH,8@P\T(\PK^C;Y@'=8?:('&<
MVW4O7[JPNPMHL-M6R5@NM:@4F%@ME>O#CX=F.RKHWERP(4)$DF/E01T&*=2(
ML^8/T[P%L3H<I5>7*/J5A^?<0EKVHZ/.])T]_JE'ERJFEF:RMC7DXG)3,I0J
MLA*FYX*7VLM-DJZ=T%T.FW+:0F2R;CO2\D`?\9U-!8,R4@&DHWAL)@$1M]8B
M/*<:!C)%)G;$LK46#8N<>I<(Q7_-7!U9P*BP7.N`3UN/4^<J*;'ZVHKLPX]B
M5353O0+-'7U&'JM%)"1^D)&T"_.;FQ;N2XCNRM/YHM**V7`&RRH-)"6VD)2`
MO26TNDNI5_#&):3GMA$%0X3[<>)X58+UBQ_IO@&<O2]G?+>7JC'.GO0W%,<3
M,F4L,I9\4K:6DQ7+,N"T&(P4P,E14F@<[&6(/-LE9E#6(,$;I6M\_:7]NZL(
M?ND(TK40E)*7`M:"K!*=8QDPF4@$B11BYO'E>M)!$"?A\J"3K9U/Z==1_P"I
M4N"=)<:RQT\SAFVIFZDXW+EK'9ZG&X:7+34])5XG@&!-18J5EF6."FEJWC6)
MHE>=`FS@KW.W?OLO[T.7#;EPVR`VD.(`02Y*DH=7J:P$J6$!14%%*#JU4W<;
MR98L@"`)Q]E%"Z;8?U`QOI5B^8NIU#G1NL&2^F71Q,@U\U5C5/6T^;\$SICH
MQ>2*""8PRUGR!@2K+"3?"PW%E8'DJ[PW>7LYFEJS+'Y1VZN]8`04EI;+7=@D
MB0C7J*-D*!B""*0-9[8Z/$?%"8\P3/NH<\PX[B8R=ZEAEO",T1^LC'*_J&,B
M=0X?YY%E@Y:JL:>?`(8JAZBGPE]F$>5#21)>:&H#%O*<F0@JPMF?S=CWJFOY
M0E-OK;.@N]X$`.DB"Z)=E2R80I$1J`TTH5O#EVA1!&LS!ZIP]U(O)F$PYBSC
MTHPG%*#%GZ`2]1J2KQ#)5+@F?LH8=1X93],,QTE:U1#FG',2Q8T<^(R4/F+4
M&*%JI=\0<N7)SF]\+>TN%H4C\]^6("RMAU14;EDI@M-(:UI;#D:=2@V85$15
M$Y]EVH21IG8)'`]9.V*/AT'ZC]-X<[>J2LA$*Y-Q+/Y;*("2!&GI\K8/18LZ
M%[@J:^&4$KIO#>-^0COOD=\;.P29[Y-OX_(NN%N?\PC;C!'"*,&=Y,L2I4D0
M3A[!1C_\Z/2?VP_\@_V<CW^S^9==*/[493TBO?YT>D_MA_Y!_LY[^S^9==>_
MM1E/2*]_G1Z3^V'_`)!_LY[^S^9==>_M1E/2*]_G1Z3^V'_D'^SGO[/YEUU[
M^U&4](KW^='I/[8?^0?[.>_L_F777O[493TBO?YT>D_MA_Y!_LY[^S^9==>_
MM1E/2*]_G1Z3^V'_`)!_LY[^S^9==>_M1E/2*5>0NI?2ZISYD6FIO*^9J,;P
MB.FLNOF/B,*KX>T\&/9UD.8)WBLB9@7+/_*J::?WERM39"2)(,>=;$//IGJ/
M:]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU
M>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/
M5ZO<]7J]SU>KW/5Z@2]1_1L>H3H;U*Z+'-4^21U$PYL/.:Z:GCJYZ$-*DGF)
M#,R*Y]RUB1WX%]]=UFL[RIVQ<.E#J8)V\0>KHHAWHR9S,,O<MFW"TI8@*`!*
M>N#@:I-_X8.;_N-7,/\`ZB>$?^=?,6?^A,LJ_P"/G_2?\E4`?[`.;_\`.5<_
MU)O\:]_PP<W_`'&KF'_U$\(_\Z^>_P"A,LJ_X^?])_R5>_V`<W_YRKG^I-_C
M7O\`A@YO^XU<P_\`J)X1_P"=?/?]"995_P`?/^D_Y*O?[`.;_P#.5<_U)O\`
M&F_%O^$^^%X]AU5@^.>L'&<9PFO4)7875Y-P.HIIE#!PLD<U4RL+@&Q'%%I]
M'N7L.!QJY6E8V$)@CR(7(J[?8-G*%2G-7`1T-(_&IX_`,VA57UIY@55`"J,I
M8.``!8``5?;B<_1GE7_,PK_2?\E5/]@'-_\`G*N?ZDW^-=_\,'-_W&KF'_U$
M\(_\Z^>_Z$RRK_CY_P!)_P`E7O\`8!S?_G*N?ZDW^->_X8.;_N-7,/\`ZB>$
M?^=?/?\`0F65?\?/^D_Y*O?[`.;_`/.5<_U)O\:CU?X`5+B%+/15_K*QVNHJ
MI=E31S9/P66*1;WLR/5$$:=B..-?1OEC:@I-PH*&PA,$>NNMI[`\X!D9JY/^
MU-_C4C_A@YO^XU<P_P#J)X1_YU\;_P"A,LJ_X^?])_R5:_V`<W_YRKG^I-_C
M7O\`A@YO^XU<P_\`J)X1_P"=?/?]"995_P`?/^D_Y*O?[`.;_P#.5<_U)O\`
M&O?\,'-_W&KF'_U$\(_\Z^>_Z$RRK_CY_P!)_P`E7O\`8!S?_G*N?ZDW^->_
MX8.;_N-7,/\`ZB>$?^=?/?\`0F65?\?/^D_Y*O?[`.;_`/.5<_U)O\:]_P`,
M'-_W&KF'_P!1/"/_`#KY[_H3+*O^/G_2?\E7O]@'-_\`G*N?ZDW^->'X!S#4
M>M7,((['^J>$?^=?/?\`0F65?\?/^D_Y*O?[`.;_`/.5<_U)O\::\)_X3Y8-
M@,%338%ZO<7P6GK*B:KK(*3)>!4R3552V^69Q#4J&DD.K.=3XGBF[^C^P?4%
M.W2UD``2F8`V`2O`#@-@IQSL&SI9E6:N$_[4C\:=/^&#F_[C5S#_`.HGA'_G
M7Q-_T)EE7_'S_I/^2IO_`&`<W_YRKG^I-_C7O^&#F_[C5S#_`.HGA'_G7SW_
M`$)EE7_'S_I/^2KW^P#F_P#SE7/]2;_&O?\`#!S?]QJYA_\`43PC_P`Z^>_Z
M$RRK_CY_TG_)5[_8!S?_`)RKG^I-_C7O^&#F_P"XU<P_^HGA'_G7SW_0F65?
M\?/^D_Y*O?[`.;_\Y5S_`%)O\:]_PP<W_<:N8?\`U$\(_P#.OGO^A,LJ_P"/
MG_2?\E7O]@'-_P#G*N?ZDW^->_X8.;_N-7,/_J)X1_YU\]_T)EE7_'S_`*3_
M`)*O?[`.;_\`.5<_U)O\:]_PP<W_`'&KF'_U$\(_\Z^>_P"A,LJ_X^?])_R5
M>_V`<W_YRKG^I-_C7O\`A@YO^XU<P_\`J)X1_P"=?/?]"995_P`?/^D_Y*O?
M[`.;_P#.5<_U)O\`&H]+^`%2T,"TU#ZRL=HJ96=EIX<GX+$@:61I7.U*H"[,
MQ8GQ)).O''?HWRQ:M2KA1/24SLP'\?`85M78'G!,G-7/]2;_`!J1_P`,'-_W
M&KF'_P!1/"/_`#KXW_T)EE7_`!\_Z3_DJU_L`YO_`,Y5S_4F_P`:]_PP<W_<
M:N8?_43PC_SKY[_H3+*O^/G_`$G_`"5>_P!@'-_^<JY_J3?XU[_A@YO^XU<P
M_P#J)X1_YU\]_P!"995_Q\_Z3_DJ]_L`YO\`\Y5S_4F_QKW_``P<W_<:N8?_
M`%$\(_\`.OGO^A,LJ_X^?])_R5>_V`<W_P"<JY_J3?XU[_A@YO\`N-7,/_J)
MX1_YU\]_T)EE7_'S_I/^2KW^P#F__.5<_P!2;_&O?\,'-_W&KF'_`-1/"/\`
MSKY[_H3+*O\`CY_TG_)5[_8!S?\`YRKG^I-_C7O^&#F_[C5S#_ZB>$?^=?/?
M]"995_Q\_P"D_P"2KW^P#F__`#E7/]2;_&E3D7\#/^I6><DYT;UAX_C`R=C&
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DZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5__9
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
